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PEDIATRIC LIVER
TRANSPLANTATION: GAZI
UNIVERSITY EXPERIENCE
Hakan Sozen1, Sinan Sari1, €Od€ul Egritas1, Gokhan
Yagci2, G€okhan Kalkan1, Buket Dalgic1 and Aydın
Dalgic1
1Gazi University, Turkey; 2GATA Medical school,
Turkey
Introduction: Liver transplantation (LT) has been very
successful in treating children with end-stage liver dis-
ease (ESLD), and offers the opportunity for a long
healthy life.
Method: Totally 24 pediatric liver transplantations
were performed to 22 children, since 2006 at Gazi Uni-
versity Transplantation Center/Ankara/Turkey. Data
retrospectively collected from patient charts and hospi-
tal files.
Results: Among 24 LTs, 13 were boy and 11 were girl.
Ten out of 24LTs were done from deceased donor, 14
were done from living donor (LDLT). Median age of
the recipient 5 years old (5 months old–16 years old).
Twelve out of 14 living LTs were done from 1st degree
relatives, remaining two were from second and third
degree relatives respectively. Reason for LTs were ful-
minant liver (n = 6), trisonemia (n = 4), bilier atresia
(n = 3), cryptogenic cirrhosis (n = 3), PFIC (n = 2),
Wilson (n = 2), neonatal hepatitis (n = 1), a1 anti-trip-
sin deficiency (n = 1) respectively. Totally 9 (37%) sur-
gical complications encountered during follow-up:
vascular (n = 3), biliary (n = 3), other (n = 3). As vas-
cular complication: HAT (n = 2) and hepatic vein
thrombosis (HVT) (n = 1). Biliary complication: biliary
stenosis (n = 2), biliary leak (n = 1) and as others; post
surgical bleeding (n = 2), spontaneous small bowel per-
foration (n = 1). One of the HAT case was required re-
transplantation, after retransplantation patient died due
to sepsis on PO10. Other HAT case succesfully solved
by conventional radiology using stents without any
problem. HVT occurred in LDLT. Thrombosis
detected mid-intraparanchimal site of left vein of the
graft. Re-transplantation successfully performed at
PO1. One of the postsurgical bleeding case was
occurred at the Roux en-Y anastomosis and required
anastomosis revision, after the surgery, patient did well.
Other bleeding case was solved with medical treatment.
Spontaneous bowel perforation diagnosed at the PO10
day. Surgery was performed succesfully. Totally 5
(22%) patients died during median 79 days (66–
2475 days); hepatic artery thrombosis (n = 1), DIC
(n = 1), small for size syndrome (n = 1), sepsis (n = 1),
unknown (n = 1) respectively.
Conclusions: Pediatric liver transplantation is a chal-
lenging and rewarding field with continued improve-
ments in patient and graft survival. A multidisciplinary
team approach coupled with improvements in organ
availability.
PPLT24-002
LIVER TRANSPLANTATION TO GIANT
HEPATIC NEUROENDOCRIN TUMOR
Hakan Sozen, Utku Yilmaz and Aydin Dalgic
Gazi University, Turkey
Introduction: Neuroendocrine tumors (NET) comprise
a heterogeneous group of rare neoplasms. Liver meta-
static or primer hepatic NETs are amenable to various
therapeutic modalities including liver transplantation
(LT).
Method: Case: 45 years old woman, from another
country, suffers from dyspepsia, weight loss and early
satiety. She underwent blood analysis, it revealed, gam-
aglutamyl transferase and alkaline phosphatase as high
as 1,172 and 369 respectively. She was cachectic and
gross hepatomegaly detected in physical examination.
Computerized tomography of the abdomen revealed
12 9 18 cm in right and 8 9 6 cm tumor in the left
liver lobe. Intrahepatic bile ducts were dilated and there
was moderate amount of ascites in the abdomen. The
tumor had been accepted as unresectable from another
center. She admitted to our center. Liver biopsy was
performed; yielded primary liver NET or metastasis of
pancreatic NET. PET CT was performed and no tumor
other than liver was founded. Endoscopic ultrasound
(EUS) was performed, but did not find any pathology.
We considered her for living donor liver transplanta-
tion based on unresectable primer liver NET, no extra-
hepatic disease and well-differentiated tumor (Ki67
<10%) reasons. After her older brother was prepared
for living donor liver transplantation, right lob liver
transplantation was succesfully performed. Liver speci-
men revealed same with the pre-surgical biopsy. No
lymph node metastasis was found in the hilum of the
liver.
Results: She has been doing very well free of metastasis
3 years after surgery.
Conclusions: The use of LT for NET is controversial.
As organs are in short supply, it is important to select
patients who are most likely to benefit from this
demanding procedure. Beyond the consensual criteria,
i.e., it has been shown that the use of stringent criteria
to select patients for LT could achieve spectacular over-
all and disease-free survival rates.
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LIVER TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA
WITH NO VIABLE TUMOR CELLS AS A
RESULT OF LOCOREGIONAL
THERAPY
Sanghoon Lee, Choon Hyuck David Kwon, Hyung
Hwan Moon, Shin-Seok Yang, Jong Man Kim, Jae
Berm Park, Sung Joo Kim, Jae-Won Joh and Suk-Koo
Lee
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: Locoregional therapy (LRT) may be used
to treat hepatocellular carcinoma (HCC) prior to liver
transplantation (LT) as a bridging therapy. However, it
remains questionable whether these treatments can alter
the outcome of LT.
Method: From March 2002 to May 2010, 257 cases of
LT were performed for the treatment of HCC at Sam-
sung Medical Center (Seoul, Korea). A retrospective
review of medical records was done.
Results: All patients had HCC and hepatitis B virus-
related liver disease. Out of the 257 cases, 184 patients
(184/257, 71.6%) received any form of LRT prior to LT
as bridging therapy. Due to the treatment effect of these
LRT, 34 patients (34/184, 18.5%) had complete necrosis
of viable tumor cells and no viable HCC present in their
explants pathologic examination. Twenty-four patients
received transarterial chemoembolization, 10 patients
received radiofrequency ablation and 8 patients received
liver resection as their bridging therapy. Among the 34
patients, three patients experienced recurrence of HCC
following LT. Initial site of recurrence were the liver in
one case (24 months post-LT), and intra-abdominal
lymph node metastases in two cases (both 6 months
post-LT).
Conclusions: Good response to LRT for HCC resulting
in complete necrosis of viable tumor cells and subse-
quent LT leads to excellent survival outcomes.
PPLT24-004
OUTCOME OF LIVING DONOR LIVER
TRANSPLANTATION USING PARTIAL
LIVER ALLOGRAFTS WITH DUAL
ARTERIAL SUPPLY
Sanghoon Lee, Choon Hyuck David Kwon, Jin Yong
Choi, Wontae Cho, Seunghwan Lee, Jong Man Kim,
Jae Berm Park, Sung Joo Kim, Jae-Won Joh and
Suk-Koo Lee
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: When multiple donor hepatic arteries
(HA) are present in living donor liver transplantation
(LDLT), whether all HAs require reconstruction
remains debatable.
Method: From 2009 to 2013, 473 cases of LDLT were
performed at Samsung Medical Center. After exclusion
of ABO incompatible and retransplant cases, data of
429 cases were retrospectively reviewed. Our center’s
criteria for HA anastomosis in case of multiple HAs is
to check for pulsatile back-flow from the smaller HA
during the donor procedure and also during the recipi-
ent procedure. A priority is set on anastomosis of both
HAs, unless good pulsatile back-flow is evident during
donor and recipient procedures.
Results: Out of the 429 cases, 33 cases (33/429, 7.7%)
were done using liver allografts with 2 HAs. 16 were
right lobe (RL) grafts, 4 were left lobe (LL) grafts and
12 were left lateral section (LLS) grafts. Among the 16
RL grafts, we anastomosed both HAs in 6 cases and
one HA in 10 cases. The two groups did not show dif-
ferences in donor and recipient age, GRWR, cold
ischemia time, macro- and microscopic steatosis of the
graft, type of bile duct anastomosis and number of bile
duct anastomoses. Postoperative results showed similar
levels of maximum AST and ALT during the 1st post-
transplant week. Rate of biliary complications were not
different between the two groups. One case of HA
thrombosis occurred (both HAs anastomosis group).
Among the 16 LL and LLS grafts, we anastomosed
both HAs in 5 cases and one HA in 11 cases. The two
groups did not show differences in donor and recipient
clinical characteristics. Postoperative outcome were not
different between the two groups. No cases of HA
thrombosis occurred in both groups.
Conclusions: Using our criteria for HA anastomosis,
we were able to achieve similar outcomes among LDLT
cases using allografts with two HAs.
PPLT24-005
PRIMARY LIVING DONOR LIVER
TRANSPLANTATION IS NOT THE
OPTIMAL TREATMENT CHOICE IN
PATIENTS WITH EARLY HCC WITH
POOR TUMOR BIOLOGY
Min-Su Park, Kwang-Woong Lee, Suk-Won Suh, Tae
You, Jeong-Moo Lee, YoungRok Choi, Nam-Joon Yi
and Kyung-Suk Suh
Seoul National University Hospital, Korea
Introduction: Liver resection (LR) and living donor
liver transplantation (LDLT) are considered the two
potentially curative treatments for hepatocellular carci-
noma (HCC); however, it remains controversial which
is the best option for early HCC patients who are eligi-
ble for LR and LDLT. The aim of this study was to
investigate whether there is a difference in the oncolog-
ic outcomes between LR and LDLT according to
tumor biology.
Method: From February 1999 to October 2010, 336
HCC patients (137 LDLTs and 199 LRs) within the
Milan criteria were reviewed.
Results: Recurrence occurred in 99 cases (29.5%): 79
out of 199 (40.2%) patients in the LR group and 19
out of 137 (13.9%) patients in the LDLT group. Four
risk factors for recurrence were identified: preoperative
alpha-fetoprotein >200 ng/mL, Edmonson grade 3 or 4,
tumor size >3 cm, and presence of microvascular inva-
sion. The four groups according to number of risk
factors showed different recurrence-free survival (RFS)
and overall survival (OS). In the favorable tumor biology
patients (groups I and II), there was a significantly worse
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RFS in those patients who underwent LR compared to
those who underwent LDLT (group I, p = 0.002; group
II, p = 0.001). The OS rates in the LR and LDLT
groups were not different (group I, p = 0.798; group II,
p = 0.981). In the poor tumor biology patients (groups
III and IV), there was no significant difference between
the two groups in terms of RFS (group III, p = 0.342;
group IV, p = 0.616). The LDLT group showed a sig-
nificantly lower OS than the LR group (group III,
p = 0.001; group IV, p = 0.025).
Conclusions: Primary LDLT should not be recom-
mended in early stage HCC patients with poor tumor
biology because of lower survival rates and a high
chance of HCC recurrence.
PPLT24-006
ICAM-1 SHRNA ATTENUATES LIVER
INJURY AFTER WARM ISCHEMIA
REPERFUSION
Benjamin Navarro1, Douglas Quan2, Xusheng Zhang2,
Xiufen Zheng2, Antonio Jevnikar2 and Weiping Ming2
1Seoul National University Hospital, Korea; 2London
Health Science Centre, University Hospital, Canada
Introduction: LIRI is linked to deleterious inflamma-
tory effect associated with liver dysfunction and rejec-
tion in liver transplantation. LIRI results from oxygen
and nutrient deprivation for a period of time followed
by restoration of blood flow. ICAM-1 is a molecule
that can mediate neutrophil involvement, which is asso-
ciated with LIRI. One therapeutic approach to LIRI is
inhibiting cell adhesion by blocking ICAM-1 expres-
sion. In the present study we examine the effect of
downregulating ICAM-1 gene expression using shRNA
to protect liver from I/R injury.
Method: shRNA vectors were constructed for ICAM-1
gene. Induction of LIRI was conducted by interrupting
blood supply to the left lateral and medial lobes of the
liver for 45 minutes followed by 6 hours of reperfusion.
The effect of ICAM-1 shRNA was evaluated through
examination of liver function by measurement of level
serum (ALT) and (AST) as well as liver histopathology.
Neutrophil accumulation was determined by (MPO)
assay. Real time PCR was used to test gene silencing
efficacy in vivo and in vitro.
Results: We demonstrated that LIRI increases ICAM-1
mRNA levels in liver tissue 6 hours after reperfusion.
shRNA treatment effectively downregulated ICAM-1
gene expression in LIRI livers. ICAM-1 gene expres-
sion in the ICAM-1 shRNA treated group was 59%
lower than the scrambled shRNA group (p < 0.01).
The serum level of ALT in the shRNA treated group
was 62% lower than the scrambled (p < 0.01) and AST
in the shRNA treated group was 65% lower than the
scrambled shRNA group (p < 0.05). In addition, neu-
trophil accumulation detected by MPO was signifi-
cantly reduced in shRNA treated group (p < 0.05).
Furthermore, the ICAM-1 treatment group exhibited
less tissue necrosis and tissue hemorrhaging than the
scrambled group (p < 0.05).
Conclusions: This study shows that the downregulation
of ICAM-1 gene expression using shRNA attenuate
LIRI via inhibition of neutrophil cell adhesion.
PPLT24-007
DELAYED BILIARY COMPLICATION
AFTER WARM ISCHEMIC INSULT IN
RAT AND EFFECTS OF
IMMUNOSUPPRESSANTS
Geun Hong, Kwang-Woong Lee, Sukwon Suh, Tae
Yoo, Hyeyoung Kim, Min-Su Park, Youngrok Choi,
Nam-Joon Yi and Kyung-Suk Suh
Seoul National University Hospital, Korea
Introduction: The rat model of bile duct damage from
DCD has not been well established. The aim of this
study is to evaluate the warm ischemic bile duct dam-
age with rat and to evaluate the effects of immunosup-
pressants.
Method: Male Strague-Dawley rats (280–300 g, 6–
7 weeks old) were used. Proper hepatic artery was
ligated above gastroduodenal artery and then, portal
vein was clamped for 30 minutes. After operation, rats
were grouped as tacrolimus (T) or rapamune (S) medi-
cation groups and no medication (C) group. Each
groups comprised of 15 rats (total number was 45) and
each groups were divided by 3 subgroups by the day of
sacrifice (1, 3 and 6 weeks). Blood sampling was per-
formed at postoperative 1 day, 1, 2, 3, 4, 5, 6 weeks in
all rats and total bilirubin, ALP, ALT, GGT was eval-
uated. H&E and sirius red staining was performed for
evaluation of biliary hyperplasia and peribiliary fibro-
sis. The peribiliary fibrosis was evaluated by Sirius red
staining and image analyzer and the ratio (fibrotic area:
normal area) was evaluated in 8 areas in each slides.
Results: Rats were sacrificed at one week showed no
bile duct proliferation in the H&E stained liver tissue.
The laboratory results showed no significant difference
between groups. Liver tissue acquired at 1, 3, 6 weeks
after operation showed different trends of bile duct
hyperplasia and fibrosis in periductal area without sep-
tal fibrosis in H&E and sirius red staining according to
immunosuppressants (table). The mean ratio of fibrotic
area of each groups was 4.83 (C6w; range, 1.44–6.92),
2.43 (T6w; 0.75–6.57), 1.71 (S6w; 1.14–3.10).
Conclusions: Rapamune has a protective effect on
peribiliary fibrosis compared with control group
(p = 0.033) in contrast to tacrolimus (p = 0.145). We
need further study about biomolecular mechanism of
bile duct ischemic damage and delayed complication
and protective effects of immunosuppressant.
PPLT24-008
PERI-TRANSPLANT AFP LEVELS:
USEFUL MARKERS PREDICTING
TUMOR RECURRENCE AFTER LIVER
TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA
Tae Yoo, Kyung-Suk Suh, Kwang-Woong Lee,
Nam-Joon Yi, YoungRok Choi, Sukwon Suh and
Jeungnoo Lee
Seoul National University Hospital, Korea
Introduction: To investigate the clinical significance of
the peri-transplant AFP levels for predicting recurrence
in HCC patients who underwent liver transplantation.
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Method: We retrospectively reviewed the data from
231 HCC patients who underwent liver transplantation
between February 2000 and December 2010. Peri-trans-
plant AFP levels (pre-transplant level, 1 month post-
transplant level and level at recurrence) were analyzed
for patient distribution and recurrence free survival.
Results: Before liver transplantation, there were 106
patients who had normal AFP levels and 125 who had
high levels. Of 125 patients with high pre-transplant
AFP levels, 97 had normal AFP levels 1 month after
transplantation (Rapid normalized group) and 28 had
persistently high levels (Non-rapid normalized group).
Of rapid normalized group, 17 showed recurrence, of
whom 11 had high AFP levels and 6 had normal levels.
However, non-rapid normalized group, 24 showed
recurrences, whom all had high AFP levels after recur-
rence. In subgroup analysis, if the patients with very
high pre-transplant AFP (>200 ng/mL) had normalized
post-transplant AFP, these patients had good recur-
rence free survival (RFS) as patients with normalized
post-transplant AFP level (Mean RFS = 99 vs
115 months, p = 0.24). But, if patients with not so high
pre-transplant level (20 < pre-transplant
AFP ≤ 200 ng/mL) had persistently high post-trans-
plant AFP, they had poor outcomes as patients with
persistently elevated post-transplant level (Mean
RFS = 3 vs 25 months, p = 0.1). Pre-transplant AFP
levels <20 ng/mL (p < 0.001), and normalized post-
transplant AFP levels (p < 0.001) showed significantly
better recurrence RFS rates. Also, in 125 patients with
high pre-transplant AFP, post-transplant AFP levels
(HR = 14.4, p < 0.001) as well as sex (HR = 3.2,
p < 0.032), tumor size (HR = 1.1, p = 0.001), microvas-
cular invasion (HR = 2.6, p = 0.005) were independent
risk factors for RFS in multivariated analysis.
Conclusions: Not only pre-transplant AFP but also
especially post-transplant AFP may provide useful clin-
ical information concerning recurrence in HCC patients
who underwent liver transplantation.
PPLT24-009
EFFECTIVE BALLOON-OCCLUDED
RETROGRADE TRANSVENOUS
OBLITERATION OF THE SMV-IVC
SHUNT IN A PATIENT WITH HEPATIC
ENCEPHALOPATHY AFTER LDLT
Zhassulan Baimakhanov, Akihiko Soyama, Mitsuhisa
Takatsuki, Yusuke Inoue, Hajime Matsushima,
Masaaki Hidaka, Amane Kitasato, Tamotsu Kuroki
and Susumu Eguchi
Nagasaki University Graduate School of Biomedical
Sciences, Japan
Introduction: Balloon-occluded retrograde transvenous
obliteration (BRTO) has become a common and effec-
tive procedure for treating hepatic encephalopathy due
to a portosystemic shunt related to cirrhosis of the
liver. However, this method of treatment has rarely
reported in patients after liver transplantation. We
herein report the case of a 52-year-old patient who
underwent living donor liver transplantation (LDLT)
due to a hepatitis C virus-infected hepatocellular carci-
noma that was complicated with portal vein thrombosis
and a large portosystemic shunt between the superior
mesenteric vein (SMV) and inferior vena cava (IVC).
Method: BRTO was performed according to the
method reported by Kanagawa et al. In brief, a 6-Fr
balloon catheter was introduced into the SMV-IVC
shunt via the right femoral vein. The SMV-IVC shunt
was visualized after retrograde venography using Io-
pamiron 300 contrast medium. Interlocking detachable
coils were used to embolize the small outflow vessels.
The sclerosing agent was a mixture of n-butyl-cyanoac-
rylate and Lipiodol (ratio=1:4) and the total volume
inserted through the 1.8 Fr microcatheter was 4 mL.
Results: After BRTO, control venography showed the
disappearance of the portosystemic shunt with suffi-
cient filling by the sclerosing agent. No complication
occurred during the procedure. Subsequently, the
patient’s blood ammonia level decreased to within the
normal range, and she has not experienced any epi-
sodes of hepatic encephalopathy since then. Presently,
nine months after BRTO, the patient is well, and fol-
low-up CT has shown no evidence of the portosystemic
shunt, with sufficient hepatic blood flow.
Conclusions: BRTO is therefore considered to be an
effective management strategy for portosystemic
encephalopathy that preserves the hepatic function
after LDLT.
PPLT24-010
INTERRUPTED BILIARY
RECONSTRUCTION IN LIVING DONOR
LIVER TRANSPLANTATION
Hossam Eldeen Soliman1, Tarek Ibrahim1, Hany
Shoreim1, Osama Hegazy1, Sherif Saleh1, Taha
Yassen1, Khaled Abuellella1, Wael Abdelrazek2 and
Ibrahim Marwan1
1National Liver Istitute, Egypt; 2National Liver
Institute, Menoufia University, Egypt
Introduction: Living donor liver transplantation
(LDLT) is a good alternative in areas without cadav-
eric transplants. Biliary variations are common up-to
40–50% of donors. The incidences of biliary complica-
tions are high especially in living donor and segmental
transplantation. We present the results of our technique
of biliary reconstruction of living donor transplants
using interrupted sutures.
Method: We had performed 210 consecutive living
donor liver transplantation in the department of Sur-
gery, National Liver institute, Menoufia University
starting from April 2003 to the end of August 2013.
They were 177 adults and 33 pediatric patients. We
used a magnification of 3.59 and 5.59 loupe with
interrupted 6/0 prolene or PDS for the anastomosis.
We reviewed graft characteristics, operative data, post-
operative details including hospital stay, the in-hospital
complications and early follow up.
Results: One hundred andeighty duct to duct recon-
struction and 30 hepaticojejunostomies were done.
There were 174 cases were done that were compared to
37 were used a posterior continuous and anterior inter-
rupted technique and two contiuous sutures were used.
Prolene sutures were used in 166 cases and PDS sutures
in 44 cases. The rate of biliary complications is 21%.
© 2014 The Authors
HPB 2014, 16 (Suppl. 2), 550–602 HPB © 2014 Americas Hepato-Pancreato-Biliary Association
Poster Panel [Liver Transplantation] 553
Conclusions: Interrupted biliary reconstruction mini-
mized the incidence of biliary complications in our cen-
ter.
PPLT24-011
RECURRENT DISEASE AFTER LIVING
DONOR LIVER TRANSPLANTATION:
RISK FACTORS, MANAGEMENT AND
OUTCOME
Emad Hamdy Salem, Tarek Ibraheem, Amr Helmy,
Maher Osman, Hesham Abdeldaem and Ibraheem
Abdelkader
National Liver Institute, Menoufiya Uneversity, Egypt
Introduction: The threat to the success of liver trans-
plantation is the recurrence of the original disease.
Although the initial concern about recurrent disease
mainly related to viral hepatitis, recurrence of nonviral
liver disease has been shown to lead to graft failure.
This study aimed to analyze the factors responsible for
disease recurrence after LDLT and the effect of disease
recurrence, and its management on the outcome of LT.
Method: After exclusion of (6 months mortality), 45
alive transplanted patients were enrolled in the current
analysis in the follow up duration from 6 to 60 months
(the demographic, preoperative, intraoperative, and
postoperative data) were studied. Univariate analysis
and then multiple analysis were done to detect the rela-
tionship between the previous data and overall recur-
rence, and between recurrence variables, and total
survival after LDLT.
Results: The 45 patients were classified according to
age into pediatrics <18 years, and adults >18 years.
The pediatric group were 14 patients (31.1%), and the
incidence of recurrence of primary disease was 1/14
(7.1%), this case was Budd Chiari syndrome. The all
pediatric mortality was 4/14 ((28.6%). The adult group
were 31 patients (68.8%), and the incidence of recur-
rence was 15/31 (48.4%) of patients. On univariate
analysis, there was no statistically significant predictors
of recurrence regarding mentioned data. The survival
of all, non recurrent, and recurrent adults was 83.9%,
93.7%, and 73.3% respectively.
Conclusions: Recurrence of primary disease after LDLT
was higher in the following (males, with CMV infections,
with co-morbidity and patients with acute rejection). It
decreases post transplantation Survival. However the
effective management of it improves survival.
PPLT24-012
GRAFT CALCIFICATION AFTER LIVER
TRANSPLANT IN PEDIATRIC
PATIENTS, 2 CASE REPORTS
Carlos Derosas1, Fabiola Vargas2, Gloria Gonzalez1,
Ximena Ortega1, Karla Moenne1, Mario Uribe1, Bessie
Hunter1, Mario Ferrario1 and Erwin Buckel1
1Clinica Las Condes, Chile; 2Hospital Luis Calvo
Mackenna, Chile
Introduction: Graft calcification is an extremely uncom-
mon complication in liver transplant (LT). In our expe-
rience in pediatric patients there are our two first cases.
Results: CASE 1: 14-month-old and 8.5 kg infant,
underwent LT for Biliary Atresia related cirrhosis. II-
III liver segments of a living donor were used. Patient
develops a primary graft dysfunction with partial
improvement. Abdominal CT angiography showed cal-
cic density in several areas of hepatic parenchyma.
Hepatic biopsy showed severe portal and centrilobular
post ischemic injury. His clinical status deteriorated, he
developed biliary complications and hemorrhagic events
deteriorating his clinical status dying 99 days after LT
due a pulmonary hemorrhage.
CASE 2: A 56 days old and 3.4 kg infant, underwent
LT for neonatal hemochromatosis related cirrhosis.
Cadaveric donor was used. Extensive backtable surgery
to achieve a monosegment graft. The patient developed
primary graft dysfunction, with progressive improve-
ment of synthetic function. A 21-day abdominal dopp-
ler ultrasound showed a heterogeneous liver
parenchyma, the abdominal CT angiography showed
parenchymal areas with calcic density that become con-
fluent in the inferior and anterior aspect of the graft,
additionally calcinosis related to the surgical wound.
Six days after a control CT angiography showed a
mayor calcic intensity in a similar distribution com-
pared the previous exam. 40 days after LT the patient
has improved her liver function near to normalize.
Conclusions: Graft calcification after LT is a low fre-
quency entity that we had not seen in our series. Pub-
lished reports give it an ominous connotation, and its
pathogenesis is related to the ischemia/reperfusion
injury to the structure and function of the hepatocyte.
PPLT24-013
NO INFLUENCE OF SUTURING
METHOD AND SUTURE MATERIAL ON
ANASTOMOTIC BILE DUCT
STRICTURE IN DBD LIVER
TRANSPLANTATION
Aliaksei Shcherba1, Dmitriy Ashurkevich2, Vyacheslav
Erokhov1, Sergey Korotkov1 and Aleh Rumo1
1Minsk Center for Organ and Tissue transplantation,
Belarus; 2Belorussian State Medical University, Belarus
Introduction: The aim of study was to evaluate the
impact of suturing method and suture material on
anastomotic bile duct strictures in DBD liver transplan-
tation (LTx).
Method: A retrospective study of prospective cohort of
patients was conducted. Suturing method was deter-
mined by protocol, based on the bile duct diameter: up
to 4 mm - interrupted sutures; 5–6 mm - continuous
suturing on posterior wall, interrupted sutures on ante-
rior wall; 7 and more mm - continuous suturing. Sutur-
ing material (prolene or PDS) was randomized
according to surgeon. Cases of choledochojejunostomy
and pediatric under 12 years old were excluded. 165
medical records of patients who underwent DBD LTx
with duct-to-duct anastomoses in a period from Jan
2009 to July 2013 were analyzed. Anastomotic stric-
tures developed in 19/165 cases (11.5%). Suturing
material data were available for 142 cases. The proto-
col include heparin administration to donor and recipi-
ent, flushig the bile from ducts in donor, use of
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streptokinase, pressure back table arterial perfusion,
shortening the donor duct before suture, no duct tubes.
Results: The rate of anastomotic strictures, 2 of 13
(15.3%), after interrupted compared to all other sutur-
ing methods, 17 of 152 (11.1%) was not different
(p = 0.64). The rate of anastomotic strictures, 11 of 80
(13.7%), after continuous compared to all other sutur-
ing methods, 8 of 85 (9.4%) was not different
(p = 0.46). Suturing material did not influence the rate
of anastomotic strictures: 9 of 56 (16%) for PDS and 5
of 86 (5.8%) for prolene (p = 0.08). In our study, we
found no impact of suturing method and suture mate-
rial on biliary strictures.
Conclusions: In the setting of protocol based managing
of bile ducts, adapted to their diameter, surgical tech-
nique and suturing material had no influence on biliary
anastomotic strictures rate.
PPLT24-014
TO REPORT OUR EXPERIENCE WITH
SEQUENTIAL LIVER AND KIDNEY
TRANSPLANTATION IN 2 PATIENTS,
BOTH ORGANS FROM A SINGLE
DONOR
Vivekanandan Shanmugam1, Gomathy Narasimhan2,
Chandrasekhar V3, Ram Prabhakar3, Rajasekhar
Perumalla4, Srinivas Reddy5, Thomas Cherian6, Rajesh
Rajalingam7, Anand Bharathan8 and Mohamed Rela9
1FRCS, India; 2MS, ASTS USA, India; 3MD, DM
Nephrology, India; 4MS, DNB, FRCS, India; 5MS,
DNB, FRCS, PhD, India; 6FRCS Gen, FRCS, India;
7M Ch GI Surgery, Postdoctoral fellowship in Liver
Transplantation, India; 8DNB GI Surgery, Postdoctoral
fellowship in Liver Transplantation, India; 9MS, FRCS,
India
Introduction: We report our experience with sequential
liver and kidney transplantation in 2 patients, both
organs from a single donor.
Method: Cinical details of donors and patients who
underwent sequential liver and kidney transplantation
were analyzed.
Results: A total of 250 Liver transplants were done
from October 2009 to August 2013. Out of this 11
combined Liver and Kidney Transplants were done
and 2 of these were sequential. Both the recipients had
primary hyperoxaluria with end stage renal failure.
Both donor and recipient underwent thorough evalua-
tion. The donors had no co -morbidities and were suit-
able according to criteria set for donor hepatectomy
and donor nephrectomy.
A total of 250 Liver transplants were done from Octo-
ber 2009 to August 2013. Out of this 11 combined
Liver and Kidney Transplants were done and 2 of these
were sequential Liver and Kidney transplants. Both the
recipients had primary hyperoxaluria with end stage
renal failure secondary to hyperoxalosis. Both donor
and recipient underwent thorough evaluation. The
donors had no co -morbidities and were suitable
according to criteria set for donor hepatectomy and
donor nephrectomy. Donor for first recipient was
19 year old elder brother and donor for second was
44 year old mother. Former donor underwent left lat-
eral sectionectomy and latter donor underwent right
hepatectomy. No major donor morbidity occurred.
Recipient outcome was excellent.
Conclusions: SLKT can be safely done from the same
donor and requires good assessment of the donor and
recipient and planned execution of the sequential pro-
cess. The time interval allowed between the two trans-
plants allows both the donor and the recipient to
recover from the Liver transplant and makes the renal
transplant safe.
PPLT24-015
IS FACTOR V LEIDEN A
CONTRAINDICATION FOR LIVER
DONATION IN LIVING DONOR LIVER
TRANSPLANTATION?
Kumar Palaniappan, Olithselvan J, Naresh
Shanmugam, Joy Verghese, Vivekandan Shanmugam,
Gomathy Narashiman, Srinivas Reddy, Thomas
Cherian and Mohammed Rela
Global Hospitals & Health City, Chennai, India
Introduction: Hepatic artery thrombosis (HAT) after
orthotopic liver transplantation (OLT) is associated
with significant morbidity and mortality. The incidence
of HAT after liver transplantation is about 2.9% in
adults and 8.3% in children with an overall rate of
4.4%. Factor V Leiden mutation (FVL) is the most
common genetic defect that predisposes to thrombosis.
The overall prevalence of heterozygous carriers of 7%,
varies among populations. The presence of FVL is a
documented risk factor for venous thromboembolism
(VTE).
Method: From January 2010 to July 2013, 240 OLT
were done at Institute of Liver Transplantation, Global
Hospitals, Chennai. Of these 160 were LDLT & rest 90
were DDLT. All potential donors are routinely
screened for thrombotic profile which includes factor V
Leiden mutation, protein C, protein S, anti-thrombin
III, anti cardiolipin antibody. Factor V Leiden is con-
sidered a contraindication for organ donation, since it
can be transmitted in the organ.
Results: Till now we have done two LDLT using
donors with Factor V Leiden mutation. Case 1 an etha-
nol related Child C Cirrhosis & donor was his sister
35 years who had factor V Leiden mutation. Recepient
was a heterozygote & had an uneventful recovery after
right lobe liver transplantation. He remains asymptom-
atic after 18 months following OLT. Case 2, was a
6 year child with Tyrosenemia & HCC (Post TACE
Status). Father the donor for left lateral segment &
child made an uneventful recovery. At follow up of
6 months, both donor & recepient have made an
uneventful recovery.
Conclusions: Utilization of grafts from these donors will
require an individualized assessment of the risks and
benefits offered to potential transplant recipients, simi-
lar to the assessment used for recipients of other mar-
ginal graft donors. Further work will be required to
validate these conclusions regarding the potential safety
of transplants using this unique donor population.
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PPLT24-016
SELECTION CRITERIA FOR LIVER
TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA
WITH PORTAL VEIN THROMBOSIS
USING TUMOR BIOLOGIC MARKERS
Kwang-Woong Lee, Kwang-Woong Lee, Tae Yoo,
Suk-Won Suh, Jeong-Moo Lee, Benjamin Navarro,
Ange Garcia, Nam-Joon Yi and Kyung-Suk Suh
Seoul National University Hospital, Korea
Introduction: We analyzed our experience with liver
transplantation (LT) for hepatocellular carcinoma
(HCC) with portal vein thrombosis (PVT) to assess the
efficacy of selection criteria using tumor biologic mark-
ers.
Method: 15 patients, with HCC combined by PVT
without systemic metastasis, who underwent liver trans-
plantation from January 2005 to February 2013 were
investigated retrospectively. Outcomes were compared
for patients who met the biologic criteria (AFP ≤200
and PIVKA-II ≤400) with patients beyond the biologic
criteria.
Results: At mean follow up of 20.1  13.9 months,
recurrence rate was 60%. 5 patients who meet the bio-
logic criteria had no recurrence of HCC and no death
at 3 years. Recurrence and overall survival rate for 10
patients with HCC with PVT beyond the criteria were
90% and 53% at 3 years. Disease free survival for
these patients was 40%, 30% and 10% at 6-month, 1-
year and 3-years respectively and was significantly
lower than patients within the biologic criteria
(p = 0.008). There were no significant differences in
tumor maximal size (median 2.4 cm vs 5.5 cm,
p = 0.95), tumor number (3.76 vs 1.86, p = 0.744),
HCC PET positivity (100% vs 90%, p = 0.343), Ed-
monson pathologic grade (worst / major 3.4 / 2.75 vs
3.25 / 2.56, p = 0.603 / p = 0.577), microvacular inva-
sion (100% vs 90% p = 0.343) between these patient
groups.
Conclusions: The biologic criteria using AFP and PIV-
KA are reliable in selection of suitable candidates for
LT for HCC with PVT.
PPLT24-017
A SMALL NATION WITH BIG DREAMS
Leonardo Santamaria-Galeotti
Caja del Seguro Social, Panama
Introduction: Panama, a small country in Central
America with strong economic growth over the past
10 years. Known worldwide mainly by the Panama
Canal through which a ship can cross the Pacific Ocean
to the Atlantic and vice versa.
Method: Less than 3 years ago, were held in Panama
only kidney transplant as a solid organ. A team of sur-
geons and hepatologist all trained in Spain started the
program cadaveric donor liver transplantation. It per-
forms the first successful liver transplant March 24,
2011 in a woman with autoimmune liver cirrhosis.
After having bad results with greater mortality than
50% in the first year, there were major changes to the
trained human resources, we obtained better instru-
ments and more stringent inclusion criteria to enter the
waiting list.
Results: Has been achieved in the last year encouraging
results in terms of morbidity and mortality in our
patients. In the last year between August 2012 and
August 2013 we performed 10 transplants with a mor-
tality of 10% (1 death the first day postoperative coag-
ulopathy refractory). Reaching a transplant rate of 2.8
per million population (the best in our region). Cur-
rently we have 7 active patients on the waiting list and
we are including an average of 2 patients each month.
At this moment I am doing a rotation of 3 months in
the Division of Liver Transplantation and Hepato-Bili-
ary Surgery Asan Medical Center, Seoul, Korea, lead-
ers worldwide in live donor liver transplantation. This
with the idea of consolidating our knowledge and sur-
gical technique and hoping that in future can begin
with living donor transplantation in our country.
Conclusions: Our short term goal is to achieve mortal-
ity rates globally accepted and be leaders in our region
of Central America and the Caribbean in terms of
transplantation rate (number of transplants per million
population).
PPLT24-018
COMPARISON FOR RECURRENCE OF
HEPATOCELLULAR CARCINOMA
BETWEEN ABO COMPATIBLE AND
ABO INCOMPATIBLE LIVING DONOR
LIVER TRANSPLANTATION
Bo Hyun Jung, Shin Hwang, Deok Bog Moon, Chul
Soo Ahn, Ki Hun Kim, Tae Yong Ha, Gi Won Song,
Dong Hwan Jung and Sung Gyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: ABO incompatible (ABOi) living donor
liver transplantation (LDLT) is an effective counterplan
for shortage of deceased donors. Since we started ABOi
adult LDLT at 2008, cases of ABOi LDLT have
increased up to 20% of whole LDLT in our hospital.
The number of LDLT for hepatocellular carcinoma
(HCC) has increased yearly to 50.3% (150 cases) of
adult LDLT in 2011. In same year, the number of
ABOi LDLT for HCC was up to 44 cases. We analyze
the results of recurrence after living donor liver trans-
plantation for HCC and compare the result between
ABO compatible and ABOi LDLT.
Method: From November 2008 to February 2013, 365
patients underwent LDLT for HCC. We classify the
patients as ABO compatible LDLT group and ABOi
LDLT group and analyze liver function, status of
HCC, and level of tumor marker retrospectically.
Results: There were numbers of recurrence for HCC
after LDLT; 330 patients in ABO compatible LDLT
group and 35 patients ABOi LDLT group. There were
no differences in age, sex, MELD score. According to
Milan, USCF and AMC criteria, there were no differ-
ences of patients number between two groups. AFP
level showed 164  63 ng/mL in ABO compatible
LDLT group versus 91  38 ng/mL in ABOi LDLT
group but there was no difference in statistically
(p = 0.308). The size of HCC showed 3.08  2.7 cm
in diameter (ABO compatible LDLT) versus
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3.76  3.6 cm in diameter (ABOi LDLT; p = 0.118).
The numbers of HCCs revealed 1.6  1.7 HCCs (ABO
compatible LDLT) versus 2.9  5.0 HCCs (ABOi
LDTL; p = 0.006).
Conclusions: There were no differences in statistically
of preoperative status of HCC between ABO compati-
ble LDLT and ABOi LDLT groups. Henceforword, we
must follow up and compare the survival rate and
recurrence free survival rate between two groups.
PPLT24-019
STRESS-INDUCED CARDIOMYOPATHY
AFTER LIVER TRANSPLANTATION
Bo Hyun Jung, Shin Hwang, Deok-bog Moon, Chul
Soo Ahn, Ki Hum Kim, Tae Yong Ha, Gi Won Song,
Dong Hwan Jung and Sung Gyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: Cardiac complications after liver trans-
plantation could lead patients up to death. Stress-
induced cardiomyopathy (sCMP) is the special form of
cardiomyopathy that is precipitated by a stressful situa-
tion. There are much stressful conditions in liver trans-
plantation which makes hemodynamic changes and can
have effects on cardiovascular functions.
Method: I present progresses of 2 patients who ocurred
revisable sCMP at immediately posttransplant period.
Results: A 63-year-old male underwent living donor
liver transplantation due to HBV LC HCC with
MELD score 12. He had been controlled atrial fibrilla-
tion (Af) by medicines and his preoperative echocardio-
gram (ECHO) showed normal. At postoperative 6th
day, his electrocardiogram had shown persistent Af
with RVR. At that time, ECHO had shown LVEF
21% with akinesia of both ventricular apex, so we had
applied ECMO (extracorporeal membrane oxygenation)
Venous-Arterial (V-A) mode. After 10 days from event,
follow-up ECHO showed resolutioin of sCMP with
normal LV systolic function (LVEF 60%). During his
condition under ECMO and sCMP, his liver function
was not changed and just normal. A 52-year-old male
had caerd before transplantation because of HBV LC
variceal bleeding with MELD score 25. Preoperative
ECHO had shown nonvalvular atrial fibrillation with
normal LV systolic function (EF 56%). He underwent
deceased donor liver transplantation. After 2 days, his
rhythm showed persistent Af and hypotension. At that
time, ECHO showed LVEF 17% with severe biventric-
ular failure due to sCMP, so he had been applied
ECMO V-A mode. After 4 days from event, follow-up
ECHO showed improvement of biventricular failure
with normal biventricular systolic function (LVEF
58%). In those days of sCMP, liver enzymes had ele-
vated to 6000 IU/mL but slowly recovered.
Conclusions: In both cases, cardiac function recovered
from sCMP completely. But cardiac dysfunction could
make transplanted graft ischemia and mortality. In
these cases, ECMO became useful modality for sCMP.
PPLT24-020
PROBLEMS IN TEN-YEAR SURVIVOR
AFTER LIVER TRANSPLANTATION
Lee Jisoo, Wontae Cho, Jin Yong Choi, Seunghwan
Lee, Hyunghwan Moon, Jong Man Kim, Choon
Hyuck David Kwon, Jae-Won Joh and Suk-Koo
Lee
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: There have been few studies of liver
transplant recipients more than 10 years. Chronic kid-
ney disease (CKD) was considered as an important
complication after liver transplantation (LT). We
described the clinical factors of long-term survivors
(>10 year) and compare the characteristics of patients
with and without CKD.
Method: We performed a retrospective analysis of the
medical records of survivors (n = 108) in recipients
who received liver transplantation between 1996 and
2002.
Results: Sixty-one patients received liver graft from liv-
ing donor and 47, deceased donor. The main indication
of LT was hepatitis B virus (HBV) or HBV-related
hepatocellular carcinoma (HCC; n = 93, 86.1%). CKD
developed in 27 patients (25.0%). Among them, three
patients received kidney transplantation. Two patients
did not received immunosuppression and 23 patients,
mycophenolate mofetil monotherapy. Median concen-
tration of tacrolimus was 2.8 ng/mL (range 0.5–9.5 ng/
mL). Fourty-six patients experienced biopsy-proven
acute rejection and 6 patients had malignancy. Four
patients died after 10 years because of heart failure
(n = 2), hemoperitoneum from unknown origin (n = 1),
and sepsis (n = 1). The proportion of male gender in
patients with CKD was higher than in patients without
CKD (p = 0.035). Age at transplantation, serum creati-
nine and estimated glomerular filtration rate (eGFR)
level prior to LT in patients with CKD were higher
than those in patients without CKD (p = 0.013 and
p < 0.001, respectively).
Conclusions: The renal function of patients who survive
more than 10 years after LT and have the risk factors
of CKD should be carefully monitored.
PPLT24-021
HEPATIC ARTERY THROMBOSIS
AFTER LIVER TRANSPLANTATION: 2
CASE REPORTS
Young Mok Park, Kwang-Ho Yang, Je-Ho Ryu,
Ki-Myung Moon and Chong-Woo Chu
Pusan National University Yangsan Hospital, Korea
Introduction: Hepatic artery thrombosis (HAT) is a
devastating complication after liver transplantation,
occurs in 3–9% of adult transplantation recipients and
it’s the most frequent arterial complication in liver
transplantation. There are numerous nonsurgical and
surgical factors including multiple rejection episodes, a
long cold ischemic time, cytomegalovirus infection,
excessive transfusion of fresh frozen plasma, cigarette
smoking, immunologic factors, coagulation abnormali-
ties, and ABO incompatibility. Treatment of HAT
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could be performed by radiological intervention. But in
some cases, may consider thrombectomy and angio-
plasty, retransplantation.
Method: Between May 2010 and April 2013, we per-
formed 105 cases of liver transplantation. HAT
occurred in 2 cases performed LDLT in our institution.
Results: CASE 1: 52-year-old man presented with
hepatocellular carcinoma (HCC) and biliary cirrhosis.
The patient underwent LDLT. On the postopeative day
(POD) 4, total bilirubin and liver enzyme elevated con-
tinuously. Checked CT showed stenosis of hepatic
artery anastomotic site and liver ischemia. Serial angi-
ography showed hepatic artery thrombosis and occlu-
sion. Stent insertion and urokinase thrombolysis was
done, but no blood flow was checked. On the next day,
the patient underwent re-transplantation (DDLT).
Thereafter, the patient’s condition was improved well,
but after 1 month, diagnosed acute cellular rejection.
CASE 2: 57-year-old man presented with HCC and
hepatitis B related liver cirrhosis. He underwent liver
resection once and 7 times transarterial chemoemboli-
zation (TACE) previously due to recurrent HCC. The
patient underwent LDLT. But the routine checked CT
showed nonocclusive thrombosis in the common hepa-
tic artery on Pod 6. On the next day performed stent
insertion. We found out partial thrombosis in the celiac
artery after 5 days. And angiography and stent inser-
tion were done. Since then, the patient was improved
without other complications and discharged on Pod 22.
Conclusions: Early diagnosis and treatment is the most
important key for prevention of several devastating
results for HAT.
PPLT24-022
INITIAL EXPERIENCE OF LIVER
TRANSPLANT IN A WELL TRAINED
TEAM
Chong-Woo Chu, Young-Mok Park, Kwang-Ho Yang,
Je-Ho Ryu and Ki-Myung Moon
Pusan National University Yangsan Hospital, Korea
Introduction: Beginning liver transplantation (LT) pro-
grams have always accompanied by lots of trial and
error and time consuming. This error and duration will
be minimized and shortened by a well trained team.
Method: Three of our five LT surgeons were trained in
the Asan Medical Center (AMC) from 2 to 4 years.
Many LT related faculties and nurses were also edu-
cated for one month in AMC. Our new LT program in
a new hospital initiated from May 2010. There was no
successful LT program in Kyungnam and Pusan area
until our LT team established. 120 LT performed from
May 2010 to August 2013 were reviewed retrospec-
tively.
Results: LDLT was 75 cases and DDLT was 45 cases.
All cases underwent without portosystemic shunt. We
commonly used caudal middle hepatic vein preserving
right lobe from May 2012. 30% of LDLT was carried
out without transfusion and all donor operation was
also performed with no transfusion. No living donor
mortality was encountered and morbidity occurred in
5.3%. All donors returned to their normal pretrans-
plantation activity. 54% of recipients were combined
with HCC and it was mainly related with hepatitis B
(77%). Their one year survival rate was 94.2% and
recurrence free survival was 83.5%. Recurrence rate
was 4.7% in inner Milan and 27% in above Milan.
About 40% of recipients had acute liver failure and
acute on chronic liver failure. Their 1 year survival rate
was 81.8%. One case that had biliary cirrhosis devel-
oped hepatic artery thrombosis after LDLT. The
patient underwent cadaveric retransplantation and
recovered well. Outflow problem occurred in 12.5%
and biliary complication was accompanied in 13.3%.
Conclusions: Our team experienced many LT cases for
relatively short period and early result was comparable
with the major centers. It might be a result of excellent
teamwork by a well trained team.
PPLT24-023
COMPARISION OF PATIENT
SATISFACTION ACCORDING TO
DIFFERENT INCISION METHODS FOR
DONOR
Suk-Won Suh, Kwang-Woong Lee, Jeong-Moo Lee,
Tae You, Youngrok Choi, Nam-Joon Yi and
Kyung-Suk Suh
Seoul National University Hospital, Korea
Introduction: As a donor age is becoming less and
female ratio is becoming more, a large abdominal inci-
sion is a major concern of some live donors and sur-
geons especially in terms of cosmetic appearance.
Method: A total of 336 donors who underwent donor
hepatectomy for living donor liver transplantation from
April 2010 to December 2012 were analyzed. Donors
were divided into 2 groups by the type of incision as
conventional group (n = 214) and minimal incision
group (n = 122) including upper midline incision
(n = 110) and transverse incision using laparoscopy
(n = 12). Demographics, clinical outcomes of donor
and recipient and patient satisfaction of cosmetic
appearance using a questionnaire were compared.
Results: In demographics, mean age was younger (28.1
vs 34.6 year, p = 0.000), female ratio was higher
(30.4%, 40.2%, p = 0.068) and BMI was lower (23.3 vs
22.5 kg/m2, p = 0.024) in conventional group than min-
imal incision group. Mean operation time (274.8 vs
267.7 minutes, p = 0.188) and hospital stay (9.4 vs
8.5 day, p = 0.000) was shorter in minimal incision
group than conventional group. Peak level of aspartate
transaminase (144.8 vs 161.5 IU/L, p = 0.014) and ala-
nine transaminase (141.3 vs 161.4 IU/L, p = 0.025)
were more elevated in minimal incision group than con-
ventional group. There was no significant difference in
postoperative morbidity and mortality of donor and
recipient in both groups. Donor satisfaction using ques-
tionnaire showed more satisfactory of cosmetic view
(p = 0.01) and self-confidence (p = 0.001) in minimal
incision group than conventional group. Sense ofdull-
ness or numbness on scar was more prominent in con-
ventional group than minimal incision group which
upper midline incision only included (40.0% vs 13%,
p = 0.027).
Conclusions: Minimal incision is technically feasible
and safe for donor hepatectomy and it also achieved
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higher patient satisfaction levels from improved cos-
metic outcomes than conventional incision.
PPLT24-024
INFLUENCE OF LIVER CONGESTION
ON THE RECURRENCE OF
HEPATOCELLULAR CARCINOMA
AFTER LIVING DONOR
Suk-won Suh, Jeong-Moo Lee, Tae You, Youngrok
Choi, Nam-Joon Yi, Kwang-Woong Lee and
Kyung-Suk Suh
Seoul National University Hospital, Korea
Introduction: Living donor liver transplantation
(LDLT) has emerged as a valuable alternative treat-
ment option for hepatocellular carcinoma (HCC). Liver
congestion is caused by interruption of regional venous
outflow and a certain extent of congestion on graft is
inevitable in LDLT. It might have an influence on clini-
cal outcomes. Therefore, we investigated the influence
of congestion on the recurrence of HCC after LDLT.
Method: A total of 153 patients with HCC within
UCSF criteria who underwent LDLT using right-hemi-
graft between November 1999 and February 2012 were
investigated. The patients were divided into two groups
according to the degree of congestion assessed by
multi-detector helical computed tomography (CT) using
a software program (Rapidia 2.0, infinitt, Seoul,
Korea). Group A, congestion ratio of belonged section
(CR) <10%, group B, CR ≥10%. Demographics, post-
operative laboratory results, morphologic changes of
graft after 6 month at CT, and presence of tumor
recurrence were analyzed.
Results: There was no significant difference of demo-
graphics including tumor characteristics in both groups.
Tumor recurrence was significantly more in group B,
30.4%, compared with group A, 9.7% (p = 0.004). Site
of tumor recurrence was no different in both groups
(p = 0.093). In multivariative analyses, congestion
>10% (p = 0.026), microvascular invasion (p = 0.001),
AFP >200 (p = 0.031) were significantly related to
tumor recurrence. Peak postoperative laboratory results
of AST (296.26 vs 227.53, p = 0.050), ALT (382.91 vs
276.98, p = 0.042), and HS CRP (5.41 vs 3.55,
p = 0.000) were more elevated in group B. After
6 months post transplantation, none had residual con-
gestive liver at CT findings. Overall regeneration rate
was similar in two groups, but the imbalance of regen-
eration rates of two sections with and without conges-
tion were prominent in group B (p = 0.012).
Conclusions: Congestion of the graft can cause ische-
mia, necrosis, and inflammatory reaction of affected
hepatic parenchyma, with compensatory regeneration
of adjunct non-congested area. These factors may pro-
mote the recurrence of HCC, therefore, liver congestion
should be minimized in LDLT for HCC.
PPLT24-025
A NOVEL PROTOCOL FOR ABO
INCOMPATIBLE LIVING DONOR
LIVER TRANSPLANTATION WITHOUT
GRAFT LOCAL INFUSION AND
SPLENECTOMY
Seung Duk Lee and Seong Hoon Kim
National Cancer Center, Korea
Introduction: Graft local infusion and splenectomy have
been established as pivotal strategies in ABO incompati-
ble (ABO-I) living donor liver transplantation (LDLT).
However, these procedures are associated with high
rates of intraoperative and postoperative complications.
Method: From January 2012 to July 2013, 20 ABO-I
LDLT patients were identified at National Cancer Cen-
ter, Republic of Korea. Our protocol for ABO-I LDLT
involved rituximab (300 mg/m2) at preoperative
2 weeks, followed by plasma exchange (target before
LDLT: isoagglutinin titer ≤1:8), basiliximab (20 mg on
operation day and postoperative day 4), and intrave-
nous immune globulin (0.8 g/day at postoperative day
1 and 4) without graft local infusion and splenectomy.
Results: The 20 patients (14 males, 6 females) who
underwent transplantation comprised liver cirrhosis
(n = 5) and hepatocellular carcinoma (n = 15). Mean
age, MELD score, and graft-to-recipient weight ratio of
these patients was 51.8 years, 11.9, and 0.84, respec-
tively. The median isoagglutinin antibody titer before
plasma exchange was 1:32 (range, 1:4–1:256). All
patients did not have graft failure. There was no hyper-
acute rejection and antibody-mediated rejection. Mean
duration of hospital stay was 13.2 days. There was no
recurrence of hepatitis B virus (0/10 patients), but recur-
rence of hepatitis C virus (1/1 patient) and one positive
CMV antigenemia (2/20 patients) after transplantation.
No bacterial and fungal infections were observed. Com-
plications included herpes zoster viral infection in one
patient, postoperative bleeding in one patient and extra-
hepatic biliary stricture in three patients.
Conclusions: The new simplified ABO-I LDLT proto-
col using rituximab, plasma exchange, basiliximab, and
intravenous immune globulin without graft local infu-
sion and splenectomy showed good graft outcomes
without hyperacute, antibody mediated rejection, and
serious infection. This protocol seems to be a simple
and effective modality for ABO-I LDLT.
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PPLT24-027
RELATION BETWEEN PRE-
TRANSPLANT VIRAL LOAD OF
HEPATITIS B VIRUS (HBV) AND POST-
TRANSPLANT RECURRENCE OF HBV
IN LIVER TRANSPLANT RECIPIENTS
WITH HBV-RELATED LIVER
CIRRHOSIS
Sung Hwa Kang, Shin Hwang, Ki-Hun Kim, Chul-Soo
Ahn, DeoK-Bog Moon, Tae-Yong Ha and Sung-Gyu
Lee
Asan Medical Center, Ulsan University, Korea
Introduction: The risk factor for hepatitis B virus
(HBV) recurrence after liver transplantation (LT) is
pre-LT viral load, resistant mutant, pre-LT use of anti-
viral agent, type of prophylaxis and so on. However,
there has not been accurate and specific clinical or lab-
oratory parameter yet. Therefore, we conducted pro-
spective study to elucidate the risk factor for HBV
recurrence after LT with the HBV DNA analysis.
Method: The study population consisted of the patient
who underwent LT in our institution from January
2010 to December 2010. The cohort size was 50.
Explant liver tissue was collected immediately after
total hepatectomy of recipient and store at 80°C prior
to DNA extraction.
Results: Meean age of patients was 51.3  6.6 (35–67)
years. There were 46 men (92.0%) in cohort. During
1-year follow period, total 6 patients developed HBV
recurrence. Among 50 patients, 29 (58.0%) received
anti-viral agent before LT. Mean level of pre-LT
serum HBV DNA was 1.03  1.49 (3.58 to 4.40)
log 10 copies/cell and HBV DNA was not detectable
in 12 (24.0%) patient. Tissue HBV DNA and
cccDNA were found in all patients. Mean level of tis-
sue HBV DNA and cccDNA was 0.79  1.2 (2.93
to 2.86) and 2.28  1.08 (4.59 to 0.62) log 10 cop-
ies/cell, respectively. There were strong correlations
between levels of pre-LT serum HBV DNA, tissue
HBV DNA and cccDNA (r = 0.65, r = 0.55,
p = 0.00). However, there are no significant difference
of DNA level between recurrence (n = 6) and non-
recurrence group (n = 44).
Conclusions: The level of pre-LT serum HBV DNA,
tissue HBV DNA and cccDNA was closely associated.
High level of tissue HBV cccDNA warranted the high
risk of HBIG prophylaxis failure and recurrence of
HBV after LT. Therefore, it is necessary to monitor
such patients intensively with application of combina-
tion therapy.
PPLT24-028
EXPRESSION PATTERNS OF SERUM
AFP AND DCP IN HEPATOCELLULAR
CARCINOMA PATIENTS WITH HBV
AND HCV UNDERGOING LIVER
TRANSPLANTATION
Sung Hwa Kang, Shin Hwang, Ki-Hun Kim, Chul-Soo
Ahn, Deok-Bog Moon, Tae-Yong Ha and Sung-Gyu
Lee
Asan Medical Center, Ulsan University, Korea
Introduction: It is rather conflicted that different tumor
markers are emphasized between Korea and Japan for
diagnosis and follow-up of hepatocellular carcinoma
(HCC) in liver transplantation (LT) recipients. This
study was conducted to compare the expression pat-
terns of serum AFP and DCP in HCC patients under-
going LT by using high-volume single institution data.
Method: From our LT database pool having >3,000
adult cases, 663 recipients who had been diagnosed of
viral hepatitis and HCC were selected. To compare the
parameters objectively, patients showing AFP
<1,000 ng/mL and DCP <1,000 mAU/mL were
included. They were divided into HBV group (n = 628)
and HCV group (n = 35). Their medial record was
reviewed retrospectively.
Results: The clinical features and tumor extents of both
groups were very similar each other. Mean and median
pretransplant AFP levels were 54.5  123.4 ng/mL and
9.8 ng/mL in HBV group and 65.1  163.7 ng/mL and
21.9 ng/mL in HCV group respectively, in which com-
parison of means showed no statistical difference
(p = 0.629) but that of median showed significant differ-
ence (p = 0.011). Mean and median pretransplant DCP
levels were 57.8  114.6 ng/mL and 23.0 ng/mL in HBV
group and 79.8  115.1 ng/mL and 28.0 ng/mL in HCV
group respectively, in which comparison of means
showed no statistical difference (p = 0.269) but that of
median also showed significant difference (p = 0.043).
The skewness and kurtosis of AFP were 3.88  0.09 and
17.33  0.19 in HBV group and 5.43  0.39 and
30.9  0.78 in HCV group, respectively. The skewness
and kurtosis of DCP were 4.74  0.09 and 25.78  0.19
in HBV group and 2.23  0.39 and 4.31  0.78 in HCV
group, respectively.
Conclusions: The results of this study implicate that the
patterns of serum AFP and DCP in HCC patients can
be differently expressed according to the types of back-
ground liver diseases.
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PPLT24-029
IN-SITU HEPATIC RESECTION OF
NON-TUMOROUS LIVER
PARENCHYME AND LIVER
AUTOTRANSPLANTATION IN THE
FAR-ADVANCED HEPATOCELLULAR
CARCINOMA WITH THE INFERIOR
VENA CAVA INVOLVEMENT
Young Seok Han and Dong Lak Choi
Catholic University of Daegu School of Medicine, Korea
Introduction: The involvement of the confluence of
hepatic veins and the inferior vena cava (IVC) in the
advanced hepatocellular carcinoma (HCC) is usually
considered to be a contraindication for hepatic resec-
tion. Extracorporeal hepatic resection and hepatic auto-
transplantation allow treatment of unresectable
hepatobiliary malignancies and improvement in out-
comes in selected cases is being reported.
Method: We present a 40 year old man with a huge
HCC which involved IVC through right hepatic vein
and the invasion of middle hepatic vein was identified.
We could not found the extrahepatic metastases. Child
A cirrhosis was demonstrated by laboratory and imag-
ing studies.
Results: At first, extended left hepatectomy was per-
formed and middle hepatic vein was reconstructed with
Dacron graft during bench-work procedure. To prevent
the spread of tumor thrombus, suprahepatic and infra-
hepatic IVC had been isolated and clamped, followed
by extracorporal veno-venous bypass. After total hepa-
tectomy of remnant liver and thrombectomy of IVC,
hepatic autotransplantation was followed by living
donor liver transplantation. During 8 month follow-up
after operation, the patient has been alive and quality
of life has been acceptable.
Conclusions: In situ hepatic resection and liver auto-
transplantation in unresectable HCC has shown a
potential treatment.
PPLT24-030
SUCCESSFUL TREATMENT OF
DIFFUSE PORTAL VEIN THROMBOSIS
AFTER SPLENECTOMY FOLLOWING
LIVING DONOR LIVER
TRANSPLANTATION PATIENT
Sung Hwa Kang, Shin Hwang, Ki-Hun Kim, Chul-Soo
Ahn, Deok-Bog Moon, Tae-yong Ha and Sung-Gyu
Lee
Asan Medical Center, Ulsan University, Korea
Introduction: Splenectomy is performed after living
donor liver transplantation (LDLT) for various resons,
including pancytopenia, ascites, left sided portal hyper-
tension. Complications of splenectomy include bleed-
ing, pancreatic injury, infection, portal vein thrombosis.
Portal vein thrombosis (PVT) is rare but dreaded com-
plication after splenectomy in LDLT recipients that
can compromise patient and graft survival. Several
treatment modality of PVT after splenectomy are
reported, including anticoagulation, thrombolysis and
surgical thrombectomy.
Method: We recently experienced a case of acute and
diffuse PVT after splenectomy in LDLT recipient who
was successfully treated with thrombectomy and sys-
temic anticoagulation therapy. The patient was a 56-
year-old female with hepatitis B virus-associated liver
cirrhosis. She underwent LDLT using modified right
lobe graft on June 2, 2006. Recently she developed
thrombocytopenia on routine laboratory exam. A CT
scan showed splenomegaly. We performed splenectomy
to resolve thrombocytopenia. On postoperative fifth
day, she complained pain on her shoulder. A CT scan
was performed and showed diffuse splenic, main portal
and intra-hepatic portal vein thrombosis with ischemic
change in anterior section.
Results: The patient was taken immediately to the
operating room. We opened splenic stump and placed
a 12-Fr Fogarty catheter. With the assistance of vascu-
lar surgeon, thrombectomy of the main portal vein was
attempted via catheter under intra-operative ultrasound
guiding. After thrombectomy, intra-operative porto-
gram revealed recanalization of the splenic vein and
main portal vein but still remained intra-hepatic portal
vein thrombosis. An interventional radiologist put the
catheter into intra-hepatic portal vein via inferior mes-
enteric vein. After several times of aspiration through
the catheter, portogram showed complete recanaliza-
tion of intra-hepatic portal vein. We put the stent into
spleno-mesenteric junction to prevent recurrent PVT.
Systemic heparinization war started immediately after
operation and was converted warfarin. A postoperative
Doppler ultrasound and CT scan showed patent main
and intra-hepatic portal vein.
Conclusions: This case showed that PVT after splenec-
tomy can be treated with surgical thrombectomy,
intra-operative interventional procedure and systemic
anticoagulation therapy.
PPLT24-031
A SINGLE CENTER EXPERIENCE OF
LIVER TRANSPLANTATION FOR
PRIMARY BILIARY CIRRHOSIS
Gil Chun Park, Giwon Song, Donghwan Jung,
Taeyong Ha, Deokbok Moon, Chulsoo Ahn, Kihun
Kim, Shin Hwang and Sunggyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: Primary biliary cirrhosis (PBC) is a
chronic cholestatic liver disease involving immune-med-
iated destruction of interlobular and septal bile ducts.
Recurrent PBC, as diagnosed by standard histologic
characteristics, has been shown to occur in 11–34% of
transplanted patients. Liver transplantation remains the
gold standard for treatment of end-stage liver disease
with greater than 80% 5-year survival.
Method: Between February 1998 and July 2009, a total
of 14 (0.61%) patients with PBC underwent liver trans-
plantation at Asan Medical center, and 2,282 patients
underwent liver transplantation for PBC at same per-
iod. Peritransplant data were collected by reviewing the
medical records retrospectively. Cases of recurrent PBC
were defined by histologic classification on liver biopsy.
Results: Median recipient age was 48.3 years and 13
(92.9%) were female. Median follow up period was
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46.5 months. Major postoperative complications were 5
(35.7%) biliary stricutures, 2 (14.3%) vascular stenosis,
2 (14.3%) bleedings, and 1 (7.1%) pneumonia. Disease
recurrence occurred in 4 (28.6%) patients, and mean
time to recurrence was 47.7 months. Retransplantation
for recurrent PBC from the deceased donor was per-
formed in 2 (14.3%) patients. Three patents died of
chronic rejection, and sepsis. The 5-year survival rate
of recipients who underwent LDLT was 83.6%. How-
ever, there were no significant factors related to recur-
rence of PBC statistically.
Conclusions: Living donor liver transplantation is a
feasible treatment option for PBC with end-stage liver
disease. Recurrent rate of PBC after LDLT is not negli-
gible. Therefore, clinical suspicion of disease recurrence
should be warranted whenever patient shows abnormal
finding in liver function tests. Timely biopsy must be
performed if indicated.
PPLT24-032
LIVING DONOR LIVER
TRANSPLANTATION USING A GRAFT
FROM A DONOR WITH SITUS
INVERSUS
Gil Chun Park, Taeyong Ha, Chulsoo Ahn, Deokbok
Moon, Shin Hwang and Sunggyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: Even in the situs inversus totalis, which
has complete 180° mirror image, to procure and even
more to implant the graft into the recipient, in which
the graft should be rotated along the axis of IVC
groove, could be very difficult. Therefore, appropriate
technical modification is necessary in the reconstruction
of the graft from the donor with situs inversus. We
introduce a case of LDLT which we performed from a
donor with situs inversus totalis.
Results: The recipient was 50 years-old male patient,
who had been diagnosed as alcoholic liver cirrhosis and
taken EVL (endoscopic variceal ligation) due to varix
bleeding. His pre-operative stage was UNOS IIb, and
the MELD score was 8. The donor was 43 years-old
female with situs inversus totalis. The surgery for donor
was processed with standard procedures and reversed
right lobe without midhepatic vein (MHV) was pro-
cured. The graft had one MHV branch drained from
segment 5 and one IRHV respectively. During the sur-
gery for recipient following total hepatectomy, the
implantation of the graft into the right upper quadrant
of recipient was performed with the piggyback tech-
nique after 180° rotation. For MHV and IRHV, the
position of which might be exchanged after 180° rota-
tion of the graft, with the branch of MHV placed in
the usual position of IRHV. We used cryopreserved
vessel as interposition graft for branch of MHV, and
anastomosed to the IVC of recipient. Because bile duct
was located under portal vein, we reconstructed bile
duct first using duct to duct method, and then recon-
structed portal vein using end to end anastomosis to
the portal vein of the recipient. Later, IRHV was anos-
tomosed to the MVH and LHV stump using cryopre-
served vessel. After the anastomosis of hepatic artery
with right hepatic artery of recipient under microscope,
the operation was finished.
PPLT24-033
NEGATIVE CONVERSION OF HLA
CYTOTOXIC CROSSMATCH TESTING
IN LIVING DONOR LIVER
TRANSPLANTATION AFTER THE
ADMINISTRATION OF INTRAVENOUS
IMMUNOGLOBULIN
Yong Keun Park, Young In Kim, Young Ae Lim,
Hee-Jung Wang, Bong-Wan Kim and Weiguang Xu
Ajou University School of Medicine, Korea
Introduction: Because sensitization to human leukocyte
antigen (HLA) is a significant barrier to transplanta-
tion, the accurate result of HLA crossmatching testing
is important to determine transplantation or to evalu-
ate the survival rate. Therefore the laboratory staffs
need to check not only the procedure of crossmatch
testing but also other factors to affect the results, such
as the patient’s history of treatment or taking medica-
tion, when the results of the HLA crossmatch testing
are doubtful. Here, we report a case of the negative
conversion of HLA cytotoxic crossmatch testing in liv-
ing donor liver transplantation (LDLT) after only
administration of intravenous immunoglobulin (Ig).
Method: The patient was a 57-year-old male patient
with alcoholic liver cirrhosis and hepatocellular carci-
noma.
Results: The result of HLA crossmatch testing to
donor was negative for NIH-complement dependent
cytotoxicity (CDC) method and 1:16 positive for anti-
human globulin (AHG)-CDC method 2 days ago
before liver transplantation. After 8 days, HLA cross-
match testing had been requested and the result of
AHG-CDC method was converted to negative. The
patient had received immune suppressant therapy with-
out plasma exchange. Therefore we had retested HLA
crossmatch testing, however, the result was same. We
had tried to recheck the patient’s history, and we could
find that he had received intravenous Ig infusion for
6 days with Ig G 5 g/day from the firth postoperative
day. He received additionally Ig G therapy for 16 days.
After transplantation, there were not any sign of
abnormal liver function, hyperacute or acute rejection
still now on the 42th postoperative day.
Conclusions: Other investigators have confirmed that
pretreatment with intravenous Ig can result in reduc-
tion of anti-HLA antibodies and effective in treatment
of allograft rejection. Therefore, we think that high
dose intravenous Ig could modify preformed antibody
associated with humoral rejection.
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PPLT24-034
FEASIBILITY OF DUAL GRAFT LIVING
DONOR LIVER TRANSPLANTATION
FROM DONORS WITH COMPLEX
PORTAL VEIN VARIATIONS
Joo dong Kim, Dong Lak Choi and Young Seok Han
Daegu Catholic University Medical Center, Korea
Introduction: Living donor liver transplantation
(LDLT) from donors with complex portal vein (PV)
anomalies is considered a challenging procedure in term
of the donor’s safety and the complexity of reconstruc-
tion in the recipient. However, the utilization of donors
with anatomical variations may be considered under
the accurative preoperative planning if more suitable
donor is not available Herein, we report a successful
dual LDLT for two donors with portal vein anomaly
for overcoming the small for size graft syndrome and
the donor safety.
Method: A 62-year-old man was referred to our institu-
tion for liver transplantation due to hepatitis B related
liver cirrhosis with hepatocellular carcinoma. The only
available donor was his son and his daughter in-law.
Three-dimensional CT of both donors revealed the con-
figurations of portal vein was anomalous venous
branches; one donor with type IV portal venous ana-
tomical variation and the other donor with type III
variation. Neither of the two available donors were
suitable as single donor due to the complexity of the
PV reconstruction and the donor safety. Therefore the
decision was made to perform LDLT using dual graft
and we planned to harvest the right posterior section
graft from first donor, together with the left lobe of
second donor. Donor hepatectomy and recipient total
hepatectomy were performed in the usual manner. The
engrafting procedures have been described in detail
elsewhere.
Results: Postoperative Doppler ultrasonography and
dynamic CT revealed good hepatic artery, portal vein,
hepatic vein flow to both grafts. He has well recovered
with normal graft function and there has been no
tumor recurrence after dual LDLT.
Conclusions: Dual graft LDLT using right posterior
section and left lobe graft could be undertaken success-
fully to overcome the small-for-size graft syndrome and
secure the donor safety in selected donors with the
complex portal vein anomalies.
PPLT24-035
RECURRENCE OF B VIRAL HEPATITIS
DESPITE HEPATITIS B
IMMUNOGLOBULIN PROPHYLAXIS
AFTER LIVER TRANSPLANTATION
Hee-Jung Wang, Jae Sung Jung, Bong-Wan Kim,
Kyung Min Kim, Weiguang Xu and Yong Keun Park
Ajou University School of Medicine, Korea
Introduction: Although favorable outcome following
liver transplantation for hepatitis B virus (HBV)-related
liver disease was made possible with long-term, high-
dose, passive immunoprophylaxis using hepatitis B
immune globulin (HBIG), overall recurrence rates with
its monotherapy were reported from 15% to 35%. In
patients receiving HBIG, HBV reinfection may be the
consequence of HBV overproduction coming from
extrahepatic sites, an insufficient protective titer of
HBIG or the emergence of escape mutants. We under-
took this retrospective study to assess recurrence rate
and its mechanism after HBIG monotherapy or
HBIG+entecavir combined therapy in our clinic.
Method: The study comprised 157 patients undergoing
liver transplantation for hepatitis B-related liver disease
during January 2005 through June 2010. One hundred
twenty patients was treated with high-dose HBIG mono-
therapy (Monotherapy group), and 37 patients with
combination entecavir and HBIG (Combination group)
after liver trasplantation. Blood samples of 3 patients
with HBV recurrence were analyzed for sequencing the
“a” determinant of surface antigen gene (S gene), show-
ing the mechanism of HBIG resistance. S gene sequence
of HBV genotype adr was used for control.
Results: Overall recurrence rate of HBV was 10.1%
(17/157), and recurrence rates of monotherapy group
and combination group were 14.2% (17/120) and 0%
(0/37), respectively. S gene sequencing of 3 patients
showed multiple mutations in all cases. G145R muta-
tion was commonly found, and other mutations were
the followings: I126T and P142T in case 1, I126T and
F134I/V in case 2 and D144E in case 3. All of recur-
rent patients were controlled with entecavir therapy
(0.5 mg, daily).
Conclusions: As HBV recurrence rate despite high-dose
HBIG monotherapy after liver transplantation was
14.2%, we think that the entecavir+HBIG combination
protocol could be considered as alternative prophylaxis
against HBV recurrence after liver transplantation for
HBV-related liver disease.
PPLT24-036
ANALYSIS OF S GENE MUTATION OF
HEPATITIS B VIRUS IN ADULT LIVER
TRANSPLANT RECIPIENTS SHOWING
RESISTANCE TO HEPATITIS B
IMMUNOGLOBULIN THERAPY
Gil Chun Park, Shin Hwang, Donghwan Jung, Giwon
Song, Taeyong Ha, Deokbok Moon, Chulsoo Ahn,
Kihun Kim and Sunggyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: A considerable proportion of liver trans-
plantation (LT) recipients who receive hepatitis B
immunoglobulin (HBIG) monotherapy for hepatitis B
virus (HBV) prophylaxis develop HBIG resistance.
Gly145Arg mutation is known as the most common
cause of HBIG resistance. This study intended to inves-
tigate the mutation patterns in the major hydrophilic
region (MHR) of amino acid sequences 100-160.
Method: The blood samples of 15 patients showing
HBIG resistance after high-dose HBIG prophylaxis
were analyzed with gene sequence analyzer. The ana-
lyzed DNA sequence included amino acid sequences 0-
226 at S/pre-S region.
Results: Various mutations in the MHR were found in
14 of 15 samples. Gly145Arg mutation was found in 8
of 13 Adr subtype samples and 1 of 2 Ayw subtype
© 2014 The Authors
HPB 2014, 16 (Suppl. 2), 550–602 HPB © 2014 Americas Hepato-Pancreato-Biliary Association
Poster Panel [Liver Transplantation] 563
samples, leading to an incidence of 60%. Next common
mutation was Gly165Trp in 8 of 13 Adr subtype sam-
ples and none of 2 Ayw subtype samples, leading to an
incidence of 53.3%. Concurrent antiviral resistance was
found in 5 patients (lamivudine resistance in 5, enteca-
vir resistance in 3 and adefovir resistance in none)
implicating occurrence of simultaneous antiviral cross
resistances. Two patients underwent retransplantation
due to progression of HBV infection despite vigorous
antiviral therapy. At the diagnosis of HBV recurrence,
mean HBV DNA load was 6.5 9 106 copies/mL and 4
patients showed paradoxical co-existence of anti-HBs
and HBsAg. Currently, two patients show HBV DNA
replication in the peripheral blood, but other 12 reveal
no DNA replication after prolonged antiviral therapy.
Conclusions: This study implicate that various muta-
tions in the “a determinant” were associated with
HBIG resistance. Treatment failure to rescue antiviral
therapy was often associated with delayed detection of
HBV recurrence rather than concurrent antiviral resis-
tance, thus frequent surveillance with more sensitive
screening tests such as HBeAg and HBV DNA PCR
assay seems to be mandatory.
PPLT24-037
GRAFT WEIGHT PREDICTION BASED
ON PREOPERATIVE CT VOLUMETRIC
MEASUREMENT FOR LIVING DONOR
LIVER TRANSPLANTATION
Xiaopeng Yang1, Chongwoo Chu2, Jeho Ryu2,
Kwangho Yang2, Jaedo Yang3, Teukgyu Choi4,
Heechul Yu3, Baikhwan Cho3 and Heecheon You1
1Pohang University of Science and Technology, Korea;
2Pusan National University Yangsan Hospital, Korea;
3Chonbuk National University Medical School, Korea;
4Humanopia Co., Ltd, Korea
Introduction: To plan the successful living donor liver
transplantation (LDLT), prediction of the graft weight
based on preoperatively estimated graft volumefrom
CT volumetric measurement is needed. For safe LDLT,
it is crucial to know the ratio of the predicted graft
weight to a recipient’s body weight. Regression equa-
tions which explain the statistical relationship between
the graft weight measured intraoperatively and the
graft volume estimated preoperatively have been devel-
oped but based on small sample sizes (n < 40) and have
not been validated. The S.D. of estimation error of the
predicted graft weight was ranged from 45.2 to 53.6 g
when existing regression equations of the graft weight
were applied to 23 Korean cases.
Method: The purpose of the study is to (1) develop a
regression equation between the graft weight measured
intraoperatively and the graft volume estimated preop-
eratively based on 64 cases provided by a medical cen-
ter and (2) validates the developed regression equation
using different cases from other medical centers.
Results: A partial analysis (n = 16) showed that the
graft weight measured intraoperatively was highly cor-
related with the graft volume estimated preoperatively
(r = 0.899, p < 0.001). A regression equation (Graft
weight = 70 g + 0.877 g/mL • Graft volume) has been
developed based on the 16 cases.
Conclusions: A more general equation will be devel-
oped and validated by including more cases from dif-
ferent medical centers. The regression equation
developed in the study can be used for accurate predic-
tion of the graft weight from the graft volume esti-
mated preoperatively.
PPLT24-038
DE NOVO HEPATITIS B VIRUS
INFECTION AFTER ADULT LIVER
TRANSPLANTATION USING
HEPATITIS B CORE ANTIBODY
POSITIVE GRAFT
Jae Hyun Han, Dong Goo Kim, Gun Hyung Na, Eun
Young Kim, Soo Ho Lee, Tae Ho Hong and Young
Kyoung You
Catholic University of Korea, Seoul St. Mary’s Hospital,
Korea
Introduction: Because of disparity between donor and
recipient, the use of marginal donor such as hepatitis B
core antibody (HBcAb) positive graft has been increas-
ing, especially where hepatitis B is endemic. However,
it is still controversial to use of HBcAb positive graft
because of the risk for de novo hepatitis B virus (HBV)
infection.
Method: From January 2000 to December 2012, we
evaluated retrospectively 178 hepatitis B surface antigen
(HBsAg) negative recipients who had undergone liver
transplantation (LT) at our hospital. De novo HBV
virus infection was defined as positive HBsAg with/
without HBV DNA detection. We analyzed incidence
and risk factors of de novo HBV infection and survival
according to the donor HBcAb status. The mean fol-
low up duration after LT was 46.9 months.
Results: 31 (17.4%) out of 178 patients received graft
from HBcAb positive donors. It showed statistically
difference in age and hepatitis B surface antibody
(HBsAb) status between HBcAb positive and negative
donors. However, there was no significant survival dif-
ference according to donor HBcAb status. Without anti
HBV prophylaxis, de novo HBV infection was occurred
in 5 (16.1%) out of 31 patients and it showed signifi-
cantly higher incidence in HBsAb negative and/or
HBcAb negative recipient. All patients were treated
with antiviral agent with/without hepatitis B immuno-
globulin (HBIG) except one patient and among them,
negative seroconversion of HBV DNA was occurred in
all 4 patients. There were no mortality cases related
with HBV infection.
Conclusions: HBcAb positive graft can be safely used
without survival difference. However, the risk of de
novo hepatitis B virus infection was significantly
increased in HBsAb negative and HBcAb negative reci-
pient. So in these cases, preoperative anti HBV prophy-
laxis should be needed. All patients with de novo HBV
infection were successfully treated with antiviral agent
and HBIG.
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PPLT24-039
MANAGEMENT OF LATE-ONSET
PORTAL VEIN COMPLICATIONS IN
PEDIATRIC LIVING-DONOR LIVER
TRANSPLANTATION
Tae Yong Ha, Yong-Pil Cho, Kyung-Mo Kim,
Gi-Young Ko and Sung-Gyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: The purpose of this study was to evaluate
retrospectively the results of PTA for late-onset PV
complications after pediatric LDLT, and to assess
whether a meso-Rex shunt is a viable option for treat-
ing restenosis of the PV after PTA in selected cases.
Method: Seventy-five children who underwent adult-to-
child LDLT were included in this study and there were
6 late-onset PV complications (8.0%).
Results: The initial therapeutic approach was PTA,
with or without stent: PTA with balloon dilation for 3
children, PTA with stent placement for 1 child, and
failure to cannulate the occluded PV for 2 children. A
meso-Rex shunt was performed in the two children
after failed PTA: 1 suffered complete occlusion of the
main PV and the other, restenosis with total thrombo-
sis after PTA with stent. The PTA was a technical and
clinical success in 4 with PV stenosis of the 6 patients
(66.7%) and successful application of a meso-Rex
shunt in the other 2 children resulted in restoration of
PV flow.
Conclusions: In conclusion, PTA is a safe and effective
procedure for treating late-onset PV stenosis after pedi-
atric LDLT. However, in growing pediatric recipients
with restenosis of the PV after PTA or chronic PV
thrombosis, a meso-Rex shunt may be a better choice
for late-onset PV complications.
PPLT24-040
LIVER RETRANSPLANTATION AT A
MAJOR LIVING DONOR LIVER
TRANSPLANTATION CENTER: THE
ASAN MEDICAL CENTER EXPERIENCE
Tae-Yong Ha, Shin Hwang, Gi-Won Song, Chul-Soo
Ahn, Ki-Hun Kim, Deok-Bog Moon, Dong-Hwan
Jung, Gil-Chun Park, Hyung-Woo Park and Sung-Gyu
Lee
Asan Medical Center, Ulsan University, Korea
Introduction: The volume of liver transplantation (LT)
at the Asan Medical Center is 3,289 LT cases including
461 cases of adult deceased donor LT, 2,603 cases of
adult living donor LT and 225 cases of pediatric LT.
Method: Of them, 99 cases (3.0%) in 95 patients
underwent liver retransplantation.
Results: The proportion of retransplantation according
to the primary diseases was 1.8% in hepatitis B virus
infection, 13.7% in hepatitis C virus infection, 19.7%
in hepatitis A virus infection, 7.8% in acute liver fail-
ure, and 5.1% in biliary atresia. Causes of graft failure
were immunologic reason in 30.3%, disease recurrence
in 22.2%, technical causes in 16.2%, and primary non-
function in 13.1%. Preoperative model for end-stage
liver disease score for retransplantation was 28.2  8.
Operation types of retransplantation included living-to-
deceased donor LT in 58.6%, deceased-to-deceased LT
in 24.2%, living-to-living donor LT in 14.1% and
deceased -to-deceased donor LT in 3%. In retransplan-
tation patients, in-hospital mortality was 22.1% and
patient survival rates were 68.3% at 1 year and 58.5%
at 5 years.
Conclusions: Survival analysis revealed that preopera-
tive patient condition was the most important factor
for survival, but combination of donor, recipient and
surgical factors may affect the overall outcomes. It is
strongly suggested to prepare a reliable survival predic-
tion model for retransplantation in order to avoid futile
retransplantation.
PPLT24-041
BILIARY COMPLICATIONS AFTER
PEDIATRIC LIVER TRANSPLANTATION
Mario Uribe1, Gloria Gonzalez2, Alex Wash3, Andrea
Alba2, Bessie Hunter2, Carlos Acu~na2, Paula Soto2,
Paulina Torrealba2 and Lilian Flores2
1Hospital Del Salvador, Chile; 2Hospital Luis Calvo
Mackenna, Chile; 3Clinica Las Condes, Chile
Introduction: Liver transplantation (LT) is the treat-
ment of patients with end-stage liver disease. Biliary
complications after LT (BCALT) are relevant because
of its high incidence (13% stenosis, 8% biliary leaks),
significantly increasing hospital admissions, the risk of
graft loss and recipient death. These complications are
managed by interventional radiology procedures, endo-
scopic or surgical resolution including re-transplanta-
tion. To identify the rate of BCALT in our group,
potential risk factors and their resolution.
Method: A retrospective, analytical study based in the
clinical data of patients transplanted between Novem-
ber 1996 and July 2013.
Results: We performed 185 transplants in 159 patients,
100 reduced-size lever grafts, 85 biliary enteric anasto-
mosis in Roux-Y. Thirty-five 35 presented with BCALT
(21 anastomotic stenosis [11.3%], 12 anastomotic leaks
[6.5%], 2 multiple intrahepatic strictures [MIHS;
1.1%]). We analyzed various potential risk factors for
BCALT with Fisher’s test, two-tailed p-value, left lat-
eral segments grafts (p = 0.0058) and living donor
grafts (p = 0.004) were statistically significant risk fac-
tors. Common bile duct end to end anastomoses versus
biliary enteric anastomoses, recipients weighting
<10 kg, arterial complications and pediatric donors
were not significant. Management: 9 patients with bili-
ary leak required surgery, 3 were managed with exter-
nal drainage. In patients with anastomotic stenosis,
percutaneous transhepatic or endoscopic dilations were
performed (1–3 procedures), 5 patients required re-
anastomosis and three patients required re-transplanta-
tion because of secondary cirrhosis.
Conclusions: In our group, the rate of biliary complica-
tions is similar compared with the reports in the adult
population. The use of left lateral segments from living
or cadaveric donors are of high risk for these complica-
tions, new split techniques should be developed to
reduced the incidence of biliary complications. Treat-
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ment with balloon dilation is the first management
option with a high success rate and low incidence of
complications due to the procedure.
PPLT24-042
LIVER-SPECIFIC MR AS THE ONLY
IMAGING TOOL IN POTENTIAL LIVER
LIVING DONORS: AN EVOLUTION OF
APPROACH
Giuliano Testa, Gregory DePrisco, Peter Kim, Robert
Goldstein, Marlon Levy, Greg McKenna, Richard
Ruiz, Nicholas Onaca, Tiffany Anthony and Goran
Klintmalm
Baylor University Medical Center, USA; 2Baylor All
Saints Medical Center, USA
Introduction: An accurate assessment of donor anat-
omy is essential in liver living donor operative plan-
ning. Most centers use 2 imaging modalities, CT for
vascular anatomy/volume and MRCP for biliary anat-
omy. This study outlines our center’s change in
approach from combination imaging (CT/MRCP) to
single modality, liver-specific MR. The aim of this
study was to assess the role of MR as the initial imag-
ing tool to screen donors and assess MR feasibility as
the only imaging modality.
Method: Over 18 months, 32 potential liver donors
had CT and MRCP, and 2 patients had liver-specific
MR as the only imaging modality. The MR findings in
all 34 patients were analyzed to assess donor suitability
and correlation accuracy between MR and operative
findings. MR protocol consists of two-point Dixon
technique for hepatic fat quantification, 3-D MRCP,
administration of hepatobiliary agent with dynamic
and delayed high resolution T1 imaging for hepatic,
portal venous, and biliary anatomy, and post contrast
MR angiography of arterial anatomy.
Results: Twenty-one donors (62%) were found to be
unsuitable based on MR findings: steatosis (n = 8),
inadequate volume and anatomy (n = 8), other reasons
(n = 5). Of 13 donors who underwent right hepatec-
tomy, 2 had MR as the only preoperative imaging
modality once the protocol was validated. The correla-
tion between the MR findings and the operative ana-
tomic findings was 100%. Mean discrepancy between
MR calculated volume and actual volume was 12% (0–
29%).
Conclusions: MR is a good initial imaging modality for
liver living donor assessment. It may potentially replace
CT and be used as the only imaging modality in living
donor assessment. Moreover, MR as first test allows
early detection of unsuitable candidates, thus, reducing
evaluation costs.
PPLT24-043
EVALUATION OF 128 CASES OF
VENOUS OUTFLOW
RECONSTRUCTION FOR RIGHT LOBE
MIDDLE HEPATIC VEIN BRANCHES IN
RIGHT LOBE LIVING DONOR LIVER
TRANSPLANTATION
Mohamed Elshobari, Mohamed Abdl Wahab, Tarek
Salah, Walid Elsaraf, Ayman Elnakeeb, Ahmed M.
Sultan, Helmy Ezzat, Ahmed Nabeh, Mahmoud Ali
and Hosam Hamed
Gastroenterology Surgical Center, Mansoura University,
Egypt
Introduction: Venous outflow reconstruction of segment
V and VIII venous branches using synthetic vascular
grafts is a controversial issue. Here we introduce our
experience withreconstruction of MHV tributaries using
synthetic and natural grafts.
Method: Between May 2004 and May 2013, 231 cases
of living donor liver transplant were done in Mansoura
Gastrointestinal Surgical Center. Natural grafts were
used in 102 cases and synthetic grafts were used in 26
cases. Synthetic graft to V alone was employed in 46
cases, VIII alone in 32 cases and combined V and VIII
in 22 cases. Synthetic vascular grafts are used in the
back table to segment V or VIII veins or both, then to
either MHV stump or IVC of recipient after revascular-
ization. Patency is judged by intraoperative and post-
operative Doppler and function of the graft.
Abdominal computered tomography (CT) is done only
if there is doubt.
Results: The mean warm ischemia time (WIT) for sin-
gle venous anastomosis was 41.47  20.48 minutes
compared to 45.91  25.17 minutes for multiple
venous anastomoses using synthetic graft and
103.29  14.85 minutes using natural grafts. After a
follow-up period of 2 years, the patency rate of vascu-
lar synthetic graft was 74% at 1 week, 52% at 1 year
and 10% at 2 years. However, Liver function tests dur-
ing the first week after surgery did not show significant
difference between the thrombosed and patent grafts.
Salvage grafts were inserted in 3 cases (V in 2 and VIII
in one) as intraoperative Doppler show segment con-
gestion with wide vein inside the liver (ligated during
donor hepatectomy).
Conclusions: Synthetic grafts and natural grafts are
good alternatives for reconstruction of middle hepatic
vein tributaries with good patency and avoid long
warm ischemia time. Synthetic grafts are safe and can
be done on backtable for any number of veins.
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PPLT24-044
UNEXPLICABLE OUTCOME OF EARLY
APPEREANCE OF DE NOVO HCC IN
THE ALLOGRAFT AFTER DDLT
Benjamin Navarro, Kwang-Woong Lee, Tae Yoo,
Suk-Won Suh, Ange Garcia, YoungRok Choi,
Nam-Joon Yi and Kyung-Suk Suh
Seoul National University Hospital, Korea
Introduction: Although only few cases have been
reported in the literature, occurrences of de novo hepa-
tocellular carcinoma (HCC) after liver transplantation
for advanced cirrhosis have been diagnosed after many
years of viral infection recurrence. We are presenting a
unique case with the earliest appearance of de novo
HCC in a patient with end stage liver disease (ESLD)
without previous malignancy and with YMDD viral
mutation.
Method: This case is a 45-year-old male with HCV,
HBV and HBsAg positive previous decease donor liver
transplantation (DDLT), however, after liver transplan-
tation HCV RNA and HBsAg were not detected, but
HBV DNA was still positive after liver transplantation
(LT). The recipient obtained a liver from a young
donor with a negative report for HCV and HBV and
otherwise healthy background.
Results: Nine months after liver transplantation in a
routine follow-up, a computerized tomography (CT)
scan detected a severe mass occupying the right lobe.
This unfortunate case has also shown a CT chest with
lung metastatic nodules in the right basal lower lobe
(BLL).
Conclusions: There are some theories left to elucidate
how de novo HCC could possibly appear in such a
short period of time in a case with a low suspicion to
occur after liver transplantation. To the extent of our
knowledge this is the first report of de novo HCC that
has emerged in such degree of severity and in a very
short period of time after LT.
PPLT24-045
RISK FACTORS FOR POSTOPERATIVE
SEPSIS AFTER LIVING DONOR LIVER
TRANSPLANTATION
Kazuhisa Takeda, Kuniya Tanaka, Koki Goto,
Takafumi Kumamoto, Kazunori Nojiri, Ryutaro Mori,
Koichi Taniguchi, Ryusei Matsuyama and Itaru Endo
Yokohama City University Graduate School of
Medicine, Japan
Introduction: The occurrence rate of sepsis after liver
transplantation is higher than after the other abdomi-
nal surgery because of the use of immunosuppressants.
Method: Between November 1997 and March 2012, 58
patients underwent LDLT in our institute. Postopera-
tive sepsis underwent LDLT occurred in 28 patients
(48.2%) and did not occur in 30 patients (48.2%). Peri-
operative data were compared between 2 groups.
Results: Among sepsis group, the main source of infec-
tion was intraabdomen (n = 16; 57.1%), lung (n = 8;
28.5%), vascular catheter (n = 3; 10.7%) and urinary
tract (n = 1; 3.5%). Sepsis was accompanied 20 days
after liver transplantation on average (0–83 days). Of
these patients, 5 patients died of sepsis related. Among
preoperative factors including gender difference, donor
and recipient age, preoperative steroid utilization, body
mass index, albumin level, there were not significant
differences between 2 groups. However, the rate of
ABO incompatibility was significantly higher in the sep-
sis group (39.2% vs 10%; p = 0.009). Among intraop-
erative factors, graft recipient weight ratio (GRWR),
operative duration, and expected blood loss were not
significantly different. However, splenectomy was per-
formed more frequently in sepsis group (64.2% vs
36.6%; p = 0.03). Among postoperative factors, the
rate of acute cellular rejection, bile duct leakage, hepa-
tic arterial thrombosis, and portal vein thrombosis were
not significantly different. However, in sepsis group,
the rate of cytomegalovirus (CMV) infection was com-
plicated more frequently (60.7% vs 33.3%; p = 0.004).
In addition, the rate of CMV infection occurred more
frequently in patients who died of sepsis compared to
survivors from sepsis (100% vs 51.8%; p = 0.04).
Conclusions: ABO incompatibility, splenectomy, and
CMV infection may be risk factors for sepsis after
LDLT. Furthermore, CMV infection was complicated
more frequently in patients who died of sepsis. Gener-
ally, because CMV infection occurred under excessive
immunosuppression, appropriate immunosuppressive
state should be necessary in order to avoid sepsis
related death.
PPLT24-046
LIVING DINOR LIVER
TRANSPLANTATION IN MONGOLIA
Badarch Bat-Ireedui
IASGO Member, Mongolia
Introduction: The leading causes of mortality were as
follows: 35.1% diseases of circulatory diseases, 21.2%
were cancer and 18.9% were injuries and poisonings.
Since 1990, cancer remains the second leading cause of
population mortality in Mongolia. In 2012, cancer
related mortality rate was 21.2% from total mortality.
The liver cancer prevalence 13.68, incidence 6.03 and
mortality 4.65 per 10,000 population. Living donor
liver transplantation implemented since 2009 in Mon-
golia under the guidance support by AMC.
Method: Since 2011 we successfully performed 9 live
donor liver transplantation at the 1st Clinical State
Hospital of Mongolia and other 9 cases were per-
formed at the ACM in Seoul, Korea. All donors and
recipients were prepared under the control of Liver
Transplantation team of 1st clinic of Mongolia. End
stage of chronic liver disease (cirrhosis) was the indica-
tions for liver transplantation.
Results: AMC livertransplantation visiting team
arrived in Ulaanbaatar 5 times and performed 9 cases
jointly with local team. Altogether we were able to do
jointly 16 standard LDLT cases and 2 dual lobe cases,
from these in10 cases done splenoectomia.
The postoperative immunesuppresive regimen:
● Tacrolimus as monotherapy (8–10 mg) in 12 patients
● Cyclosporine as monotherapy (80–120 mg) in 6
patients
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The drug level and recipients and donor follow up
guided by AMC Liver Transplantion Center protocols.
In postoperative period:
● Mortality in one case- due to late fullminant hepati-
tis
● HBV replication 1
● No acute and chronic rejection observed
● Hyperbillirubinemia-in 1 case (jaundice)
Acute pancreatitis in 1 case with successful early diag-
nosis and appropriate treatment.
Conclusions: The success rate of LDLT with joint
teams is 94.5% in 1 till 3 years. This achievement dem-
onstrate that the high technological surgical care as
LDLT practice is available to implement safely in mid-
dle and low income countries under direct support
training and involvement from high developed country
like Korea.
PPLT24-047
PORTAL HYPERTENSION IN PATIENTS
WAITING FOR LIVER
TRANSPLANTATION FOR HCC ON
CIRRHOSIS: IMPACT ON RESPONSE
TO TACE AND SURVIVAL
Francois Faitot, Antonio Sa Cunha, Rene Adam,
Oriana Ciacio, Gabriella Pittau, Denis Castaing, Gilles
Pelletier, Didier Samuel and Eric Vibert
APHP, France
Introduction: In patients waiting for liver transplanta-
tion (LT) for hepatocellular carinoma (HCC), drop out
due to progression alters the results of LT. Transarteri-
al chemoembolization (TACE) is used to prevent this
drop out. No datas exist regarding the impact of PHT
at listing on the results of LT and especially on the effi-
cacy of TACE during waiting time.
Method: 243 patients consecutively listed for LT for
HCC on cirrhosis between January 2000 and January
2010 were included. PHT was defined according to
EASL definition of clinically significant PHT ie esopha-
geal varices OR low platelet count (<100,000/mm3) and
splenomegaly (diameter >12 cm). The impact of PHT
on pathological response to TACE and survival was
evaluated.
Results: Among the 243 listed patients, 155 had clini-
cally significant PHT. These patients had a higher
MELD score (14.6 vs 12, p = 0.002) but a comparable
tumor burden. There were 23% DO in the 155 patients
with PHT versus 9% in the 88 patients without PHT
(p = 0.03). PHT was an independent factor of DO for
TP (OR = 3.05 IC [1.18–7.87], p = 0.02) as was the
absence of chemoembolization (OR = 2.79 IC [1.08–
7.19], p = 0.03). PHT was not associated with a lower
rate of TACE (p = 0.931). Complete tumor necrosis
after TACE occurred significantly more often in the
group without PHT versus with PHT (32% vs 12%;
p = 0.006). Overall survival in intention-to-treat was
significantly lower in patients with PHT (76% vs 65%
at 5 years, p = 0.046). In transplanted patients, PHT
was not associated with worse overall (80% vs 79%,
p = 0.62). There was no difference in recurrence-free
survival (p = 0.53) and time to recurrence.
Conclusions: PHT is associated with a significant risk
of tumor progression in patient listed for LT with an
associated high drop out rate. In this population,
TACE was applicable with the same rate but seemed
less efficient in term of complete tumor necrosis.
PPLT24-048
FATE OF POTIENTIAL DONORS FOR
LIVING DONOR LIVER
TRANSPLANTATION
Ok kyung Kim, Sanghee Song, Ok Soo Kim, Sukwon
Suh, Tae Yoo, Youngrok Choi, Nam-Joon Yi, Kwang-
Woong Lee and Curie Ahn
Seoul National University Hospital, Korea
Introduction: Evaluation process of potential donors is
important for donor safety and optimal outcome of
recipients. Exclusion rate during evaluation process had
been reported from 50% to 85% in previous report.
However, it differs according to the ethical and medical
environment and center policy as well. Living donor
liver transplantation (LDLT) is prevalent in Korea.
However, there has been no report about exclusion rate
and reason in Korea. (Aims) In this study, we aimed to
elucidate the fate of potential live liver donors.
Method: Prospective data collection of the potiential
live liver donor
● Characteristics
● Rates and reasons of exclusion
Results: Among 173 recipients, 120 patients received
LDLT finally. Among 173 recipients, 29 recipients
(16.8%) had more than 1 potential donor. 62% of
donors was male and 54% was siblings of the recipi-
ents. Among 208 potential donors, 120 donors (57.7%)
finally received donor hepatectomy for living donation.
84 cases (40.4%) were excluded for various reasons.
Among 84 excluded cases, 43 cases were excluded due
to donor reasons. The other 41 cases could not donate
due to recipient reasons e.g. death, infection or
Deceased donor LT. Donor reasons for exclusion con-
sisted of medical problems (n = 16, 37%), withdrawal
of consents (n = 11, 26%), small remnant volume
(n = 3, 7%), and others (n = 13, 30%). Fatty liver was
main reason for initial exclusion in 9 patients. Among
them, 4 cases tried diet and 3 cases finally succeeded
for donation.
Conclusions: The main reasons for donor exclusion
were medical problem and withdrawal of consent.
Therefore, thorough medical clearing and careful exam-
ination for donor voluntarism are important in donor
evaluation process.
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PPLT25-001
PATTERN OF ADENOVIRUS
MEDIATED GENE DELIVERY INTO
THE COLD LIVER GRAFT
Hae Won Lee, Kwang-Woong Lee, Kyung-Suk Suh,
Nam-Joon Yi, YoungRok Choi, Hyeyoung Kim,
Suk-Won Suh, Tae Yoo and Jeong-Moo Lee
Seoul National University College of Medicine, Korea
Introduction: Gene transfer into the liver graft has sev-
eral potential advantages including immune or non-
immune related settings. When considering donor
safety in living donor liver transplantation and multiple
organ harvest from a deceased donor, cold preserved
liver graft has been considered as good target for spe-
cific gene delivery into the liver graft. Recombinant
replication deficiency adenovirus has been studied for
this purpose. However, there are a few reports regard-
ing adenovirus into the cold preserved liver graft. In
this study, we investigate the pattern of gene delivery
into the liver graft.
Method: At the first step, GFP coding serotype 5
(Ad5-GFP) was applied into 7 HCC cell lines
(PLCRF5, Hep3B, SNU182, SNU387, SNU423,
SNU449, Huh7) for 1 hour. Transfection rate was mea-
sured by measuring GFP expression 2 days after cul-
ture. Two different temperatures (37°C and 4°C) were
used during contact. At the second step, hepatocyte
and non-parenchymal cells were isolated from SD rat
and investigated transfection rate at similar condition.
At the third step, Ad5-GFP was injected via tail vein
of wild type and adenovirus-vaccinated SD rat. Trans-
fection rate was measured by In vivo imaging.
Results: 30–60% transfection rate was observed in
SNU182, SNU387 and normal hepatocyte. 100% trans-
fection rate was observed in the other 5 cell lines. There
was no big difference between 37°C and 4°C condi-
tions. Transfection rate was low (<20%) in non-paren-
chymal cells. No tail vein injected adenovirus was
accumulated into the liver in adenovirus vaccinated
rats.
Conclusions: Adenovirus can be transfected into the
cold preserved hepatocyte at similar rat with that in
body temperature. However, transfection rate is around
50% in hepatocyte and low in non-parenchymal cells.
Neutralizing antibody that most of adults have should
be overcome for clinical application.
PPLT25-002
MRP2 EXPRESSION IN HUMAN
HEPATOCYTES AFTER LIVER
TRANSPLANTATION
Hae Won Lee, Kyung-Suk Suh, Nam-Joon Yi,
Kwang-Woong Lee, YoungRok Choi, Hyeyoung Kim,
Suk-Won Suh, Tae Yoo and Jeong-Moo Lee
Seoul National University College of Medicine, Korea
Introduction: Multidrug resistance-related protein fam-
ily (MRP) 2 is a bile salt transporter on canalicular
membrane of hepatocyte as a major determinant of
bile flow. Early graft damage after liver transplantation
(LT) could result in changes of MRP2 expression. The
purpose of this study is to evaluate the changes of
MRP2 expression can be a marker predicting post-LT
outcome.
Method: A total of 43 paraffin-embedded liver graft
tissues within 2 months after LT were stained using
monoclonal antibodies to determine the MPR2 pattern.
Normal MRP2 pattern in 15 matched living liver
donors was homogenous canalicular staining (type C0)
but no membranous staining of cytoplasm.
Results: In the recipients, MRP2 staining pattern was
different from the donors. Thirty-seven tissues among
41 graft tissues (90.2%) showed cytoplasm membra-
nous staining and 34 tissues (82.9%) showed abnormal
canalicular staining. The abnormal canalicualr staining
was classified into three types; normal homogenous
staining (type C0, n = 7, 17.1%), focal staining (type
C1, n = 15, 36.6%) and no staining (type C2, n = 19,
46.3%). The median operation time was longer in
patients with type C2 (557.6 minutes) than those in
patients with type C0 (393.6 minutes) (p = 0.040). The
rates of complications associated with graft dysfunction
were higher in patients with type C2 (100%) than those
in the others (type C0, 28.9% and type C1, 46.7%)
(p = 0.000).
Conclusions: The post-LT MRP2 expression could be
changed. The degree of MRP2 canalicular expression
was associated with long operation time and post-LT
complications representing graft damage during early
post-LT period.
PPLT25-003
SUCCESSFUL TREATMENT OF
FUNGAL (ASPERGILLOSIS) ABSCESS
AND CO-INFECTED WITH CMV IN
BOTH BRAIN AND LUNG DEVELOPED
AFTER ORTHOTOPIC LIVER
TRANSPLANTATION FOR TOXIC
FULMINANT HEPATITIS
Koo Jeong Kang, Keun Soo Ahn, Yong Hoon Kim,
Hyoung Tae Kim, Ui Jun Park, Won Hyun Cho, Tae
Jun Park, Byung Kook Jang and Ealmann Kim
Kyemyung University Dongsan Hospital, Korea
Introduction: Invasive aspergillosis of CNS is one of
the most significant and fatal opportunistic fungal
infection developed in the liver transplant (LT) recipi-
ents. We report a case of a LT recipient who developed
brain and lung abscess caused by combined aspergillus
and cytomegalovirus (CMV) infection.
Method: A 55-year-old female underwent deceased
donor LT for fulminant hepatic failure induced by
toxic mushroom ingestion. Preoperatively, she was
comatous status and her MELD score was 28. She had
no active bacterial or viral infection including CMV
preoperatively.
Results: Orthotopic LT underwent on 3rd day after
admission. The 56 year-old male donor had no evi-
dence of any infection. Postoperatively, the graft func-
tion was well immediately. On postoperative 4th day, her
consciousness recovered and weaned off ventilator. The
patient was discharged on the 25th post-operative day
without complication. Immunosuppressions consisted of
prednisone, mycophenolate mofetil and tacrolimus. One
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month post-transplantation, the patient admitted again
due to persistent nausea, vomiting, headache and visual
disturbance. Chest CT revealed 2 cm sized abscess in
right lower lung field and brain MRI displayed multiple
solid masses scattered in the whole brain. Pathological
examination by aspiration biopsy of lung and exci-
sional biopsy of brain abscess revealed aspergillus fumi-
gates combined with CMV infection. Therapeutic dose
of Ganciclovir (5 mg/kg/day) and Voriconazole (8 mg/
kg/day) applicated to the patient intravenesouly. Dur-
ing 2 months of treatment, size of lung and brain
abscess were decreased very slowly. Headache and
visual disturbance were improved progressively. She
was discharged 63th days after treatment with change
of medication, Voriconazole (200 mg twice a day
orally) and prophylactic dose of Valganciclovir
(900 mg/day orally). The patient has been doing well
without recurrence for 12 months.
Conclusions: We successfully treated acute phase of
fungal abscess in the brain and lung infected with
aspergillosis combined CMV infection after LT.
PPLT25-004
THE ROLE OF INTERFERON-GAMMA
INDUCIBLE PROTEIN 10 (IP10) IN
ACUTE PHASE GRAFT INJURY
INDUCED CISPLATIN RESISTANCE
AFTER LIVER TRANSPLANTATION
Wei Geng, Chungmau Lo, Kevin Ng, Changchun Ling,
Xiang Qi, Changxian Li, Xiaobing Liu, Yuenyuen Ma
and Kwan Man
The University of Hong Kong, Hong Kong, China
Introduction: Hepatocellular carcinoma is one of the
most fatal diseases worldwide. Liver transplantation
dramatically improved the survival rate of HCC
patients. However, tumor recurrence remains a huge
threat to HCC patients without any promising curative
treatment. Chemotherapy, as one of the potential treat-
ments to recurrent HCC, did not show any significant
effect either.
Method: A rat orthotopic liver transplantation model
was established with applying whole or small-for-size
(50%) graft and followed by rat hepatoma cell injection
to generate tumor. The expressions of multidrug resis-
tant genes and IP10 were compared between small and
whole grafts group. IP10 expression was further vali-
dated in clinical samples. The role of IP10 was exam-
ined in vitro and vivo. IP10 neutralizing antibody was
employed as an adjuvant therapy to sensitize cisplatin
treatment. The underlying mechanism was also
explored.
Results: The expressions of multidrug resistant genes
were significantly up-regulated in tumor from small-
for-size group. The expression of IP10 was constantly
higher in liver and tumor in small-for-size group. IP10
was overexpressed in around 45% HCC patients. Cir-
culating IP10 showed significant correlations with
tumor recurrence and small graft ratio in HCC patients
with liver transplantation. In vitro studies demon-
strated that overexpression of IP10 could promote
HCC cell proliferation significantly under cisplatin
administration. In vivo studies illustrated that overex-
pression of IP10 well correlated with larger tumor vol-
ume and less tumor necrosis after cisplatin treatment.
IP10 neutralizing antibody could significantly sensitize
cisplatin treatment in vitro and in vivo. Mechanism
studies implied that IP10 overexpression may improve
cisplatin resistance via ER stress (ATF6-Grp78) signal-
ing pathways.
Conclusions: The graft injury could induce the overex-
pression of IP10 which may responsible for late-phase
cisplatin resistance. Overexpression of IP10 may induce
cisplatin resistance by activation of ATF6-Grp78 ER
stress signalings. IP10 neutralizing antibody could be a
potential therapy to sensitize cisplatin treatment in
HCC patients.
PPLT25-005
SUCCESSFUL TREATMENT OF
HEPATIC ARTERY STENOSIS USING
PERCUTANEOUS TRANSLUMINAL
ANGIOPLASTY FOLLOWING ABO
INCOMPATIBLE LIVING DONOR
LIVER TRANSPLANTATION
Young-Dong Yu, Dong-Sik Kim, Sung-Won Jung and
Sung-Ock Suh
Korea University Anam Hospital, Korea
Introduction: In living donor liver transplantation
(LDLT), the hepatic arteries tend to be smaller than
those in cadaveric transplantation. Stenosis of the
hepatic artery is one of the fatal complications in liver
transplantation, and rapid treatment is mandatory to
avoid fatal results. Percutaneous transluminal angio-
plasty (PTA) is one of the treatments used to improve
hepatic artery stenosis. We report our experience of
successfully treating hepatic artery stenosis following
ABO incompatible living donor liver transplantation.
Method: A 49-year-old male patient (blood type O)
diagnosed with hepatocellular carcinoma and liver cir-
rhosis due to hepatitis B received ABO incompatible
living donor liver transplantation from his son (blood
type B). After initial decrease of liver enzymes follow-
ing liver transplantation the aspartate transaminase
(AST) and alanine transaminase (ALT) levels started to
increase on the seventh postoperative day.
Results: After excluding other causes for liver enzyme
elevation, plasmapheresis was performed for suspected
graft dysfunction by alloantibodies and the AST, ALT
levels decreased. On the 22nd postoperative day, re-ele-
vation of liver enzymes occurred. We performed splenic
artery embolization for suspicion of splenic artery steal
syndrome again after excluding other causes for liver
enzyme elevation. While performing splenic artery
embolization, severe stenosis at the arterial anastomosis
site was noted on the angiogram. Due to persistent ele-
vation of liver enzymes following splenic artery emboli-
zation and abnormal wave form of the intrahepatic
artery on doppler sonogram, PTA was performed. Fol-
lowing PTA, the patient’s AST, ALT started to
decrease.
Conclusions: Since it can be successfully treated using
PTA, hepatic artery stenosis should be suspected if
other causes of graft dysfunction have been ruled out
following living donor liver transplantation.
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PPLT25-006
ROLE OF SPLENECTOMY IN
PATIENTS WITH HEPATOCELLULAR
CARCINOMA AND ADVANCED
CIRRHOSIS WITH NO POTENTIAL
DONOR
Toshiro Ogata1, Koji Okuda2, Yusuke Hirakawa2,
Masafumi Yasunaga2, Hisashi Kuroda1, Masaya
Tanaka1, Hiroyuki Horiuchi2, Hisafumi Kinoshita2,
Hiroyuki Tanaka2 and Satoru Todo1
1Saint Mary’s Hospital, Japan; 2Kurume University,
Japan
Introduction: The benefits and risks of splenectomy for
anticancer or antiviral therapy in cirrhotic patients
have been discussed. Splenectomy may be applied as
another treatment option in hepatocellular carcinoma
(HCC) and cirrhosis when there is no potential donor
for liver transplantation.
Method: We retrospectively investigated the long-term
outcome of splenectomy on survival in advanced cir-
rhotic patients with HCC and thrombocytopenia.
Between 1999 and 2009, 46 cirrhotic patients with
thrombocytopenia (Child-Pugh class B or C) who
underwent splenectomy for the simultaneous or second-
ary treatment of HCC (hepatectomy, radiofrequency
ablation, hepatic arterial infusion chemotherapy, and
transcatheter hepatic arterial chemoembolization) at
our institutes were estimated. Survival, liver function
tests (total bilirubin, albumin, prothrombin time, plate-
let count, Child-Pugh score), portal venous pressure,
clinical course and complication were retrospectively
estimated and statistically analyzed.
Results: The 1-, 3-, and 5-year survival rates were
93.5%, 76.0%, and 37.9%, respectively. Splenectomy
resulted in a significant reduction in mean portal
venous pressure from 21.2 to 16.8 mmHg and improve-
ments in liver function tests such as total bilirubin, pro-
thrombin time, platelet count, Child-Pugh score for
3 years, and albumin for 2 years. The mean frequency
of treatment for HCC recurrence after surgery was 3.0
times (range: 1–11). Seven patients out of 16 scheduled
for Interferon (IFN) therapy after surgery achieved a
sustained virological response (SVR). Multivariate
analysis identified SVR after IFN therapy as an inde-
pendent significant prognostic factor (Hazard ratio
0.18, 95%CI 0.03–0.65, p = 0.006). Postoperative com-
plications including liver failure (n = 1), portal throm-
bosis (n = 7), ascites (n = 5), and bacterial infections
(n = 4) were observed in 14 patients (30%).
Conclusions: Splenectomy can be a feasible supportive
therapy for the continuation of anticancer therapy and
completion of IFN therapy based on improvements in
liver function and thrombocytopenia with minimum
complications in patients with HCC and advanced cir-
rhosis with no potential donor.
PPLT25-007
EFFICACY AND SAFETY OF
EVEROLIMUS WITH REDUCED
TACROLIMUS COMPARED TO
STANDARD TACROLIMUS IN
RECIPIENTS OF LIVING DONOR LIVER
TRANSPLANT: DESIGN OF A
RANDOMIZED STUDY
Gi-Won Song1, Sung-Gyu Lee1, Gary Levy2, Jae-Won
Joh3, Chao-Long Chen4, Wei-Chen Lee5, Sven Kohler6,
Guido Junge7, Shinji Uemoto8 and Kyung-Seok Suh9
1Asan Medical Center, Ulsan University, Korea;
2University of Toronto Transplant Institute, Canada;
3Samsung Medical Center, Sungkyunkwan University,
Korea; 4Kaohsiung Chang Gung Memorial Hospital,
Kaohsiung, Taiwan; 5Linko Chang Gung Memorial
Hospital, Taoyuan, Taiwan; 6Novartis, Switzerland;
7Novartis, Switzerland; 8Kyoto University Medical
Center, Kyoto, Japan; 9Seoul National University
Hospital, Korea
Introduction: Living donor liver transplantation
(LDLT) is a treatment option for patients with end-
stage liver disease, particularly in Asia where availabil-
ity of deceased donor organs is limited. Here we pres-
ent a study, designed to evaluate the efficacy and safety
of everolimus (EVR) with reduced tacrolimus (rTAC)
compared to standard TAC (TAC-C) in LDLT
recipients.
Method: H2307 is a 24-month (M), multicenter, ran-
domized, controlled study planned to enroll 470 LDLT
recipients (male and female ≥18 years). After LT and a
30-day run-in period with TAC (5–15 ng/mL)  myco-
phenolate mofetil  anti-IL2 induction and steroids (to
mitigate wound healing complication and to allow allo-
graft regeneration), patients will undergo stratified ran-
domization (RND) in 1:1 ratio to receive EVR (C0 3–
8 ng/mL) + rTAC (C0 3–5 ng/mL) or TAC-C (8–
12 ng/mL from RND to M4; 6–10 ng/mL from M4 to
end of study). Stratification is based on hepatocellular
carcinoma (HCC) status at time of LT. Inclusion crite-
ria include: (1) HIV negative status and (2) known
HCV and HBV status. Exclusion criteria include: (1)
HCV negative subjects receiving transplant from HCV
positive donor, (2) MELD score >35 within 1 M prior
to transplantation, and (3) HCC with extra hepatic
spread or macrovascular invasion. Study objectives
include composite efficacy failure rate of treated biopsy
proven acute rejection, graft loss or death, evolution of
renal function from RND to M12 and M24, and inci-
dence of adverse events. Specific objectives include inci-
dence and time to HCC recurrence, evolution of HCV
viral load and allograft regeneration.
Results: The study will be run at 41 centers across 11
countries. First patient to be enrolled in August 2013
and M12 results are expected in early 2016.
Conclusions: For the first time, a randomized, multi-
center study is performed in a large cohort of LDLT
recipients, comparing the efficacy and safety of EVR+r-
TAC versus TAC-C.
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PPLT25-008
RISK FACTORS FOR BILIARY
COMPLICATIONS AFTER LIVER
TRANSPLANTATION: SINGLE CENTER
LONG-TERM RESULTS
Weiguang Xu, Bong-Wan Kim, Yong Keun Park and
Hee Jung Wang
Ajou University School of Medicine, Korea
Introduction: Biliary complication (BC) is one of the
major causes of morbidity and/or mortality of the liver
transplant patients. Refined preparation of graft’s and
recipient’s bile ducts is regarded as the most important
to prevent BC after liver transplantation (LT), as well
as fine anastomosis technique, short ischemic time, and
appropriate selection of the graft also necessary. Surgi-
cal procedure of LT in our center has been stabilized
since 2006, in this study, we analyzed long-term out-
come of biliary reconstruction in LT to evaluate risk
factors of BC other than technical issues.
Method: Between February 2006 and February 2012,
total 195 consecutive patients received LT (72 DDLT,
123 LDLT) at our hospital. The operative procedures
of duct preparation, biliary anastomosis were done in
same way according to deceased or living donor. BC is
defined as biliary stricture (BS) and bile leakage (BL).
BC was diagnosed by clinical, laboratory, and radiolog-
ical findings of BS and BL. Median follow-up period of
all recipients was 36 months (range 1–84 months).
Results: Among total 195 recipients, 27 (13.8%)
patients experienced BC during follow-up (21 BS and
10 BL). Risk factors of the BC in total 195 patients
were LDLT, GRWR <0.8%, and warm ischemic time
(p < 0.05). Risk factors of BS were GRWR<0.8% and
warm ischemic time (p < 0.05), and risk factor of BL
was nil. Incidence of BC in DDLT was 4.2% (3/72)
and in LDLT 19.5% (24/123). Risk factors of BS in
LDLT (15.4%, 19/123) were cold and warm ischemic
time and small bile duct (p < 0.05), and there was no
risk factor of BL in LDLT (6.5%, 8/123).
Conclusions: According to the data in this study, BC is
still higher in LDLT than DDLT. In LDLT, selection
of large size bile duct and shorten ischemic time should
be necessary to reduce BS after LT.
PPLT25-009
PREVENTION AND RISK FACTORS OF
HEPATITIS B RECURRENCE AFTER
LIVING DONOR LIVER
TRANSPLANTATION
Gun Hyung Na, Dong Goo Kim, Jae Hyun Han, Eun
Young Kim, Soo Ho Lee, Tae Ho Hong and Young
Kyoung You
Catholic University of Korea, Seoul St. Mary’s Hospital,
Korea
Introduction: Without effective prophylaxis, liver trans-
plantation (LT) for hepatitis B virus (HBV)-related
liver disease is frequently complicated by severe and
rapidly progressive HBV recurrence. We analyzed the
combination of low-dose hepatitis B immunoglobulin
(HBIG) and the new nucleos(t)ide analogue, entecavir,
as prophylaxis for HBV recurrence after living donor
liver transplantation (LDLT).
Method: A total of 315 patients with positive hepatitis
B surface antigen (HBsAg) underwent LDLT at our
transplant center between July 2003 and December
2011. Our protocol for post-transplantation HBV pro-
phylaxis was a combination of low-dose HBIG and nu-
cleos(t)ide analogues.
Results: During a median follow-up period of
49 months post-transplant, 10 patients (3.2%) had
HBV recurrence, which was significantly related to
HCC at transplantation (p = 0.041) and post-LT antivi-
ral agent (p < 0.001) in multivariate analysis. The level
of HBV DNA and hepatitis B e antigen (HBeAg) state
at transplantation were not significant factors for HBV
recurrence (p = 0.342 and p = 0.802 respectively). In
170 patients with HCC at LDLT, HCC recurrence was
significantly related to HBV recurrence (p < 0.001).
Among 10 patients with HBV recurrence, three are
alive and two had lost HBsAg. The remaining seven
patients died of HCC recurrence.
Conclusions: The combination of low-dose HBIG and
nucleos(t)ide analogues is safe and effective for HBV
prophylaxis after LDLT. As a post-LT antiviral treat-
ment, entecavir is more effective than lamivudine. HCC
at transplantation was significantly associated with
HBV recurrence. HBV-related HCC patients who
undergo LDLT require close virological monitoring.
PPLT25-010
TIPS AND PITFALLS OF
INTRAOPERATIVE DIRECT SPLENO-
RENAL SHUNT LIGATION AT LIVER
TRANSPLANTATION IN PATIENTS
WITH BIG SPLENO-RENAL SHUNT
Hyeyoung Kim, Kwang-Woong Lee, Nam-Joon Yi,
Hae Won Lee, YoungRok Choi, Suk-Won Suh, Tae
Yoo, Jeong-Moo Lee and Kyung-Suk Suh
Seoul National University College of Medicine, Korea
Introduction: The patient with big spleno-renal shunt
(SRS) is challenging at liver transplantation (LT), irre-
spective of organizing portal vein (PV) thrombus. We
introduced the clinical outcome of 16 patients who
received intraoperative direct SRS ligation.
Method: Among 580 recipients from January 2010 to
June 2013, 16 patients underwent intraoperative SRS
ligation. SRS was easily found and isolated below the
distal pancreas in all cases. Pre-LT MELD score was
15.9  6.4 (8–33). Main PV diameter was
7.9  2.9 mm (4.0–13.9). PV thrombectomy was
accompanied in 7 cases.
Results: Except one hospital mortality, 15 patients
showed favorable outcome. The mortality was related
with sepsis, but not with liver dysfunction. One patient
received simultaneous splenic artery (SA) ligation due
to strong PV flow during LT. Massive and prolonged
ascites after LT was presented in four patients with
small diameter of PV (<7.5 mm). They were living
donor recipients, and not related with pre-LT ascites.
Among them, one patient received SA embolization at
postoperative days 30, and ascites was well controlled
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after that. In the other three, ascites was tolerable and
well controlled by drainage and/or diuretics. After the
case of SA embolization, we performed test clamp of
SRS before ligation in small diameter of PV, and
applied PV pressure monitoring in patients who showed
a sign of portal hypertension such as bowel edema. In
two cases, we applied total or partial SRS ligation
under PV pressure monitoring, within 8 mmHg of pres-
sure difference between pre- and post-SRS ligation.
There was no portal hypertensive sign in the other 12
patients. Fifteen patients have maintained normal liver
function until last follow-up.
Conclusions: Intraoperative SRS ligation was safe and
effective method to solve big SRS. However, severe
portal hypertension after shunt ligation needed to be
concerned in small diameter of PV, and selective simul-
taneous intraoperative portal pressure monitoring could
be helpful for prevention of it.
PPLT25-011
IS AFP LEVEL A BETTER PROGNOSTIC
OF SURVIVAL THAN TUMOR BURDEN
IN PATIENTS WITH
HEPATOCELLULAR CARCINOMA
UNDERGOING LIVING DONOR LIVER
TRANSPLANTATION?
Andrzej Komorowski1, Karan Julka2, Bhavin
Vasavada2, Chih-Che Lin2 and Chao-Long Chen2
1Maria Sklodowska-Curie Memorial Cancer Centre,
Poland; 2Chang Gung Memorial Hospital, Taiwan
Introduction: HCC is one of the leading causes of
death worldwide. The commonly used criteria for list-
ing patiens for treatment with living donor liver trans-
plant (LDLT) are Milan and University of California,
San Francisco (UCSF) criteria. We analyzed our expe-
rience with LDLT in patients with HCC and HCV
associated liver disease in order to determine if AFP is
a better predictor of outcome than the tumor burden.
Method: We have identified all patients with HCV
related liver disease and HCC who have undergone
LDLT in one center during the period from December
2000 to December 2012. Outcomes from the prospec-
tive database were compared for patients who met
Milan criteria (single tumor ≤5 cm, maximum of 3 total
tumors with none >3 cm) or not, and for patients with
different cut-off AFP level. Univariate and multivariate
analysis of factors influencing overall survival (OS) and
recurrence free survival (RFS) were performed.
Results: A total of 115 patients with HCC and HCV
associated liver disease received LDLT during the study
period. OS was 91.7% at 5 years, 82.9% at 3 years and
80.2% at 5 years. Number of tumors (HR = 1.61) the
overall tumor size (HR = 1.12) and MELD score (cal-
culated without HCC exception points; HR = 1.09)
were significant factors influencing survival on univari-
ate analysis. True MELD score was also significantly
influencing RFS on univariate (HR = 1.18) and multi-
variate analysis (HR = 1.53). The serum AFP level had
no influence on overall and recurrence free survival
regardless of the cut-off point. There was no difference
in outcomes for patients within and beyond Milan cri-
teria.
Conclusions: Tumor burden and MELD score were
factors influencing OS and RFS in patients undergoing
LDLT for HCC and HCV associated disease. Pretrans-
plant AFP level did not influence outcome.
PPLT25-012
LIVING DONOR LIVER
TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA
Sumihito Tamura, Yasuhiko Sugawara, Rihito Nagata,
Junichi Kaneko, Tomohiro Tanaka, Taku Aoki,
Takeaki Ishizawa, Kiyoshi Hasegawa and Yoshihiro
Sakamoto
The University of Tokyo, Japan
Introduction: Treatment of hepatocellular carcinoma
(HCC) among patients with end-stage liver disease rea-
mins a challenge. Liver transplantation is the most
effective option. From a global stand point, Asian
experience is unique in that the majority is based on
living donors.
Method: Considering the advantages of lving donor,
we have cautiously expanded the indication for HCC
beyond the Milan criteria to maximum tumor size of
5 cm and upto 5 nodules [5-5 rule criteria: TC].
Between 1996 and 2012, 123 recipients underwnet
LDLT with HCC at our institution. Outcomes of these
recipients were studied.
Results: 59% was HCV and 32% was HBV. 3 years
overall survival rate was 81%. 116 cases were within
the TC among which 107 cases were within the Milna
criteria [MC]. Overall 3 years recurrence rate was 9%.
3 years recurrence rate of those within TC was 8%.
Cases outside TC presentd with 3 years recurrence rate
of 50%. 3 years survival within MC, outside MC but
within TC, outside TC were, 94%, 88% and 54% rep-
ectively. Outside TC presented with significantly infe-
rior outcomes, whereas expansion to TC did not affect
the outcome significantly.
Conclusions: The result may justify the expansion of
criteria outside MC and also the application of TC.
Strict adherence to MC should be considered a relative
issue in the LDLT setting.
PPLT25-013
SPLIT LIVER TRANSPLANTATION FOR
PEDIATRIC PATIENTS IN ASAN
MEDICAL CENTER
DongHwan Jung, SungGyu Lee, Shin Hwang, KiHun
Kim, ChulSoo Ahn, DeokBog Moon, KyungMo Kim
and DaeYeon Kim
Asan Medical Center, Ulsan University, Korea
Introduction: Because of donor liver shortage, split
liver transplantation (SLT) has been developed to
enlarge the relatively constant pool of organs. In
Korea, SLT has been performed in deceased donor
liver transplantation.
Method: From 1999 to June 2013, our center per-
formed 51 cases of SLT including children and adults.
Among them, 19 cases of SLT were performed for chil-
dren.
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Results: All pediatric SLTs were ABO compatible and
5 cases were re-transplantation. Age of pediatric SLTs
was from 7 months to 11 years old. Males and Females
were 9 and 10, respectively. Body weights of recipients
were from 6.9 to 27.3 kg. 16 recipients were alive now.
1 and 5 year survival rates were 89.5% and 78.3%,
respectively.
Conclusions: SLT for pediatrics was acceptable opera-
tion for pediatric recipients as living donor liver trans-
plantation.
PPLT25-014
THE OUTCOME OF THE PATIENTS ON
WAITING LIST FOR
RETRANSPLANTATION AFTER LIVING
DONOR
Mitsuhisa Takatsuki, Masaaki Hidaka, Akihiko
Soyama, Tomohiko Adachi, Amane Kitasato, Tamotsu
Kuroki and Susumu Eguchi
Nagasaki University, Japan
Introduction: The aim of study is to show the outcome
of the patients on the waiting list for retransplantation
after living donor liver transplantation (LDLT) in
Nagasaki University.
Method: Of the 185 primary LDLTs in Nagasaki
Univ., 21 cases (11%) were considered as requiring re-
transplantation for various causes of graft dysfunction.
They consisted of 11 males and 10 females, with med-
ian age of 53 (range 0–65). The indication of retrans-
plantation included graft failure in 8, biliary
complication in 3, HCV recurrence in 2, cholestatic cir-
rhosis in 2, chronic rejection in 2, acute rejection,
small-for-size syndrome, portal vein thrombosis, intra-
hepatic biliary stricture in 1 each. The outcome of these
cases was retrospectively reviewed.
Results: The median period from primary LDLT to
the time of consideration for retransplatation was
320 days (range, 13–2334). Eighteen of 21 cases (86%)
showed their will to receive retransplantation, and all 3
who did not hope retransplantation died. Nine of 18
cases (50%) hoped to undergo LDLT, while other 9
cases hoped to receive deceased donor liver transplanta-
tion (DDLT). Finally, 7 patients underwent retrans-
plantation from living donors again, and no DDLT
was performed. Of these 7 patients, 4 (57%) are cur-
rently doing well with good graft functions.
Conclusions: One-third of the patients on waiting list
of retransplantation after primary LDLT underwent re-
transplantation finally, with reLDLT only, possibly due
to the scarcity of DDLT in Japan.
PPLT25-015
SURGICAL TREATMENT FOR EARLY
STAGE HEPATOCELLULAR
CARCINOMA IN TRANSPLANTATION
ERA
Yong Keun Park, Bong-Wan Kim, Weiguang Xu and
Hee Jung Wang
Ajou University School of Medicine, Korea
Introduction: Liver transplantation (LT) is the best
treatment option for hepatocellular carcinoma (HCC)
meeting the Milan criteria (MC). However, due to lim-
ited organ availability, hepatic resection (HR) followed
by salvage LT in case of recurrence or liver cirrhosis
progression could be an alternative strategy. Our aim
in this study was to evaluate oncologic outcome after
HR of early stage HCC which’s potentially transplanta-
ble, with special reference to salvage LT strategy.
Method: We retrospectively studied 457 patients (396
HR and 61 LT) with HCC fulfilling MC from July
1994 to December 2011. Prognostic factors for tumor
recurrence and survival after HR were analyzed. Addi-
tionally, we sought to characterize the candidates for
this strategy through analysis of the factors influencing
to poor recurrent pattern which precluded SLT and
converted the situation to a dismal prognosis.
Results: Pathological analysis after surgery revealed 79
patients (19.9%) exceeded the Milan criteria. After a
median follow-up of 45 months, 5-year disease-free,
and overall survival rates after HR were 46.8% and
72.4%, respectively. 204 patients experienced HCC
recurrence after HR, and 24 among them were per-
formed salvage LT. The overall 5-year survival rates of
primary LT group and salvage LT group were 77.0%,
and 78.6%(p = 0.899). Predictive factors for non-trans-
plantable recurrence (nTR) due to recurred tumors
beyond MC included Child-Pugh class B, >3 cm in
tumor size, microvascular invasion, intrahepatic metas-
tasis, pathological beyond Milan criteria, and histologic
staging of fibrosis IV. According to the number of risk
factors, prognosis of patients who had 3–5 factors
groups was poorer than those of 0–2 factors groups
(p = <0.001).
Conclusions: Despite satisfactory survival outcomes,
HR for HCC meeting MC should be restricted to
patients with few risk factors of nTR. Salvage LT for
recurred HCC after HR is a valid treatment strategy
for selected patients with favorable outcome.
PPLT25-016
PRECISE RECONSTRUCTION OF VEINS
AND BILE DUCTS IN RAT LIVER
TRANSPLANTATION
Hongdong Wang, Chonghui Li, Xinlan Ge, Kesen Xu,
Ai-Qun Zhang and Jiahong Dong
PLA General Hospital, China
Introduction: Rat orthotopic liver transplantation
(ROLT) remains a technically demanding procedure,
especially regarding the reconstruction of the suprahe-
patic vena cava (SHVC). In this study, a new microsu-
ture technique was developed for anastomosis of the
SHVC, and a special single-groove cuff and blade-cut
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stent were introduced. With these modified techniques,
we aimed to make a precise anastomosis of the SHVC
and to provide optimal cuffs and stents for the recon-
struction of the veins and bile ducts.
Method: According to different microsuture techniques
for the SHVC and different types of cuffs and stents,
three ROLT groups were created to compare the oper-
ation times and prognoses. Sham operations were per-
formed as controls in the fourth group. The time
expenditures with each step were compared among the
transplantation groups. Biochemical parameters were
tested at the end of a one-month observation period.
The short- and long-term survival rates of the trans-
plantation groups were recorded and compared.
Results: Our new microsuture technique was faster
than the conventional continuous suture technique for
SHVC anastomosis (p < 0.05). The use of a single-
groove cuff for reconstruction of the portal vein (PV)
and the infrahepatic vena cava (IHVC) shortened the
anastomotic time (p < 0.05). The use of blade-cut stents
resulted in fewer biliary complications and better sur-
vival over the short and long terms (p < 0.05).
Conclusions: Our new microsuture technique and the
single-groove cuffs proved to be a precise method for
venous reconstruction which shortened the anhepatic
time and the anastomotic time significantly. The blade-
cut stents apparently reduced the incidence of biliary
complications. In summary, with this precise microsu-
ture technique and delicate cuffs and stents, excellent
long-term survival can be achieved easily and stably for
ROLT.
PPLT25-017
HOW GASTROESOPHAGEAL
VARICOSE BECOME PROMINENT
EVEN AFTER LIVING DONOR LIVER
TRANSPLANTATION
Yoshihiro Matsumoto, Ken Shirabe, Toru Ikegami,
Tomoharu Yoshizumi, Yuji Soejima, Mizuki
Ninomiya, Yo-ichi Yamashita, Hideaki Uchiyama,
Hirofumi Kawanaka and Yoshihiko Maehara
Kyushu University, Japan
Introduction: Although it is well known that liver
transplantation using a whole liver graft treat portal
hypertension including esophago-gastric varices
(EGVx), it is undetermined whether living donor liver
transplantation (LDLT) does.
Method: We retrospectively analyzed 137 cases, under-
going adult-to-adult LDLT for end stage liver diseases.
Results: The primary disease was cirrhosis due to Hep-
atitis B virus, or Hepatitis C virus (n = 76, 62.6%), pri-
mary biliary cirrhosis (n = 26, 21.1%), primary
sclerosing cholangitis (n = 5, 4.1%), and other causes
(n = 15, 12.2%). Among 137 cases, 122 (89.0%) had
EGVx, and endoscopic treatment was performed in 73
recipients (53.3%) before LDLT. After LDLT, risky
EGVx was identified in 23 recipients (16.8%), including
12 patients with persistent EGVx and newly developed
or worsened EGVx in 11. The mean post-LDLT period
as having risky EGVx was 2.3 years. The bleeding of
EGVx occurred in 7 of 23 (30.4%) cases with rEGVx
after LDLT. Treatment for EGVx after LDLT was
comprised of endoscopic treatment (n = 9, 39.1%), bal-
loon occluded-retrograde transvenous obliteration
(n = 4, 17.4%), and surgical approach (n = 7, 30.4%).
Uni- and multi- variate analyses showed that having
rEGVx before LDLT (66.6% vs 30.0%, p < 0.01),
donor age >40 years (34.2% vs 60.9%, p = 0.018),
post-LDLT cholangitis (52.2% vs 23.7%, p = 0.008)
and intraoperative simultaneous splenectomy (21.7% vs
51.7%, p = 0.007) were the significances for risky rEG-
Vx after LDLT. The 5-year graft survival with EGVx
or without EGVx was 66.1% and 77.2%, respectively
(p = 0.100).
Conclusions: The current study revealed that no sple-
nectomy and cholangitis after LDLT could be the risk
factors for having rEGVx after LDLT. The relevant
treatment for rEGVx after LDLT expected for avoid-
ance of rEGVx rupture.
PPLT25-018
PROLONGED USE OF STEROIDS IS A
RISK FACTOR FOR RECURRENCE OF
HEPATOCELLULAR CANCER AFTER
LIVER TRANSPLANTATION
Quirino Lai1, Ivo Graziadei2, Alfonso W Avolio3, Gerd
Otto4, Massimo Rossi5, Giuseppe Tisone6 and Jan
Lerut1
1University Hospitals St. Luc, Universite catholique
Louvain, Belgium; 2Medical University Innsbruck,
Austria; 3University Cattolica, Agostino Gemelli
Hospital, Rome, Italy; 4University of Mainz, Mainz,
Germany; 5University Sapienza, Umberto I Hospital,
Rome, Italy; 6Foundation PTV, University Tor Vergata,
Rome, Italy
Introduction: Great debate still exists about the optimal
immunosuppression (IS) after liver transplantation
(LT) in patients with hepatocellular cancer (HCC). The
aim of the present study is to retrospectively analyse
the impact of IS used in relation to HCC recurrence
after LT in a large HCC LT patient population.
Method: Six collaborative European transplant Centers
have been integrated in order to create the European
Hepatocellular Cancer Liver Transplant Study Group
(EurHeCa-LT) database: 633 patients with radiological
diagnosis of HCC transplanted during the period
March 1987–July 2010 were analyzed.
Results: At Cox regression analysis, no steroid discon-
tinuation was the most important independent risk
factor for HCC recurrence (HR 3.10; p < 0.0001), fol-
lowed by the initial use of mTOR inhibitors (HR 2.61;
p 0.01). Stratifying the entire cohort according to the
discontinuation of steroids, patients that never discon-
tinued steroid administration during all the study per-
iod had markedly inferior disease-free survival (5-year
56% vs 86%; p < 0.0001). In Milan Criteria (MC)-IN
patients, continued use of steroids was the unique risk
factor for HCC recurrence (HR 2.41; P-value 0.05). In
MC-OUT patients, independent risk factors for recur-
rence were the initial use of mTOR inhibitors (HR
5.58; P-value 0.005) and the continued use of steroids
(HR 4.21; P-value 0.009). Splitting the entire popula-
tion according to absence or presence of microvascular
invasion, continued use of steroids was the unique
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independent risk factor for HCC recurrence in both
scenarios (HR 2.58 and 3.01; respectively, P-value
0.04).
Conclusions: Prolonged use of steroid is a clear risk
factor for HCC recurrence, especially in MC-OUT
patients and patients presenting microvascular invasion.
Early withdrawal of steroids is advocated in such
patients in order to lower the risk for recurrence. This
observation may be another piece of the puzzle when
extending the inclusion criteria of LT for HCC.
PPLT25-019
EARLY ENTERAL FEEDING ENHANCES
NUTRITIONAL STATUS IN RECIPIENTS
AFTER LIVING DONOR LIVER
TRANSPLANTATION: INTERIM
RESULTS
Jong Man Kim, Sung-Hye Kim, Hyun Jung Kim,
Seunghui Hong, Hyunsook Lim, Sunsim Youn,
Kyeongsug Kim, Miyong Rha, Choon Hyuck David
Kwon and Jae-Won Joh
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: Malnutrition is common in patients with
end-stage liver disease and is a risk factor for post-
transplant morbidity. Additionally, liver transplanta-
tion itself induces poor general condition in recipients.
The goal of this study was to assess the safety of an
enteral feeding diet in patients undergoing living donor
liver transplantation (LDLT) and to investigate its
effects on nutritional status.
Method: Between January 2013 and May 2013, Seven-
teen patients were performed LDLT and enrolled in
the randomized controlled study. Early enteral feeding
group (EN group, n = 8) was defined as patients with
enteral feeding diet through Levin tube which was
started 12 hours after transplantation. Control group
(n = 9) was defined as patients received oral diet after
gas out. We identified the clinical characteristics and
nutritional status before and after LDLT in each
group.
Results: Median age and the model for end-stage liver
disease (MELD) score were 52 years (range 36–
65 years) and 11 points (range 6–22 points), respec-
tively. All patients in the EN group tolerated and did
not show ileus, nausea, and vomiting. There was no
statistical difference in clinical characteristics in pre-
and peri-transplant period between EN group and con-
trol group. The time between transplantation and oral
intake in the EN group was shorter than in the control
group (3 days vs 5 days; p = 0.014). The mid-arm cir-
cumference and mid-arm muscle circumference in the
EN group were higher than in the control group at
1 week and 1 month after LDLT (p < 0.05). The sub-
jective global assessment in EN group was lower than
in the control group at 1 week and 1 month after
LDLT (p < 0.05).
Conclusions: Our results suggest that early enteral feed-
ing may improve postoperative nutritional status and
hastening recovery after LDLT.
PPLT25-020
PREDICTION OF BILIARY
COMPLICATIONS AFTER LIVING
DONOR LIVER TRANSPLANTATION
BASED ON SERUM CYTOKINE
PROFILE
Jong Man Kim, Jeong Hyun Kim, Jin Yong Choi,
Wontae Cho, Seunghwan Lee, Hyunghwan Moon,
Choon Hyuck David Kwon, Eun-Suk Kang, Jae-Won
Joh and Suk-Koo Lee
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: Biliary tract complication is the major
concern associated with living donor liver transplanta-
tion (LDLT). For the early detection of post LDLT
complication, many laboratory parameters have been
studied including various cytokines. To explore the
immunological activation status and the clinical signifi-
cance, the cytokine secretion pattern of LDLT patients
who developed biliary complications was analyzed.
Method: Serum samples from LDLT recipients were
collected 1 day before and 3, 7, 14, and 30 days after
transplantation. Each sample was tested for Interleukin
(IL)-2, IL-4, IL-6, IL-8, IL-10, IL-12, Interferon (IFN)-
r and tumor necrosis factor-a using multiplex bead flow
cytometry.
Results: Eleven patients without any complication and
6 patients with biliary complication showed differential
cytokine profiles in serum. Biliary complication group
(four biliary stricture and two biliary obstruction
patients) displayed significantly increased concentra-
tions of IL-12, IFN-r, IL-10 and IL-4 on post-trans-
plant day 3 and 7.
Conclusions: Profiling of cytokine secretion in serum of
patients in the first month of LTLD may be helpful for
the prediction and diagnosis of biliary complications
within 1 year.
PPLT25-021
OUTCOME OF LIVER
RETRANSPLANTATION: ANALYSIS OF
A 24-YEAR EXPERIENCE IN A SINGLE
CENTER
Hyeyoung Kim, Kwang-Woong Lee, Nam-Joon Yi,
Hae Won Lee, YoungRok Choi, Suk-Won Suh, Tae
Yoo, Jeong-Moo Lee and Kyung-Suk Suh
Seoul National University College of Medicine, Korea
Introduction: Liver retransplantation (re-LT) is only
option for survival of patients with irreversible graft
failure and the need of re-LT has been increasing in
transplant era. The aim of this study was to evaluate
the outcome of re-LT during 24 years in a single major
center.
Method: We conducted a retrospective analysis in
patient who underwent LT between March 1988 and
September 2012.
Results: Among 1,219 LTs during 24 years, 3.1% were
re-LT (n = 38). Twenty eight patients were adult (mean
52 years), and 10 were child (mean 5.7 years). Most
common indication of early re-LT was primary non-
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function in both of adult (87.5%) and child (75.0%).
And most common indication of late re-LT was biliary
complication in both (40–50%). Preoperative major co-
morbidity was very common (>80%) and infection was
most frequent (about 50%) in both. Living donor re-
LT comprised around 20% in both. Inhospital mortal-
ity was 35.7% in adult and 40% in child, and the main
cause of death was sepsis, 81.8% in adult and 25% in
child. Survival rate at 3 month, 1-, 3- and 5- years was
89.4%, 56.5%, 50.3% and 50.3% in adult, 70%, and
60%, 60% and 60% in child.
Conclusions: Survival after re-LT is poorer than after
primary LT regardless of the cause of graft failure.
However, re-LT is the only treatment for graft failure
and candidate for re-LT is increasing. Therefore, we
need more effort to control of perioperative infection
and to improve the survival after re-LT.
PPLT25-022
EXCELLENT SHORT-TERM OUTCOME
OF REDUCED DOSE OF
MYCOPHENOLATE MOFETIL WITH
TACROLIMUS COMBINATION
IMMUNOSUPPRESSION IN ADULT
LDLT AND THE PRECEDING
PRELIMINARY PHARMACOKINETIC
STUDY
Hyeyoung Kim, Nam-Joon Yi, Kwang-Woong Lee,
Hae Won Lee, YoungRok Choi, Suk-Won Suh, Tae
Yoo, Jeong-Moo Lee and Kyung-Suk Suh
Seoul National University College of Medicine, Korea
Introduction: In Korea and other Asian countries, a
reduced dose of mycophenolate mofetil (MMF) has
been used clinically based on the side effects, instead of
conventional fixed dose. There are a few studies on the
feasibility and efficacy of reduced dose of MMF. We
tried to assess the pharmacokinetic study for reduced
dose of MMF, and to evaluate actual dose of MMF in
clinical situation and the short-term outcome of that
with tacrolimus combination in living donor liver trans-
plantation (LDLT).
Method: We retrospectively reviewed adult recipients
who underwent LDLT between October 2009 and
December 2011, and who were administered MMF
(mainly 1.0 g/day) with tacrolimus (through level, 8–
12 ng/mL), with 1 year follow-up after LT. In advance,
we performed a prospective clinical trial in 15 recipi-
ents, and the area under the curve from 0 to 6 hours
(AUC0-6) of mycophenolic acid at postoperative day
(POD) 7 and 14 were checked.
Results: In pharmacokinetic study, the AUC0-6 in all
cases was sub-therapeutic (<30 mg h/L). All 74 recipi-
ents were initially administered reduced dose of MMF
as 1.0 g/day, but, 41.9% (n = 31) needed additional
dose reduction or stop due to related side effects within
12 months after LT. Leukopenia was in 36.5%, gastro-
intestinal problem 6.8%, and infection 5.4% during
study period. At 12 months after LT, 17.6% adminis-
tered lower dose of MMF (0.5 g/day), and 16.2%
needed permanent stop for side effect. The overall
biopsy proven acute cellular rejection was 2.7%. The 1-
, 6- and 12-months rejection-free survival was 98.6%,
98.6% and 97.3%. Patient and graft survival were
100% at 12 months after LT.
Conclusions: Reduced dose of MMF was pharmacoki-
netically sub-therapeutic. However, clinically, MMF
needed reduced dose adjustment based on the side
effects, and reduced dose of MMF with tacrolimus
combination immunosuppression was feasible and safe
with an excellent short-term outcome in adult LDLT.
PPLT25-023
LONG-TERM FOLLOW-UP OF A CASE
OF HEMOPHILIA A SUCCESSFULLY
TREATED WITH AUXILIARY PARTIAL
ORTHOTOPIC LIVER
TRANSPLANTATION
Yong Keun Park, Bong-Wan Kim, Weiguang Xu and
Hee Jung Wang
Ajou University School of Medicine, Korea
Introduction: Factor replacement therapy in hemophilic
patients results in easier bleeding management. How-
ever, the use of contaminated factors from the multi-
donored pooled factors makes patients vulnerable to
risk of viral infections, liver cirrhosis, and hepatocellu-
lar carcinoma (HCC). We believe that liver transplanta-
tion offers an effective therapeutic option to cure
hemophilia, although there is no known trial of liver
transplantation for a hemophilic patient without liver
cirrhosis and/or hepatocellular carcinoma (HCC) in the
world. We encountered such a hemophilic patient who
underwent an auxiliary partial orthotopic liver trans-
plantation (APOLT).
Method: The patient was a 37 year old male with mod-
erately severe hemophilia A (VIII 1.2%), who is known
to be anti-HCV positive (HCV-RNA PCR negative),
anti-HBs positive, and HIV negative. He had a normal
liver without liver cirrhosis and HCC. The donor was
the patient’s 35 year old wife, who was non-hemophilic,
HBsAg negative, and anti-HCV negative. We per-
formed the APOLT procedure with the approval of the
Institutional Ethical Committee for this procedure.
Results: The APOLT was carried out with sufficient
factor VIII coverage just before and during surgery. A
left lobe partial liver graft taken from the donor was
orthotopically transplanted to the recipient after resec-
tion of the native left lobe, while preserving the native
right lobe. Postoperatively, the patient tolerated the
procedure and tacrolimus was maintained for immuno-
suppression. In this recipient, blood factor VIII activity
significantly increased soon after the APOLT, and has
been maintained above 20% without any further bleed-
ing episodes for the past 6 years since the procedure.
Conclusions: An APOLT for a hemophilic patient was
successfully performed, and the hemophilia was eradi-
cated. This finding therefore suggests that APOLT may
be one of the effective therapeutic options for hemo-
philia.
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PPLT25-024
REUSE OF A RIGHT LIVER GRAFT
Bong-Wan Kim, Yong Keun Park, Weiguang Xu and
Hee Jung Wang
Ajou University School of Medicine, Korea
Introduction: Hepatic encephalopathy (HE) is a major
cause of death in the patients with fulminant hepatic
failure unless liver transplantation (LT) is not per-
formed within time. Moreover, brain damage followed
by HE could be irreversible and progressive to brain
death even after LT. We report a successful reuse of a
right liver graft from a recipient diagnosed as brain
death after LDLT.
Method: A 32-year-old female (blood-type B+) with
fulminant hepatic failure due to acute hepatitis A was
admitted at our hospital. Despite of intensive care, her
HE was not improved. The emergency LDLT was
decided and performed on hospital day 4. A right liver
with middle hepatic vein graft (weight 590 g) was trans-
planted from her younger sister (blood-type O+). The
graft was well functioning and the serum ammonia and
urea was normalized within a day after LDLT. How-
ever, she was not recovered from HE and diagnosed
brain death on postoperative day 6. Her family decided
to donate the transplanted liver graft to other patient,
and second LT by reuse of graft was performed on 8th
day after first LDLT. The second recipient was a 43-
year-old man (blood-type B+) who suffered end-stage
liver cirrhosis by HBV. The second LT was successfully
performed with usual manner using duct-to-duct biliary
reconstruction.
Results: The graft weight measured 920 g during 2nd
LT, and wedge liver biopsy of the reused graft showed
histologically normal lobular architecture without any
swelling or congestion. The postoperative course of the
2nd recipient was uneventful and discharged on post-
transplant day 28. The graft is well functioning until
now for more than 5 years without serious complica-
tion.
Conclusions: In our experience of this case, we
observed rapid and complete histological liver regenera-
tion of the partial graft. The LT by reuse of a right
liver graft is technically feasible, and the reused graft is
also well functioning as usual liver graft.
PPLT25-025
LIVING DONOR LIVER
TRANSPLANTATION FOR
NONALCOHOLIC STEATOHEPATITIS
Tomohiro Tanaka1, Yasuhiko Sugawara2, Noriyo
Yamashiki1, Sumihito Tamura2, Junichi Kaneko2,
Yutaka Takazawa2, Taku Aoki2, Kiyoshi Hasegawa2,
Yoshihiro Sakamoto2 and Norihiro Kokudo2
1The University of Tokyo Hospital, Japan; 2Graduate
School of Medicine, University of Tokyo, Japan
Introduction: The number of patients referred for liver
transplantation (LT) with non-alcoholic steatohepatitis
(NASH) has been increasing recently. However, infor-
mation on living donor liver transplantation (LDLT)
for NASH is still limited.
Method: This study was conducted to document the
details of LDLT for NASH in a Japanese LT center.
Among all the LDLTs performed in our institution
since April 1996 to March 2013 (n = 425), we identified
7 patients undergoing LDLT for NASH.
Results: Five patients were female. Six out of all the
seven patients (86%) had BMI >25 at LDLT. Three
received their graft from their children, and 4 did from
their spouses. The median follow-up period post-LDLT
was 5.0 years and all were alive at the last follow up.
Biopsy- proven recurrent NASH following LDLT was
detected in one patient, and no other signs of recur-
rence were detected among the remaining 6 recipients.
No significant comorbidities were observed following
donor surgery among the respective 7 living donors
during the follow up period. We also retrospectively
reviewed 22 patients with NASH-related end stage liver
diesease (ESLD) who were evaluated but rejected for
LDLT during the same period in our clinic. Ten out of
the 22 candidates (45%) were rejected because of the
reasons which presumably were related to the nature of
NASH.
Conclusions: The outcome of LDLT for NASH-related
ESLD in our institution was excellent, but the sample
size was too small to lead robust conclusions. Further
studies in larger patient cohort both on recipients and
living donors are required.
PPLT25-026
THE RESULTS OF EARLY PROTOCOL
LIVER BIOPSY IN HEPATITIS C VIRUS
RELATED RECIPIENTS IN THE
FAVORABLE INTERLEUKIN-28B
GENOTYPE PREVALENT AREA
Hyeyoung Kim, Kwang-Woong Lee, Nam-Joon Yi,
Hae Won Lee, YoungRok Choi, Suk-Won Suh, Tae
Yoo, Jeong-Moo Lee and Kyung-Suk Suh
Seoul National University College of Medicine, Korea
Introduction: Recently, there is a trend of protocol
biopsy based hepatitis C virus (HCV) treatment. The
aim of this study was to evaluate the results of early
protocol biopsy in HCV related recipients in the favor-
able interleukin-28B genotype prevalent area, Korea.
Method: We retrospectively reviewed the results of
early protocol biopsies (3, 6 and 12 months after LT)
in patients who underwent LT due to HCV related liver
disease between January 2010 and June 2012. In case
of fibrosis or inflammation on histology irrespective of
liver function test (LFT), we started HCV treatment
with ribavirin and pegylated interferon. Additionally, in
case of significant LFT abnormality with histologic
mild hepatitis, we started HCV treatment.
Results: Among 428 recipients, 36 patients (8.4%)
related with HCV. Among them, 63.9% (n = 23)
underwent protocol biopsies more than once within a
year after LT. Mean age was 57.6 years and 60.9%
was living donor LT. The genotype I and II were
47.8% and 34.8%, respectively. At 3 months after LT,
15 patients underwent protocol biopsy and 46.7%
(n = 7) started the HCV treatment. Besides the patients
on HCV treatment, 12 recipients underwent protocol
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biopsy at 6 months and 58.3% (n = 7) started the
HCV treatment based on biopsy. And, among the
remained 9 recipients, 8 underwent biopsy at
12 months and 37.5% (n = 3) started the HCV treat-
ment. Finally, 73.9% (n = 17/23) underwent HCV
treatment due to HCV recurrence after LT based on
early protocol biopsy, and among them, EVR was pres-
ent in 88.2% (15/17). Except 4 patients on HCV treat-
ment, SVR was present in 53.8% (n = 7/13).
Conclusions: In this present study, more than two-third
of HCV related recipients went into HCV treatment
based on early protocol biopsy after LT. Early protocol
biopsy based HCV treatment after LT can be effective
for HCV related recipients.
PPLT25-027
ARTERIAL ANASTOMOSIS USING
SURGICAL MICROSCOPE IN LIVE
DONOR LIVER TRANSPLANTATION
Chul Soo Ahn, Shin Hwang, KiHun Kim, DeokBok
Moon, TaeYong Ha, GiWon Song, Donghwan Jung,
GilChun Park and SungGyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: Sufficient hepatic arterial flow is essential
for graft survival with optimal function and decreasing
postoperative complications in live donor liver trans-
plantation.
Method: But in general, partial graft’s hepatic arteries
are small in size with thin and week vascular wall and
sometimes graft had multiple arteries. In recipient,
arterial sumps are relatively hypertrophied and edema-
tous with fragile intima which is prone to get injury
preoperatively or intraoperatively. So surgical micro-
scope is applied with meticulous and precise tech-
niques for the reconstruction of hepatic arteries.
Gentle and systemic hilar dissection is needed to pre-
vent additional injury to hepatic arteries. Recipient’s
arterial stump is selected by direct inspection of color,
pulsation, blood flow from its opening, and size
matching with donor’s stump. Simple interrupted
suture with intimal approximation technique is applied
with various modified methods according to arterial
conditions. Tension-free anastomosis is essential to
prevent late stricture of artery. If the graft has multi-
ple hepatic arteries, all of its sumps should be recon-
structed.
Results: Alternative arterial flow is needed when all
recipient’s hepatic artery was injured. Right gastroepi-
ploic artery can be the first possible choice. Close fol-
low up of reconstructed hepatic artery is inevitable,
early detection and early management can save the
graft and patient.
Conclusions: In conclusion, sufficient arterial flow for
transplanted graft can be achieved by meticulous and
precise anastomosis with various technical modification
under the surgical microscope following close postoper-
ative monitoring.
PPLT25-028
THE USEFULNESS OF
CRYOPRESERVED VEIN GRAFT FOR
RIGHT LIVER GRAFT IN LIVING-
DONOR LIVER TRANSPLANTATION
Masahiro Yan, Shintaro Yamazaki, Tokio Higaki,
Masatoshi Makuuchi and Tadatoshi Takayama
Nihon University School of Medicine, Japan
Introduction: Living-donor liver transplantation
(LDLT) using a right liver graft is a routine procedure in
adults. The use of an allogenic cryopreserved vein for
hepatic vein reconstruction facilitates full vascularization
and minimizes graft congestion. We reports two cases of
LDLT with right liver graft and mentioned the usefulness
of allogenic cryopreserved autologous graft in LDLT.
Method: First case, a 53-year-old man with hepatitis B
cirrhosis underwent LDLT. The graft weighed 740 g
but the estimated liver congestion area is 320 g
(43.2%). We decided to use a cryopreserved iliac vein
(length, 65 mm; diameter, 22 mm) as a homograft for
reconstructing the hepatic veins. Four drainage veins
(RHV, MHV, V8 and IRHV) were gathered to one
large vein graft trunk. The double inferior vena cava
(IVC) method was used to put on the right graft. Sec-
ond case, a 29-year-old man with hepatitis B cirrhosis
underwent LDLT. The graft weighed 758 g but the
estimated liver congestion area is 389 g (51.3%). Three
pieces of cryopreserved vein graft was gathered and
make it one large vein graft. Five drainage veins
(RHV, V8, V5 and IRHV x 2) were gathered and
attached right graft. The double inferior vena cava
(IVC) method was used to put on the right graft.
Results: No adverse event observed cryopreserved vein
graft. Good patency was obtained and no congestion
area observed for a long periods.
Conclusions: Using a cryopreserved autologous graft
and full reconstruction of drainage vein in LDLT was
feasible methods for overcoming graft congestion.
PPLT25-029
OUTFLOW RECONSTRUCTION WITH
CRYOPRESERVED VEIN GRAFT FOR
LEFT LIVER GRAFT IN LIVING-DONOR
LIVER TRANSPLANTATION
Shunsuke Yamagishi, Shintaro Yamazaki, Tokio
Higaki, Masatoshi Makuuchi and Tadatoshi Takayama
Nihon University School of Medicine, Japan
Introduction: Direct anastomosis of the hepatic veins to
a thin inferior vena cava (IVC) can sometimes cause a
bend at the anastomotic site, which results in outflow
occlusion. The deformation of the outflow anastomosis
caused by graft regeneration can lead to hepatic vein
stenosis and graft congestion. The key to obtain full
graft functioning, the enlargement of the outflow chan-
nel of the left liver graft was mandatory.
Method: In case of the left liver graft with caudate
lobe, we use an autologous vein and a cryopreserved
vein graft to widen the outflow of left liver graft. More-
over, the short hepatic vein (SHV) from caudate lobe
also reconstructed with a brunch of cryopreserved vein
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graft. The SHV of the caudate lobe can be resected
with part of the recipient’s IVC. The venoplasty of the
liver graft was performed at the back table with cryop-
reserved vein graft. The cryopreserved vein graft was
attached around the outflow vessel of the liver graft to
act as a large circular cuff and the branch was anasto-
mosed to the SHV to act as a conduit and a part of
the side wall of the cuff. The single large circular cuff
was simply attached to the vena cava in recipient site.
Results: The favorable vascular patency and blood flow
achieved with this approach have been confirmed by
Doppler ultrasonography and enhanced computed
tomography. The operation time and the liver graft
cold-preservation time for the simplified technique are
shorter than those for the previous methods.
Conclusions: This technique can be suitable when the
distance between the hepatic vein and the caudate vein
is large. This venoplasty technique is an effective
method of overcoming outflow stenosis. The applica-
tion of this technique in the presence of a suitable SHV
may facilitate graft function.
PPLT25-030
RADIOTHERAPY AS DOWN STAGING
TREATMENT TO LIVING DONOR
LIVER TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA
Jin Yong Choi
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: Curative surgical resection cannot be an
option for most patients with hepatocellular carcinoma
(HCC) because of underlying liver disease or extent of
tumor. Radiotherpay (RT) for HCC is not generally
considered a treatment of choice but RT has been used
in advanced HCC patients such as portal venous tumor
thrombosis (PVTT) and multiple large tumors.
Recently, some studies showed that RT may be bridge
to living donor liver transplant (LDLT). We report our
experience with RT as pretransplant therapy.
Method: Between May 1996 and March 2013, total
1,360 patients treated by LT in our institution. Thirteen
patients had history of RT and we analyze these
patients retrospectively. Objective tumor response is
evaluated with CT and/or MRI according to modified
RECIST criteria and outcomes is estimated by disease
free survival (DFS) and overall survival (OS).
Results: Before RT, seven patients exceed Milan crite-
ria, and four patients have PVTT (Table 2). All
patients are LDLT and interval between RT and
LDLT is 719.7 days (Table 3). 3, 6 months and 1 year
DFS is 82.5%, 73.3%, 55.0%, respectively. And as
shown in Table 4, 5, low AFP group (<20 ng/mL) and
good objective tumor response after RT group have
good prognosis compare with the other group.
Conclusions: LDLT is feasible in advanced HCC
patients who have low AFP levels and good tumor
response after RT.
PPLT25-031
USE OF DEXMEDETOMIDINE IN LIVER
TRANSPLANT RECIPIENTS WITH
POSTOPERATIVE AGITATED
DELIRIUM
Jin Yong Choi
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: Agitated delirium has frequently occurred
after liver transplantation (LT) in the intensive care
unit (ICU) and sedative agents are used to treat.
Recently, dexmedetomidine has been considered to be a
promising agent for agitated delirium.
Method: This study took place between January 2010
and October 2012, when our institution performed 380
LT procedures. Of these, 42 recipients were retrospec-
tively enrolled. Sixteen recipients were enrolled in the
dexmedetomidine group and 26 recipients were placed
in the haloperidol group. The end-point was discharge
from the ICU.
Results: There were no significant drug-related compli-
cations in either group. Dexmedetomidine did not
cause hypotension that required new inotropic infu-
sions while the recipients were on the study drug. Dex-
medetomidine significantly decreased the ICU LOS
compared to haloperidol, from 13.7 to 8.3 days, and
also decreased the ICU LOS after the occurrence of
delirium, from 10.1 to 3.1 days (p = 0.039 and
p = 0.009, respectively). In the dexmedetomidine group,
the dose of supplemental midazolam needed was lower
than in the haloperidol group (1.5 mg vs 6.85 mg,
p < 0.001), while the use of supplemental lorazepam
was lower in the haloperidol group (3.06 mg vs
0.31 mg, p < 0.001). Recipients in the dexmedetomidine
group rarely needed rapid tranquilization (RT).
Conclusions: Dexmedetomidine is a promising agent
for the treatment of ICU associated agitated delirium
in LT recipients.
PPLT25-032
OPTIMIZING PROTOCOL FOR ADULT
ABO-INCOMPATIBLE LIVING DONOR
LIVER TRANSPLANTATION
Jun-Bae Bang, Bong-Wan Kim, Hee Jung Wang,
Yong-Keun Park and Weiguang Xu
Ajou University School of Medicine, Korea
Introduction: The ABO-incompatible living donor liver
transplantation (ABO-I LDLT) is getting popular as a
therapeutic option for end-stage liver disease. However,
perioperative procedure of the ABO-I LDLT are vari-
ous among centers by their experience. The aim of this
study is to determine the optimal procedure for ABO-I
LDLT by comparing outcomes of patients who under-
went ABO-I LDLT using 3 different protocols in our
institute.
Method: From 2008 to 2012, fifteen ABO-I LDLT
were performed and all 15 recipients were commonly
addressed preoperative prophylaxis of Rituximab
(170 mg/m2), plasma exchange (PE) to decrease anti-
ABO antibody and postoperative administration of IV
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globulin (1.5 gm/Kg). Group I (n = 6) patients received
hepatic artery infusion (HAI) therapy and splenectomy.
Group II (n = 7) underwent splenectomy without HAI.
Group III (n = 2) had no HAI or splenectomy. Other
procedures and immune suppression therapies were
applied to 15 patients in the same way. The follow-up
period was median 17 (2–56) months. The clinical,
immunological and surgical data were analyzed and
compared between groups.
Results: Two patients (13.3%) had in-hospital mortal-
ity (1 due to pneumonia and 1 by MOF) and remaining
13 (86.7%) were recovered and discharged with favor-
able liver function after ABO-I LDLT. The biopsy pro-
ven antibody-mediated rejection (AMR) occurred in 4
cases (1 [17%] in group I, 1 [14%] in group II, and 2
[100%] in group III), and two of 4 patients with AMR
developed ischemic type biliary complication (1 in
group I, 1 in group III). Cytomegalovirus infection
occurred in three patients (2 in group I, and 1 in group
II), and bacterial infection in one (1 in group I).
Conclusions: The splenectomy may have important role
to reduce AMR without increasing infectious complica-
tion in ABO-I LDLT. And the role of HAI is uncertain
in our series. In conclusion, the protocol for ABO-I
LDLT could be optimized with preoperative prophy-
laxis of Rituximab and PE, and intra-operative splenec-
tomy, and post-operative administration of IV
globulin.
PPLT25-033
THE PITFALL IN FAMILIAL LIVING
DONOR LIVER TRANSPLANTATION
FOR METABOLIC DISORDERS
YoungRok Choi, Nam-Joon Yi, Hyeyoung Kim,
Min-Soo Park, Suk-Won Suh, Tae Yoo, Hae Won Lee,
Kwnag-Woong Lee and Kyung-Suk Suh
1Seoul National University College of Medicine, Korea
Introduction: The aim of this study was to investigate
the results of liver transplantation (LT) for metabolic
diseases using familial donors.
Method: Autosomal recessive genetic diseseas (Wilson’s
disease, Glycogen storage disease, Congenital fibrosis,
Calori’s disease complex type, tyrosinemia type I, Fac-
tor H deficiency, PFIC and citrullinemia) were
included. 43 LT for 41 recipients were performed
between March 1998 and December 2011. Among
them, familial donor LT (FDLT) was 21 cases and
non-familial donor LT (non-FDLT), including deceased
donor LT, was 20 cases. Metabolic related complica-
tion for donors and recipients after LT were analyzed
retrospectively.
Results: The median age of recipients and donors was
13 years old (range 0.2–52) and 35.5 (21–51) in FDLT,
15 (1–30) and 22 (4–58) in non-FDLT. All living
donors were previous healthy and postoperative liver
function was normalized within 4 months. Recipients
who received grafts from their blood-related family had
no differences in postoperative course compare to non-
FDLT except 2 cases. One recipient, 25 year-old male
who had Wilson’s disease, received the graft from his
sister. Graft-versus-recipient body weight (GRWR) was
0.95%. After re-LT because of graft dysfunction with-
out definite causes, he died of multi-organ failure. The
other recipient was 17 year-old girl with hyperammone-
mia of unknown etiology underwent LT with liver graft
from her mother. GRWR was 1.99%. Her serum
ammonia was elevated without definite causes since
postoperative 10th day and she showed decreased men-
tality with ammonia 4977 lg/dL on POD 23. After she
underwent deceased donor LT due to graft dysfunction,
the level of serum ammonia went down to normal ref-
erence range and she recovered.
Conclusions: When there is potential risk in LT for
metabolic diseases using familial living donor graft, the
selection of a donor in the recipient’s blood related
family member needs to be cautious.
PPLT25-034
LIVER TRANSPLANTATION IN
INFANCY IS NOT RISKIER THAN LT IN
OLDER AGE
Jeik Byun, Nam-Joon Yi, Jeong-Moo Lee, Suk-Won
Suh, Tae Yoo, YoungRok Choi, Kwang-Woong Lee
and Kyung-suk Suh
Seoul National University Hospital, Korea
Introduction: Since 1967 when the first successful LT
was introduced, LT has been the key therapy for end
stage liver diseases. However, whether LT in infancy is
risky is still a matter of debate.
Method: From 1992 to 2010, 152 children had under-
gone an ABO compatible LT in Seoul National Univer-
sity Hospital. Forty-three patients were operated at the
age less than 12 months (Group A) and 109 patients
were more than 12 months (Group B). The mean age
of the recipients was 7 (range 3–11) months in Group
A and 74 (range 12–210) months in Group B. The
grafts’ and patients’ survival rates and post-LT compli-
cations were analyzed. This study was approved by the
Institutional Review Board (H-1208-030-121).
Results: The postoperative PTLD and portal vein com-
plication were more common in Group A (14.0%,
18.6%) than in Group B (1.8%, 3.7%; p < 0.05). The
1-, 5-, and 10-year graft survival rates were similar
between two groups (p > 0.05); 93%, 89%, and 89% in
Group A and 91%, 89%, and 87% in Group B. The 1-
, 5-, and 10-year patient survival rates were 93%, 93%,
and 93%, in Group A and 92%, 90%, and 88% in
Group B (p > 0.05).
Conclusions: LT in infancy showed as good results as
those of older age.
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PPLT25-035
CLINICAL OUTCOMES OF RIGHT
LOBE SPLIT LIVER VS. WHOLE LIVER
TRANSPLANTATION FROM DONORS
OLDER THAN 70 YEARS
Riccardo Memeo1, Nicola De’Angelis1, Chady
Salloum1, Philippe Compagnon1, Alexis Laurent1,
Gerard Pascal1, Cyrille Feray1, Daniel Cherqui2 and
Daniel Azoulay1
1Hopital Henri Mondor, France; 2Hopital Paul Brousse,
France
Introduction: The imbalance between organ supply and
transplant recipients led to extended-criteria liver
donor.
Method: This study aimed to compare right lobe split-
liver transplantations (RL-SLT) with whole liver trans-
plantations (OLT) from donors older than 70 years.
Seventy-one patients who received RL-SLT were
matched for age, sex, and Model for End-stage Liver
Disease with 71 patients who underwent OLT-donors
>70-year-old. Clinical outcomes were compared
between groups. The mean recipient age was
56.2  8.8 years.
Results: HCC was the most common indication for
transplantation (57%). Longer operation time was
associated with RL-SLT (7.3  1.8 hours vs
6.1  1.5 hours; p = 0.0006). Short-term (<2 months)
re-transplant was necessary in 3 patients in the RL-
SLT group (2 portal thrombosis, 1 PNF) and in 3
patients (3 PNF) in the OLT-donors >70-year-old
group. Two cases of postoperative mortality occurred
in the RL-SLT group (1 hemorrhage, 1 multi-organ
failure), and 5 cases in the OLT-donors >70-year-old
group (4 sepsis, 1 hemorrhage). Kaplan–Meier analysis
demonstrated no group differences for 1-year and 3-
year survival rates, which were respectively 92% and
86.3% in the RL-SLT group, and 84.5% and 73% in
the OLT-donors >70-year-old group (p = 0.2)
Conclusions: Both RL-SLT and OLT from old donors
can be safely used to expand the donor liver pool,
showing acceptable clinical results and low complica-
tions rates.
PPLT25-036
PATIENTS IN INTENSIVE CARE UNIT
WERE GIVEN A CAREFUL
CONSIDERATION TO LDLT
Nuri Lee, Jong Man KIM, Suk-Koo Lee, Jae-Won
Joh, Sung Joo Kim, Choon Hyuck David Kwon and
Jae Berm Park
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: A high model for end-stage liver disease
(MELD) score (≥35) was closely associated with poor
posttransplantation outcome in patients who underwent
living donor liver transplantation (LDLT). Addition-
ally, there is little information regarding which factor
would negatively impact the survival of patients with
high MELD scores. The aim of this study was to iden-
tify factors associated with the in-hospital mortality of
patients after LDLT.
Method: We retrospectively analyzed 774 patients
underwent adult LDLT using right graft between 1996
and 2012. Exclusion criteria were retransplantation,
children, left graft, and inadequate medical recording.
Preoperative variables were retrospectively and statisti-
cally analyzed.
Results: The overall 3 months survival rate was 92%
for patients. Acute progression of disease, severity of
hepatic encephalopathy, Child-Pugh class C, hepatore-
nal syndrome, use of continuous renal replacement
therapy, use of ventilator, ICU care before transplanta-
tion, and MELD scores ≥35 were identified as potential
risk factors by univariate analysis. However, only ICU
care before transplantation and MELD scores ≥35 were
independent risk factors for 3 months mortality after
LDLT.
Conclusions: Patients with high MELD score were
often managed in ICU prior to transplantation. LDLT
in these patients should be cautiously considered as
treatment.
PPLT25-037
TECHNICAL ASPECTS OF THE
COMPLEX LIVER TRANSPLANTATION
FROM LIVING RELATED DONORS
Sergey Voskanyan, Alexandr Ammosov, Alexey
Artemiev, Victor Degtyarev and Evgeny Naydenov
State Scientific Center Burnazyan FMBC of the FMBA
of Russia, Russia
Introduction: To present technical aspects of the com-
plex liver transplantation from living related donors.
Method: 65 living-related liver transplantations have
been performed in our clinic. Complex reconstruction
of portal venous inflow or outflow from the cava vein
from liver graft was required in 42 cases, because of
the anatomical features and lesions of the cava gate of
liver. Saving the middle hepatic vein in the donor’s
liver was a prerequisite.
Results: Isolated venous outflow from 8 segment of the
liver to middle hepatic vein according computed
tomography and its diameter was more than 5 mm
were an indication for vascular reconstruction, which
was carried out by implantation in the embouchment
hepatic veins, right or middle hepatic vein and inferior
vena cava. In addition, its implantation was performed
in inferior vena cava with the right hepatic vein after
the formation of the common fistulas at “back table”.
Isolated venous outflow from 6 segment of the liver
according computed tomography was an indication for
vascular reconstruction, which was carried out by iso-
lated implantation of right hepatic vein to the inferior
vena cava. Trifurcation of the portal vein was in 5
patients, its reconstruction and formation common
embouchment of the portal vein via using autovenous
Y-shaped portal conduit at “back table”. Four patients
had a short stump of the right portal vein and anasto-
mosis was formed between the portal vein of the recipi-
ent and autovenous portal conduit. Six recipients
detected thrombosis of the portal vein and thrombecto-
my was performed. In 2 recipients detected complete
fibrous obliteration of the portal vein and its recon-
struction was performed by autovenous prostheses.
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Conclusions: Presented technologies allows to achieve a
good venous inflow and outflow from liver transplant
and thereby provide a satisfactory immediate and long
term results of the living-related liver transplantations,
even in complex cases.
PPLT25-038
COMBINATION THERAPY WITH
SIROLIMUS AND SORAFENIB IN
RECURRENT HEPATOCELLULAR
CARCINOMA AFTER LIVER
TRANSPLANTATION
Wontae Cho, Jong Man Kim, Jin Yong Choi, Seung
Hwan Lee, Sanghoon Lee, Jae Berm Park, Choon
Hyuck David Kwon, Jae-Won Joh1, Sung Joo Kim
and Suk-Koo Lee
Samsung Medical Center, Sungkyunkwan University,
Korea
Introduction: Sirolimus and sorafenib have both been
used in recurrent hepatocellular carcinoma (HCC)
patients after liver transplantation (LT). In the present
study, we evaluated the side effects and efficacy of a
combination therapy consisting of sirolimus and sorafe-
nib.
Method: We retrospectively reviewed patients who had
recurrent HCC after LT between 2005 and 2012. Toxic-
ity was evaluated by reviewing medical records for each
follow-up visit. Efficacy was evaluated according to the
modified RECIST guidelines.
Results: A total of 24 patients who received combina-
tion therapy were reviewed to evaluate drug toxicity.
Side effects included hand-foot syndrome (n = 12,
50%), diarrhea (n = 7, 29.2%), fatigue (n = 2, 8.3%),
and alopecia (n = 1, 4.2%). Among the 24 patients
enrolled in this study, 19 were evaluated for efficacy. A
complete response was observed in only 1 case (5.3%),
while a partial response was observed in 2 cases
(10.5%). Five cases (26.3%) showed disease stabiliza-
tion. The median overall survival after initiation of the
combination therapy was 21.6 months. In comparison,
26 recipients with recurrent HCC received non-combi-
nation therapy. The median survival of patients receiv-
ing a non-combination therapy was 12.0 months.
However, there was no statistically significant difference
in patient survival rate between the combination and
non-combination therapy groups (p = 0.101).
Conclusions: Combination therapy of sorafenib and si-
rolimus for recurrent HCC LT recipients may be useful
for disease management. However, controlled prospec-
tive study is needed to further evaluate the safety and
efficacy of combined sorafenib and sirolimus therapy.
PPLT25-039
LIVER TRANSPLANTATION FOR
IATROGENIC BILE DUCT INJURIES
SUSTAINED DURING
CHOLECYSTECTOMY
Pietro Addeo, Anne-Catherine Saouli, Elie
Oussoultzoglou, Serena Langella, Bernard Ellero,
Marie-Lorraine Woehl-Jaegle and Philippe Bachellier
Hepato-Pancreato-Biliary Surgery and Liver
Transplantation, France
Introduction: The aim of this study was to report a sin-
gle-center experience and review the literature on liver
transplantation (LT) for iatrogenic bile duct injury
(BDI) sustained during cholecystectomy.
Method: A retrospective review of two prospectively
maintained databases of BDI and LT between 1991
and December 2012 was performed. For the same per-
iod, a review of the literature on LT for BDI was
undertaken.
Results: Six patients, with a mean age of 55.3 years
(range 52–55), referred at a mean interval of
206 months (range 96–384) for BDI underwent LT. All
patients had class E Strasberg BDI and underwent mul-
tiple previous BDI repairs. Mortality, morbidity, and
retransplantation rates were 16.6%, 50%, and 16.6%,
respectively. Five patients were alive at a mean follow-
up time of 80.4  92 months. Seventy-two patients
listed or transplanted for BDI were identified and
reviewed. Indications for LT included chronic or acute
liver failure (12.5%), and the delay between BDI and
referral for LT ranged from 1 day to 180 months.
Associated vascular injuries were present in 32% of the
patients, and 60% of the patients had previous failed
BDI repairs. The overall mortality was 30.5%, and the
morbidity ranged from 60% to 100%. The overall 5-
year survival reached 75%.
Conclusions: A long interval of time between BDI and
referral to tertiary centers, a high rate of associated
vascular injuries, and multiple failed previous repair
attempts characterize the history of patients undergoing
LT for BDI. Operative morbidity and mortality rates
of LT are particularly high due to multiple previous
repair attempts and recurrent preoperative biliary infec-
tion.
PPLT25-040
A CASE REPORT OF JUMP GRAFT
WITH POLYTETRAFLUOROETHYLENE
(PTFE) FROM INFERIOR MESENTERIC
VEIN FOR PORTAL INFLOW DUE TO
PORTOMESENTERIC THROMBOSIS IN
DECEASED DONOR LIVER
TRANSPLANTATION
Se Wung Han, Hee Chul Yu, Jae Do Yang, Hong Pil
Hwang, Se Wung Han and Baik Hwan Cho
Chonbuk National University Hospital, Korea
Introduction: Severe portal vein thrombosis (PVT) is
often considered a relative contraindication for living
donor liver transplantation due to the risks involved
and higher morbidity.
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Method: Improvement in operative techniques resulting
in higher success rates have removed PVT from the list
of contraindications in deceased donor liver transplan-
tation.
Results: In this report, we describe a surgical technique
for deceased donor liver transplant in patient with
portomesenteric thrombosis using polytetrafluoroethyl-
ene (PTFE) graft from inferior mesenteric vein (IMV)
for portal inflow.
Conclusions: IMV is one of potential source for portal
inflow in liver transplant.
PPLT25-041
A CASE REPORT OF SUCCESSFUL
TREATMENT WITH COVERED STENT
OF PARTIAL DISRUPTION OF THE
BILIARY ANASTOMOSIS IN LIVING
DONOR LIVER TRANSPLANTATION
Jae Young Moon, Hee Chul Yu, Jae Do Yang, Hong
Pil Hwang, Jae Young Moon and Baik Hwan Cho
Chonbuk National University Hospital, Korea
Introduction: Biliary complications are still the major
source of morbidity for liver transplant recipients. Bile
leaks are usually requiring therapy, including percuta-
neous interventions, endoscopic management, and reo-
perations.
Method: This case report presents a patient with partial
disruption of the bile duct anastomosis site with biloma
treated with a covered stent at 4 months following living
donor liver transplantation. Signs of in-stent distal part
stenosis developed 6 and 12 months following covered
stent placement, which were resolved by balloon dilation.
There were no complications during the interventions.
Results: The latest follow-up, at 3 months following
percutaneous intervention, shows a patent covered stent
without any clinical or morphological sign of further
restenosis.
Conclusions: This successful treatment result suggests
that covered stent implantation can be a minimally
invasive option for simultaneous treatment of partial
bile duct defect following liver transplantation in
selected cases.
PPLT25-042
A NEW MODIFIED TECHNIQUE IN
CLOSURE OF BILE DUCT STUMP IN
LIVING DONOR HEPATECTOMIES
Hany Shoreim1, Osama Hegazy1, Amro Aziz1, Hossam
Eldeen Soliman1, Sherif Saleh1, Taha Yassen1, Ibrahim
Salama1, Khaled Abuelella1 and Koichi Tanaka2
1National Liver Istitute, Egypt; 2Kyoto, Japan
Introduction: Donor safety is a critical issue in LDLT,
biliary complication in living donor hepatectomies
(LDH) is still common.
Method: A new modified technique in closure of bile
duct stump in LDH by “using interrupted non absorb-
able sutures and placing of surgical clip below suture
line” aiming to decrease the high biliary leak (BL) rate.
Results: To evaluate the usefulness of the new tech-
nique; it was applied for consecutive 50 donor hepatec-
tomies and the outcome as regard BL was compared
with the 140 previously performed LDH in whom BL
was reported in 26 donor (18.5%). These 140 patients
were divided into 2 groups: 1- Group A (n = 94) with
sump closure using continuous sutures, BL rate was
19.1% (n = 18). 2- Group B (n = 46) with stump clo-
sure using interrupted sutures, BL rate was 12.4
(n = 8). The 50 donor with the new technique consid-
ered as group C; minimal conservatively treated BL
occur in only 4% (n = 2). Management of BL in the 3
groups was studied and compared.
Conclusions: Significant marvelous reduction in BL rate
was observed by using the new modified technique in
closure of bile duct stump in LDH.
PPLT25-043
LIVING DONOR LIVER
TRANSPLANTATION WITH DUAL LEFT
GRAFTS - FIRST IN LATIN AMERICA
Jo~ao Nicoluzzi, Fabio Porto Silveira, Matheus Macri,
Mauro Monteiro and Fabio Silveira
Angelina Caron Hospital, Brazil
Introduction: Living donor liver transplantation
(LDLT) expanded the therapeutic possibilities for liver
failure patients. The necessary correct match between
the liver mass donated and received sometimes limits
its use.
Method: Report of case and surgical details addressing
the technique of liver transplantation using dual left
grafts.
Results: Well-succeded case in a 52 years old male with
alcoholic chirrosis.
Conclusions: The procedure is technically complex and
demands more resources than other graft types, but
can expand the applicability of LDLT.
PPLT25-044
COMPLICATIONS OF BILIARY
ANASTOMOSIS IN LIVING DONOR
LIVER TRANSPLANTATION: A
RETROSPECTIVE STUDY ON RISK
FACTORS AND MANAGEMENT
TECHNIQUES
Lynette Mee-Ann Loo, Iyer Shridhar Ganpathi, Alfred
Wei Chieh Kow, Stephen KY Chang and
Krishnakumar Madhavan
National University Hospital Singapore, Singapore
Introduction: Biliary complications are well-known
complications causing morbidity in many recipients
following living donor liver transplantation (LDLT).
This early series of patients from a tertiary academic
medical centre in Singapore aim to elucidate the peri-
operative factors, especially intra-operative technical
factors associated with biliary complications and the
management of biliary complications in this group of
patients.
Method: Retrospective 7 years case-series of 24 consec-
utive adult patients from National University Hospital,
Singapore who underwent LDLT from 2007 to 2013.
Median follow up is 494 days (52–2,106 days).
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Results: Three patients (12.5%) developed biliary stric-
ture with the subsequent biliary complications managed
with repeated endoscopic retrograde cholangio-pancrea-
tography (ERCP) and biliary stent inserted. All these
patients are alive at the time of the commencement of
this study. Overall mortality is 16.7%. From literature,
known risk factors such as small diameter of donor’s
bile duct, multiple ducts, use of right lateral sector and
biliary leakage may contribute to the incidence of bili-
ary anastomosis. In our study, there was no significant
difference between the ductal anatomy or size and
warm ischaemia time of those with complications ver-
sus those without biliary complications. However, all
cases with biliary stricture had acute rejection of liver
during the early phase post-transplantation within the
same admission as the index transplantation surgery.
Conclusions: This single-centre retrospective study sug-
gested that peri-operative factors such as acute rejec-
tion of liver may be associated with biliary anastomotic
stricture.
PPLT25-045
MAJOR ITERATIVE SURGERY CAN BE
SAFELY PERFORMED IN LIVER
TRANSPLANT RECIPIENTS RECEIVING
M-TOR INHIBITORS WITHOUT
THERAPEUTIC DISCONTINUATION: A
PRELIMINARY REPORT
Lilian Schwarz, Francois Cauchy, Filomena Conti,
Ailton Sepulveda, Fabiano Perdigao, Denis Bernard,
Yvon Calmus, Olivier Soubrane and Olivier Scatton
Saint Antoine University Hospital, France
Introduction: Mammalian target rapamycin inhibitors
(m-TORi) are increasingly used in patients undergoing
liver transplantation (LT). Yet, there is raising concern
that they could also impair wound healing and favor
the development of several surgical complications. This
report aimed to evaluate both feasibility and safety of
major iterative surgery in liver transplant recipients
receiving m-TORi based immunosuppression without
therapeutic discontinuation.
Method: From 2007 to 2012, 6 liver transplant recipi-
ents underwent a total of 9 iterative major abdominal
or thoracic surgical procedures without m-TORi dis-
continuation or specific dosage adjustment. Their pre-
operative characteristics, operative results and
postoperative outcomes were retrospectively analyzed.
Results: Indications for m-TORi were de novo or
recurrent malignant disease in 5 patients and calcineu-
rin inhibitors related neurologic toxicity in 1 patient.
Emergency surgery was performed in one case and elec-
tive procedures were performed in 8 cases including 5
for malignant disease and 3 for late surgical complica-
tions following LT. Abdominal, thoracic and both
abdominal and thoracic procedures were performed in
6, 2 and 1 cases respectively. No patient died postoper-
atively. One major complication was observed but no
patient required reoperation. No evisceration, incisional
surgical site infection nor lymphocele was reported.
During follow-up, two patients developed incisional
hernia at 12 and 18 months respectively.
Conclusions: Major iterative surgery in liver transplant
recipients receiving m-TOR inhibitors is both feasible
and safe without therapeutic discontinuation or specific
dosage adjustment.
PPLT25-046
LONG-TERM SURVIVAL OUTCOME OF
LIVING DONOR LIVER TRANSPLANT
RECIPIENTS HAVING
PATHOLOGICALLY NON-VIABLE
HEPATOCELLULAR CARCINOMA
Hyung Woo Park, Shin Hwang and Sung Gyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: Complete necrosis of hepatocellular car-
cinoma (HCC) lesions has been occasionally found in
the explant pathology after pretransplant treatment.
This study intended to investigate the long-term prog-
nostic effect of loss of tumor viability after HCC
treatment in living-donor liver transplantation (LDLT)
recipients.
Method: Study patients were 37 patients who demon-
strated non-viable HCC on explant pathology and fol-
lowed up >5 years. Patient medical records were
reviewed retrospectively.
Results: Common primary disease was hepatitis B
virus-associated liver cirrhosis (n = 34). Explant tumor
number was single in 29 and mean maximal tumor size
was 2.1  0.9 cm (range: 0.8–4.0). There was no
patient showing microvascular invasion. Median value
of alpha-fetoprotein was 12 ng/mL (range: 1–1,160).
Only one patient showed recurrence at 20 months, but
he is still alive for more than 6 years after adrenalec-
tomy and repeated pulmonary metastasectomy, thus 5-
year HCC recurrence rate was 2.1%. There were two
late mortality cases, each one due to graft failure and
gastric cancer recurrence. Overall patient survival rate
was 97.3% at 5 years and 92.7% at 10 years.
Conclusions: The results of this study revealed that pre-
transplant treatment-induced loss of tumor viability
definitely decreased the risk of posttransplant HCC
recurrence. Therefore, the patients showing non-viable
HCC can be regarded as belonging to the super-selec-
tion group having minimal risk of HCC recurrence,
thus routine HCC screening is exempted.
PPLT25-047
TREATMENT OF INTRADUCTAL
PAPILLOMATOSIS WITH LIVING
DONOR LIVER TRANSPLANTATION
FOLLOWING PHOTODYNAMIC
THERAPY
Hyung Woo Park, Shin Hwang and SungGyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: Diffuse involvement of the biliary system
with intraductal papillomatosis is a very difficult condi-
tion because it carries high risk of malignant transfor-
mation but surgical resection is usually not feasible. We
herein present a case of intraductal papillomatosis
treated by living donor liver transplantation (LDLT)
following photodynamic therapy.
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Results: The patient was a 49-year-old male showing
diffuse involvement of the whole biliary system. Percu-
taneous transhepatic cholangioscopic examination
revealed diffuse involvement of the villotubular ade-
noma with focal high grade dysplasia consistent with
well-differentiated adenocarcinoma. As the first step,
photodynamic therapy was performed through the
PTBD tract. The second step was planned to perform
LDLT and staged pancreatoduodenectomy. Ten days
after photodynamic therapy, LDLT using modified
right lobe graft was performed and the patient recov-
ered uneventfully. Pathologic evaluation revealed intra-
ductal papillary neoplasm with associated invasive
carcinoma, with lymphovascular invasion but clear bile
duct margin. However 2 months after transplantation,
retroperitoneal abscess developed. The patient’s condi-
tion was not improved through supportive manage-
ment. At posttransplant 7 months, the patient
underwent laparotomy under the impression of periap-
pendiceal abscess, but there was only negative finding.
The patient gradually recovered after prolonged
abdominal drainage. Because of the prolonged course
of intractable abdominal infection and no change in
the residual intrapancreatic bile duct, the plan to per-
form staged pancreatoduodenectomy was discarded.
Currently, 16 months after transplantation, the patient
is doing well without any evidence of recurrence.
Conclusions: Through this case, we suggest that liver
transplantation combined with photodynamic therapy
can be a therapeutic option for intraductal borderline
malignancy.
PPLT26-001
OUTCOME AND PROGNOSTIC
FACTOR OF LIVING DONOR LIVER
TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA
WITH BILE DUCT INVASION
Deok Bog Moon, Sung-Gyu Lee, Shin Hwang, Ki-Hun
Kim, Chul-Soo Ahn, Tae-Yong Ha, Gi-Won Song,
Dong-Hwan Jung, Gil-Chun Park and Wan-Jun Kim
Asan Medical Center, Ulsan University, Korea
Introduction: Less than 10% of icteric hepatocellular
carcinoma (HCC) was related to obstruction of bile
duct by the tumor. Most of the patients underwent
conservative management without hepatectomy due to
decompensated liver function and/or advanced tumor
characteristics. Liver transplantation, however, may be
a great help to some of those patients. This study was
to examine the outcome of liver transplantation for
HCC patients with bile duct tumor thrombus and to
evaluate the prognostic factors.
Method: From October 1993 to December 2009, 13
patients (1.6%) among total 809 liver transplant
patients for HCC had bile duct invasion confirmed on
explants biopsy, and underwent living donor liver
transplantation (LDLT). According to Ueda type, they
were consisted of type I in 4, II in 3, III in 6 patients.
Clinical data were reviewed retrospectively and the pri-
mary end point was survival after LDLT.
Results: The overall survival curve after LDLT for
HCC bile duct invasion is almost same to the hepatec-
tomy for HCC bile duct invasion, 3-YSR 30% in
LDLT. However, disease free survival is significantly
better in LDLT patient, 3-YSR is 41%. The overall
and disease free survival after LDLT for HCC bile duct
invasion is significantly lower than Non-bile duct inva-
sion HCC LDLT patients. However, 2-YSR overall
and disease-free survival after LDLT for HCC bile duct
invasion was more than 50%. In clinicopatologic pro-
files, hypermetabolic PET scan was common, 67%, and
macrovascular vessel invasion was frequently accompa-
nied, 31%. When gross portal vein invasion was not
present, 2-YSR was 72.9%, but when gross portal vein
invasion was present, 2-YSR was dismal, 40%.
Conclusions: Although we can not suggest any conclu-
sion based on statistics due to too small sample size,
LDLT might be a plausible treatment option for HCC
bile duct invasion patients with deteriorated liver func-
tion and without gross vascular invasion.
PPLT26-002
RISK FACTORS AFFECTING
SUSTAINED POST-TRANSPLANT
DIABETES MELLITUS AFTER LIVER
TRANSPLANTATION
A-Lan Lee, Dong Jin Joo, Jung Jun Lee, Su Hyung
Lee, Kyu Ha Huh, Gi Hong Choi, Myoung Soo Kim,
Jin Sub Choi and Soon il Kim
Yonsei University College of Medicine, Korea
Introduction: The aim of this study was to identify risk
factors affecting sustained post-transplant diabetes
mellitus (PTDM).
Method: Of 217 adult recipients who underwent living-
donor liver transplantation between September 2005 and
June 2012 in our center, twenty-three PTDM patients
were reviewed. We classified PTDM patients to transient
(T; PTDM duration <12 months) and sustained (S;
PTDM duration ≥12 months) groups. Total bilirubin
(TB), aspartate transaminase (AST) and alanine trans-
aminase (ALT), and international normalized ratio
(INR) were used for liver injury markers. We analyzed
the levels of AST, ALT, TB, INR, FK-506, and lactate
at post-transplant 1 day and 1 week in both groups.
Results: Of total 23 PTDM patients, viral infections as
cause of transplantation were 20 patients in hepatitis B
viral infection and only 1 patient in hepatitis C viral
infection. Mean age and body mass index (BMI) of the
patients were 51.6  7.0 years and 22.7  2.7 kg/m2.
The S group was 69.6% of total PTDM patients. The
univariate analysis showed mean age of recipients was
significantly different in both groups (48.0  2.3 in T
group, 53.1  7.8 in S group, p = 0.027). However,
recipients’ BMI, donors’ age and BMI did not show
any statistically differences in both groups. As liver
injury markers, the level of AST, ALT, TB and INR at
post-transplant 1 day and 1 week did not have differ-
ences in both groups. Also, FK-506 level and lactate
level at post-transplant 1 day and 1 week did not show
any associations with the S group.
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Conclusions: Liver injury markers did not have associa-
tions with the sustained PTDM patients. However,
recipients’ age affected occurrence of sustained PTDM.
PPLT26-003
PROGNOSTIC FACTORS IN 176
PATIENTS DIAGNOSED OF
HEPATOCELLULAR CARCINOMA ON
CIRRHOTIC LIVER TREATED WITH
ORTHOTOPIC LIVER
TRANSPLANTATION
Francisco Sanchez-Bueno, Pablo Ramirez, Ricardo
Robles, Francisco Acosta, Manuel Miras, Jose Antonio
Pons, JesusDe la Pe~na and Pascual Parrilla
Hospital Clinico Universitario “Virgen de la Arrixaca”,
Spain
Introduction: The aim is to analyze prognostic factors
that may have influence on the survival in our 176
patients diagnosed from hepatocellular carcinoma
(HCC) on cirrhotic liver and who underwent liver
transplantation.
Method: In 946 patients, 176 were HCC on cirrhotic
liver. Mean age: 62.5 years with a male predominance
(84.1%) and predominating post-hepatitis caused by
HCV (85.2%). In 52 patients a chemoembolization had
been made before the surgery (lipiodol and adriami-
cine) and in 15 cases resection surgery was carried out.
In 32 cases (18.2%) we found an incidental HCC. In
the explanted liver we analyzed cancer staging by using
the TNM classification modified by the American Liver
Tumor Study Group. Hepatectomy was carried out by
the piggy-back technique (98.9%). The average in more
than six month survival patients was 94.7 months (6–
193 months). In 20 cases, adjuvant chemotherapy was
given by using Doxorubincin. A single and multiple
variant analysis of clinical and histological parameters
was made in order to analyze which prognostic factors
have impact on survival.
Results: Post operatory mortality (30 days) was 10.2%
related to 11 lung-caused sepsis, 3 arterial thrombosis,
2 MOF and 2 PIF. In the long term evolution there
was tumor recurrence in 48 cases and 11 “de novo”
tumours. Actuarial survival at 1, 3 and 5 years was
79%, 66% and 57% respectively being higher in inci-
dental cases comparing to non-incidental tumors
(p < 0.05). Predictive factors in the evolution of HCC
were pTNM staging and vascular invasion.
Conclusions: The presence of HCC in a cirrhotic
patient forced us to a meticulous pre-operatory staging
of the tumor because, in our series, histological analyze
of the explanted liver shows that pTNM staging has a
predictive value in long term survival.
PPLT26-004
A NOVEL ORGAN DONOR FACILITY: A
DECADE OF EXPERIENCE WITH LIVER
DONORS
MB Majella Doyle, Neeta Vachharajani, Jeffery
Lowell, Gene Ridolfi and William Chapman
Washington University, USA
Introduction: Historically transplant surgeons have
traveled to donor hospitals, performing complex, time-
sensitive procedures with unfamiliar personnel. This
often involves air travel, significant delays, and fre-
quently occurs over night. In 2001, we established the
nation’s first organ recovery center. The goal was to
increase efficiency, reduce costs, and reduce surgeon
travel.
Method: Liver donors and recipients, donor costs, sur-
geon hours, and travel time, from April 1, 2001
through December 31, 2011 was analyzed. 915 liver
transplants performed at our center were analyzed
based on procurement location (living donors and
donation after cardiac death donors were excluded).
Results: In year-1, 36% (9/25) of donor procurements
occurred at the Organ Procurement Organization
(OPO) facility, rising to 93% (56/60) in the last year of
analysis. Travel time was reduced from 8 to 2.7 hours
(p < 0.0001), with a reduction of surgeon fly-outs by
93% (14/15) in 2011. Liver organ donor charges gener-
ated by the donor were reduced by 37% overall for
donors recovered OPO-Facility versus acute care hospi-
tal.
Conclusions: Organs recovered in this novel facility
resulted in significantly reduced surgeon hours, air tra-
vel, and cost. This practice has major implications for
cost containment and OPO national policy and could
become the standard of care.
PPLT26-005
SURVEILLANCE PROTOCOL FOR
HEPATOCELLULAR CARCINOMA
RECURRENCE AFTER LIVING DONOR
LIVER TRANSPLANTATION
Bo Hyun Jung, Shin Hwang, Deok Bog Moon, Chul
Soo Ahn, Ki Hun Kim, Tae Yong Ha, Gi Won Song,
Dong Hwan Jung and Sung Gyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: This study intended to establish an actual
risk-based long-term screening protocol for hepatocellu-
lar carcinoma (HCC) recurrence after liver transplanta-
tion (LT).
Method: The study population were 334 HCC patients
who underwent primary living-donor LT with follow-
up period ≥5 years. Their medical records were
reviewed retrospectively.
Results: Overall 10-year survival rate was 67.5% with
4.8% perioperative mortality. HCC recured in 68
(21.4%) of 318 survived patients during a mean follow-
up period of 77 months. Cumulative HCC recurrence
rate was 20.7% at 5 years and 22.2% at 10 years.
Annual recurrence rate was 11.4%, 6.6% and 2.0%
during first, second and third years, respectively. In
“within-Milan” group, annual incidence of HCC
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recurrence was higher during first 3 years, and thereaf-
ter only 6 cases of sporadic recurrence happended over
11 years; in “beyond-Milan” group, recurrence was
very common during first 3 years, but no more after
3 years. AFP rise became an initial dlue to perform
further imaging study to diagnose recurrence in 43
(63.2%), whereas recurrence was detected incidentally
on routine imaging study in other 25 (36.8%) showing
no AFP rise. Initial sites of HCC recurrence were graft
liver in 26, lung in 16, abdominal cavity in 10, bone in
6, brain in 1, and multiple metastases in 6. Median pos-
trecurrence survival period was 10 months with 3-year
survival rate of 13.2%. There was a close correlation
between pretransplant AFP level and AFP rise after
HCC recurrence.
Conclusions: In conclusion, annual risk of posttrans-
plant HCC recurrence was significantly different
depending on Milan criteria. Patients beyond Milan cri-
teria is indicated for frequent follow-up with tumor
marker tests and imaging studies for first 3 years, and
those within Milan criteria is recommended to follow
up for 10 years, primarily with tumor marker tests.
PPLT26-006
MANAGEMENT PROTOCOL FOR
EXTERNAL BILIARY DRAINAGE IN
ADULT PATIENT UNDERGONE LIVING
DONOR LIVER TRANSPLANTATION
USING DUCT-TO-DUCT ANASTOMOSIS
Bo Hyun Jung, Shin Hwang, Deok Bog Moon, Chul
Soo Ahn, Ki Hun Kim, Tae Yong Ha, Gi Won Song,
Dong Hwan Jung and Sung Gyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: Biliary complication has been regarded as
the most intractable complication following living
donor liver transplantation (LDLT). To reduce biliary
complications, we adopted external biliary drainage
method, in which the risk of anastomotic bile leak
reduces and subsequently that of stenosis is also low-
ered. But, this procedure induces patient discomfort
due to prolonged catheter keeping. This study intended
to optimize the management protocol for external bili-
ary drainage.
Method: A prospective study was performed with 60
adult patients undergone LDLT operation using duct-
to-duct anastomosis and external biliary drainage dur-
ing a study period of 6 months in 2011. The techniques
of external biliary drainage consisted of placement of a
thin silastic tube across the anastomotic line, penetra-
tion of the common bile duct wall and percutaneous
placement. This tube was naturally drained for first 1–
3 weeks and then clamped. This tube was removed
after 6–12 months to prevent bile leak.
Results: For 42 patients showing low-output bile drain-
age (<200 mL/day), rapid clamping exercise for 2–
3 days between 1 and 2 weeks was successfully
achieved at first trial in 36 patients (86%) and other 6
patients underwent delayed clamping trials due to ini-
tial rise of liver enzymes. For 18 patients with high-out-
put drainage (>200 mL/day), clamping exercise was
delayed by 1 week and clamping between 2 and
3 weeks was successfully achieved at first trial in 14
patients (78%). There was no difference in the success
rates of clamping in both groups (p = 0.71). The trans-
fixed external tube was released after 6 months and
removed during 6–12 months after LDLT. Bile perito-
nitis from bile leak after spontaneous or incidental
removal of the catheter occurred in 3 patients.
Conclusions: Our current protocol based on bile output
drainage appears to be effective method leading to
uneventful clamping of external biliary drainage tube,
leading to minimization of patient discomfort.
PPLT26-007
ACUTE LIVER FAILURE INDUCED BY
FOLIUM SENNAE LEAF
Hyung Joon Han1, Tae-Jin Song1, Sam-Youl Yoon1,
Pyoungjae Park2, Wan-Bae Kim2, Sae Byeol Choi2 and
Sang-Yong Choi2
1Korea University Ansan Hospital, Korea; 2Korea
University Guro Hospital, Korea
Introduction: Folium Sennae consists of the dried leaf-
lets of Cassia senna L. (Fabaceae). Senna is an herb.
The leaves and the fruit of the plant are used to make
medicine. Senna is an FDA-approved nonprescription
laxative. It is used to treat constipation and also to
clear the bowel before diagnostic tests such as colonos-
copy. Usually, short-term use in occasional constipa-
tion. Senna may cause mild abdominal discomfort such
as colic or cramps. A single case of hepatitis has been
described after chronic abuse. Long-term laxative abuse
may lead to electrolyte disturbances (hypokalaemia,
hypocalcaemia), metabolic acidosis or alkalosis, malab-
sorption, weight loss, albuminuria, and haematuria.
Weakness and orthostatic hypotension may be exacer-
bated in elderly patients when stimulant laxatives are
repeatedly used.
Method: A 44-year-old female presented at our emer-
gency department complaining of dark yellowish-col-
ored urine and jaundice. She had been taking Chung
Nok Cha (청녹차 in Korean, Senna folium) for a week
because of chronic constipation. The examinations
revealed an acute ill-appearing woman with icteric
sclera. The complete blood count was normal. The bio-
chemical parameters were as follows: prothrombin
time, 20.7 seconds (international normalized ratio 1.82)
and serum creatinine, 0.6 mg/dL. The liver function
tests were as follows: aspartate aminotransferase
1306 IU/L; alanine aminotransferase 807 IU/L; serum
total bilirubin, 9.9 mg/dL; serum direct bilirubin,
4.9 mg/dL; serum albumin, 3.9 g/dL. Hepatitis sero-
logic test were as follows: hepatitis B surface antigen,
negative; hepatitis B surface antibody, positive; hepati-
tis C antibody, negative; hepatitis E antibody IgM,
negative; hepatitis A antidoby IgM, negative and IgG,
positive.
Results: The patient eventually underwent liver trans-
planataion because of progressive changes of mental
status and persistent hyperbilirubinemia. The patient
discharged uneventfully.
Conclusions: It is the first case report in the world
about Senna-induced liver failure. We should know the
potential heaptic toxicity of Senna folium.
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PPLT26-008
ROUX-EN-Y HEPATICOJEJUNOSTOMY
FIRST IN DECEASED DONOR LIVER
TRANSPLANTATION
Ghalia Doumane1, Fabrizio Panaro1, Thibault Mura2
and Francis Navarro1
1Department of Surgery, France; 2Centre d’Investigation
Clinique, France
Introduction: Biliary complications remain the “Achil-
les’ Heel” of deceased donor liver transplantation
(DDLT). Although duct-to-duct biliary reconstruction
(DDBR) is considered as standard, Roux-en-Y hepati-
co-jejunostomy (RYHJ) can be preferred in selected
cases, especially in retransplantation or if bile duct vas-
cularisation is compromised. The aim of the study was
to assess that RYHJ is safe as DDBR in term of biliary
complications, patient and graft survival in DDLT.
Method: We retrospectively collected the medical
recorded data of 328 patients who underwent a DDLT.
We compared demographic data, indication, surgical
and post-operative data of two groups of recipients
(301 patients with DDBR and 27 patients with RYHJ).
Furthermore, we reported the patient and graft survival
rates, incidence of biliary complications (stenosis, leak,
cholangitis and non anastomotic stenosis [NAS]). All
patients received anti-calcineurin immunosuppression.
We used Kaplan–Meier survival curves, univariate and
multivariate Cox proportional hazards models to com-
pare complication rates, patient and graft survival
between DDBR and RYHJ groups.
Results: The median length of follow-up was
55 months (SD: 0–114). Patient and graft survival were
88% and 85%, respectively. Univariate analysis showed
that there was no difference in patient survival
(RR = 0.86, p = 0.704), graft survival (RR = 0.54,
p = 0.573), incidence of arterial complication
(RR = 1.29, p = 0.668) and reoperation (RR = 0.843,
p = 0.529). There was no significative difference either
in incidence of leaks (RR = 1.419, p = 0.498), anasto-
motic strictures (RR = 1.676, p = 0.219) and NAS
(RR = 0.368, p = 0.074). Cholangitis and veinous com-
plications were significantly higher in RYHJ group
(RR = 0.38, p = 0.013 and RR = 0.332, p = 0.0275
respectively). Moreover, analysis between the two
groups was adjusted on recipient’s age, gender, MELD
score and BMI, donor’s BMI, indication of transplan-
tation, chronical renal failure and immunosuppressive
regimen. Multivariate analysis only showed a significa-
tive difference for cholangitis (RR = 0.34, p = 0.03),
whereas there was no significative difference for veinous
complications (RR = 0.37, p = 0.12).
Conclusions: Despite the limits of our study, RYHJ
seems to increase the risk of cholangitis after DDLT.
PPLT26-009
A RARE CASUE OF REFRACTORY
ASCITES FOLLOWING LIVER
TRANSPLANTATION: REPORT OF A
CASE
Sacit Coban, Fahrettin Yildiz, Murat Taner Gulsen
and Vahap Saricicek
Gaziantep University Medical Faculty, Turkey
Introduction: We present a case of a 34-year-old man
who underwent liver transplantation for criptogenic cir-
rhosis and developed refractory ascites on postopera-
tive day 22.
Method: Following a prolonged work-up we could not
find the cause of the ascites. The laboratory tests includ-
ing liver enzymes were within normal ranges. In this
patient, infectious causes such as CMV and tbc were
ruled out. On radiologic tests, computed tomography
(CT) scan demonstrated marked ascites with normal
flow in VCI, Portal vein and Hepatic artery. Doppler
sonography of liver demonstrated normal doppler wave-
forms in these vessels. Liver biopsy was performed on
postoperative day 25. Biopsy shoved no pathologic find-
ings. Radiological and biochemical tests did not reveal
renal pathology. Serum-ascites albumin gradient
revealed a low gradient indicating ascites of non-portal
hypertensive etiology and total protein of ascites fluid
was 2.8 g/dL. The ascite fluid culture was negative.
Results: We started medical treatment of furosemid
and spiranolakton. On postoperative day 45 the ascites
was changed from severe to mild sonographically. With
the continuation of treatment on postoperative day 60
the ascites were resolved. We stopped the medical treat-
ment of furosemid and spiranolakton.
Conclusions: Now the patient is on postoperative 9th
month with no ascites.
PPLT26-010
THE PROTECTIVE EFFECT OF
PURIFIED MICRONIZED FLAVONOID
FRACTION ON ISCHEMIA/
REPERFUSION INJURY OF THE RAT
LIVER
Sacit Coban1, Fahrettin Yildiz1, Alpaslan Terzi2,
Nurten Aksoy2, Muharrem Bitiren2 and Hakim Celik2
1Gaziantep University Medical Faculty, Turkey; 2Harran
University School of Medicine
Introduction: Hepatic Ischemia/reperfusion injury (I/R)
remains as an important problem in some conditions
such as hepatic surgery for trauma or cancer, hemor-
rhagic shock, and liver transplantation. Oxygen-derived
free radicals have been implicated in the development
of hepatic IR. Flavonoids have been subjected to con-
siderable investigations due to its antioxidant and anti-
inflammatory properties. But there is no previously
reported study about its effect on hepatic I/R. We
investigated the effects of micronized purified flavonoid
fraction (MPFF) on hepatic I/R injury in rats.
Method: Thirty rats were recruited in the study as fol-
lows: group A: sham operation (n = 10), group B: I/R
(n = 10), and group C: I/R + MPFF (n = 10). In group
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C, rats received (80 mg/kg/day) MPFF by gavage for
3 days before surgery, 30 minutes prior to ischemia
and just before the reperfusion. In group B and C, all
rats were subjected to 60 minutes of hepatic ischemia
followed by 60 minutes reperfusion period. After reper-
fusion period all rats were sacrified. Blood samples
were taken and serum aspartate aminotransferase
(AST), alanine aminotransferase (ALT), lactate dehy-
drogenase (LDH) levels were measured to asses liver
functions. Liver tissues were taken for histological eval-
uation and to determine the total antioxidant capacity
(TAC), catalase (CAT), total oxidant status (TOS), oxi-
dative stress index (OSI) and myeloperoxidase (MPO).
Results: The present data showed a decrease in AST,
ALT and LDH levels in the MPFF treated rats when
compared with I/R group rats (p < 0.001 for all). In
the MPFF treated rats tissue levels of TOS, OSI and
MPO were significantly lower than those in I/R group
(p < 0.01, p < 0.001, and p < 0.05, respectively).
Increases in TAC and CAT levels were statistically sig-
nificant in the MPFF treated rats compared to I/R
group (p = 0.01 for both).
Conclusions: The present study demonstrates that
MPFF ameliorates I/R-induced liver damage probably
by antioxidant and anti-inflammatory properties.
PPLT26-011
NECROTIC DERMAL LESIONS IN A
LIVER-TRANSPLANTED PATIENT:
REPORT OF A CASE
Fahrettin Yildiz, Sacit Coban, Murat Taner Gulsen
and Vahap Saricicek
Gaziantep University Medical Faculty, Turkey
Introduction: We report a case of a 45-year-old man
with necrotic dermal lesions who underwent orthotopic
liver transplantation 5 months ago for cirrhosis of liver
secondary to HBV and HCC.
Method: His chronic immunosuppressive regimen con-
sisted of prednisone and tacrolimus at dosage of
3.5 mg orally twice daily. Consequently, the patient
developed a skin lesion. Biopsy demonstrated dermal
inflammation with foci of necrosis and lymphohistiocy-
tic infiltrate. On labaratory findings liver enzymes were
in normal ranges. The evaluation of CMV, tbc and
other infectious causes were revealed negative.
Results: Then we reduce the dose of tacrolimus to
2 mg orally twice a day. Then the dermal lesions
regressed withot any aditional therapy.
Conclusions: Dermal necrosis maybe one of the very
rare side effects of long-term immunosuppressive ther-
apy with calcineurin inhibitors.
PPLT26-012
AN EQUATION CALCULATED FROM
PRE OPERATIVE HEPATIC CT
VOLUMETRY, CAN PREDICT THE
ACTUAL GRAFT WEIGHT IN ADULT
LDLT?
Mohammad Taha, Emad Hamdy and Amr Mostafa
National Liver Institute - Menoufiyia University, Egypt
Introduction: The volumetric analysis of the liver using
CT datasets has become an important for the preopera-
tive assessment for LDLT. CT allows determination of
the graft volume required by the recipient and the vol-
ume remaining with the donor. In borderline cases,
minimal deviations in liver volumetry may lead to a
complications, such as SFSS or liver failure.
Method: This study conducted in National-Liver-Insti-
tute- Menoufiyia University - Egypt: from 2003 to
2013, 164 cases of LDLT had CT-volumetric measure-
ment of the donor liver which was compared with the
intra operative grafts volume.
Results:
1. The calculated Graft volumes is significantly cor-
related with & higher than the actual graft
weights.
2. In our series there were 18 adult cases developed
SFSS.
3. A-formula for accurate prediction of intraopera-
tive graft weight: W introp=
216.4 + (0.6678 9 V preop).
Conclusions:
1. The CT-volumetry must be accurate to assure
enough residual liver volume to the donor & not
only enough volume to the recipient.
2. SFSS mostly developed with cal. GRWR <1%,
so we should use grafts with cal. GRWR ≥1%.
3. A linear equation was developed for accurate
prediction of a right liver lobe graft weight prior
to surgery.
PPLT26-013
PAEDIATRIC LIVER TRANSPLANT
PROGRAM IN CZECH REPUBLIC:
15 YEARS OF EXPERIENCE
Libor Janousek, Jiri Fronek, Martin Oliverius and
Pavel Trunecka
IKEM, Czech Republic
Introduction: Pediatric recipients represent only 15–
20% of liver transplant waiting list, they suffer the
most from the scarcity of size-matched cadaveric
organs. The introduction of deceased donor techniqes
of full size, reduced and in situ split-liver transplanta-
tion helped to cure the critical shortage of suitable-
sized grafts in our country.
Method: A retrospective analysis of 1,004 consecutive
liver transplants performed at a single institution
between 1997 and 2012, of those 71 pediatric liver
transplantations with median followup of 5 years were
analysed. Graft types included 48 whole, 14 reduced, 7
split and 2 live-donor grafts. Both split-liver and live-
donor were left lateral segment grafts. The indications
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for liver transplantation were biliary atresia 44% and
metabolic diseases 40%. Detailed analysis of preopera-
tive, intraoperative, and postoperative variables was
undertaken. Survival was estimated using the Kaplan–
Meier method.
Results: Some 118 children were listed for liver trans-
plantation, 10/118 (8.4%) died whilst waiting, median
waiting time for transplant was 118 days. Recepient
median age at transplantation was 11 (0.5–17) years,
and median weight was 12 (4.4–43) kg. The 1 and 5-
year patient survival was 85% and 80%, graft survival
was 75% and 71% respectively. Vascular thrombosis
occured in 13% (arterial thrombosis: 10%; portal
thrombosis: 3%) 4 grafts were lost. Biliary complica-
tions occured in 18% (bile leak from cut surface in
10%, anastomotic stricture in 8%). The incidence of
acute rejection was 20%.
Conclusions: The Czech pediatric liver program started
mainly as full size graft one, graft reduction followed
by split liver did help to cure the pediatric graft short-
age. The need and demand for live donor transplant
was minimal so far. Our 15 years of experiance
includes all the available transplant techniques with
reasonable transplant outcomes.
PPLT26-014
LIVING DONOR LIVER
TRANSPLANTATION IN PAKISTAN: A
FIRST REPORT
Faisal Dar1, Abdlul wahab Dogar1, Haseeb Haider
Zia1, Amna Liaqat1, Minhal Pervaiz1, Nasir Ayub
Khan1, Mohammad Salih1, Muhammah Omar
Qureshi1, Najam ul hassan Shah1 and Mohmed Rela2
1Shifa International Hospital, Islamabad, Pakistan;
2Global Hospital Chennai, India
Introduction: LDLT is the standard treatment for liver
failure in Asia, where the liver disease burden is
immense. Here we report the first experience of LDLT
from a single center in Pakistan.
Method: All patients who underwent LDLT from May
2012 to June 2013 were included. Demographic, clini-
cal, operative details and postoperative events were
recorded. Recipient’s data was prospectively collected
and analyzed retrospectively on SPSS v 19.
Results: A total of 39 recipients were included. Median
age was 45.3 (12–73) years, 29 (74.3%) were males and
10 (25.6%) were females. Commonest indication was
HCV in 28 (71.7%), cryptogenic cirrhosis in 5 (12.8%),
HBV in 2 (5.2%) and 4 (10.3%) others. Child-Pugh
grading was C in 23 (58.9%), B in 13 (33.3%) and A in
1 (2.5%). The median MELD was 17 (8–30). Right
lobe graft was done in 36 (92.3%), left lobe in 2 (5.1%)
and 1 (2.5%) patient had whole liver (as domino graft).
Fifteen (38.4%) right lobe grafts required hepatic vein
branch reconstruction. Five (12.8%) right lobe grafts
had complete MHV. Twenty six (66.6%) patients had
single and 13 (33.3%) had 2 bile ducts reconstructions.
Median cold ischemia time was 64 minutes (4–215);
median warm ischemia time was 48 minutes (18–90).
Median duration of surgery was 9 hours (5–14). Med-
ian hospital stay was 15.5 days (8–28). Three (7.7%)
patients were re-explored during postoperative period.
Pleural tap was required in 14 (35.8%) patients, CRRT
in 4 (10.2%) and acute cellular rejection in 3 (7.7%).
Eight (20.5%) recipients have died and 31 (79.4%) are
alive with good graft function.
Conclusions: This is the beginning of a new era for
Pakistan which is overburdened with liver disease.
LDLT remains the only realistic option for these
patients. Being a new center, this was a sizeable num-
ber of patients with decent results.
PPLT26-015
VASCULAR COMPLICATIONS IN
BILIARY ATRESIA PATIENTS
UNDERGOING LIVING DONOR LIVER
TRANSPLANTATION- ANALYSIS OF 110
PATIENTS OVER 10 YEARS
Bhavin Vasavada1, Karan Julka1, Andrzej
Komorowski2, Muhammad Zakaria3 and Chao Long
Chan4
1Fellow liver surgery and transplant, India; 2Fellow liver
surgery and liver transplantation, Poland; 3Fellow liver
surgery and liver transplantation, Pakistan; 4Professor
and superintendent, Taiwan
Introduction: Vascular complications are very common
in pediatric living donor liver transplants. We present
our experience in vascular complications in biliary atre-
sia patients undergoing liver transplantation.
Method: All the patients who have undergone living
donor liver transplant for biliary atresia between Janu-
ary 2003 to March 2013 were retrospectively analyzed.
Age, sex, recipient weight, recipient nutrition status
(weight by age z score as per who), graft weight, grwr,
operative blood loss, portal vein size mismatch, no of
arterial anastomosis, donor recipient arterial size mis-
match, hepatic venous anastomosis technique, cold
ischemia and warm ischemia time, duration of anhepat-
ic phase, GRWR, type of graft, duration of surgery,
primary transplant, timing of kasai procedure were
analyzed. p < 0.05 was considered to be statistically sig-
nificant.
Results: Total 110 patients have undergone living
donor liver transplantation for biliary atresia between
2003 and 2013. There were 56 males and 54 females.
Median age at transplant was 13.5 months. 11 were
primary transplant and 99 were post kasai procedure.
100 left lateral, 4 left lobe and 4 right lobe grafts were
used. 22 patients developed vascular complications.10
patients developed hepatic artery thrombosis .9 patients
of hepatic artery thrombosis were managed with redo
hepatic artery anastomosis and 1 patient managed with
radial artery interposition graft.5 patients developed
portal vein stenosis and was managed by portal vein
stenting.5 patients developed portal vein thrombosis
and portal vein thrombectomy and reanastomosis was
done.1 patients developed stenosis at the site of venous
anastomosis and was managed by stenting.1 patient
developed both hepatic artery thrombosis and portal
vein throbosis and eventually succumbed to this com-
plications. Total 5 mortality noted 2 were in vascular
complication group. GRWR greater than 2.5 was sig-
nificantly associated with vascular complications
(p = 0.017).
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Conclusions: Vascular complications are frequently
seen in liver transplantation for biliary atresia. Large
for size grafts are significantly associated with vascular
complications.
PPLT26-016
DIVERSITY OF GUT MICROBIOTA
AMONG CIRRHOTIC LIVER
TRANSPLANT CANDIDATES
ACCORDING TO THE SEVERITY OF
LIVER DISEASE
Micha Grazt, Irena Kosinska, Zbigniew Lewandowski,
Wacaw Hoowko, Karolina Grazt, Karolina Maria
Wronka, Micha Wasilewicz and Marek Krawczyk
Medical University of Warsaw, Poland
Introduction: Although liver cirrhosis is known to be
related to specific changes in the composition of gut
microflora, only limited data is available for liver trans-
plant candidates. The purpose of this study was thus to
evaluate the associations between gut microbiota and
the severity of liver disease in this particular population
of patients.
Method: This prospective study was based on 34 cir-
rhotic patients listed for liver transplantation in the
Department of General, Transplant and Liver Surgery
in the period between 2012 and 2013. Counts (per 1 g
of wet feces) of yeasts and the following bacteria were
assessed: Bifidobacterium, Lactobacillus (including
hydrogen peroxide producing strains), Bacteroides,
Enterococcus, Clostridium, Pseudomonas, Escherichia
coli and Proteus species, and other proteolytic Entero-
bacteriaceae family members. Associations between the
composition of gut microflora and Model for End-stage
Liver Disease (MELD) score and Child classification
were established. Spearman’s correlation coefficient and
U Mann–Whitney test were applied for statistical
analyses, with the level of significance set to 0.05.
Results: There was a significant negative correlation
between the counts of Bifidobacterium species and
MELD score (R = 0.446, p = 0.008). More specifi-
cally, Bifidobacteria counts were significantly negatively
correlated with serum bilirubin (R = 0.474,
p = 0.005) but neither with International Normalized
Ratio nor serum creatinine. No other significant corre-
lations were observed between the remaining microbi-
ota and MELD score. Similarly, patients belonging to
Child class B or C (n = 28) had a tendency towards
decreased counts of Bifidobacteria as compared to
those belonging to Child class A (n = 6; median
8.0 9 108 versus 2.0 9 109, p < 0.057), but also
towards increased counts of Escherichia coli (median
1.0 9 107 versus 2.6 9 105, p < 0.060).
Conclusions: Decreasing numbers of Bifidobacterium
species are characteristic for gut microflora of cirrhotic
liver transplant candidates with more severe liver dis-
ease. Thus, probiotics containing these potentially bene-
ficial bacteria might be useful in patients listed for liver
transplantation.
PPLT26-017
DOES LIVER GRAFT SIDE INFLUENCE
OUTCOMES IN LIVING DONOR LIVER
TRANSPLANTATION WITH SMALL
FOR SIZE GRAFTS?
Karan Julka, Bhavin Vasavada, Andrzej Komorowski,
Choa-long Chen and Chih chi Wang
Kaohsiung Chang Gung Memorial Hospital, India
Introduction: The recent outcomes of living donor liver
transplantation (LDLT) using small for size liver grafts
(SFSLG; graft recipient weight ratio; GRWR <0.8)
along with portal vein flow modulation has shown
encouraging results. By expanding this donor pool,
more attention is now turned towards using left sided
liver grafts. However, the outcomes of using a SFS left
lobe graft in LDLT have not been clearly elucidated.
We aim to compare the outcomes, with respect to graft
dysfunction, in patients undergoing right or left lobe
LDLT.
Method: From 2006 to 2009, 54 patients undergoing
LDLT with GRWR <0.8 were retrospectively analyzed
and divided into Group L (left liver graft; n = 30) and
Group R (right liver graft; n = 24). The demographic,
clinical and operative variables were compared among
the groups. Portal vein flow (PVF) modulation, splenic
artery ligation or splenectomy, was done when portal
flow was >250 mL/min/100 g of liver graft. The out-
comes with respect to graft dysfunction were compared
among the groups using the Kaplan–Meier survival
curves. The mean follow up period was
20  13.4 months. Univariate analysis was done to
analyze factors associated with graft dysfunction.
Results: The incidence of graft dysfunction was signifi-
cantly more in Group L (p = 0.043). The groups were
well matched except for the PVF, which was more in
Group L (p = 0.004) but <250 mL/min/100 g and hav-
ing Area under ROC = 0.64. The mean graft recipient
weight ratio was 0.71  0.06 and was comparable
among the groups (p = 0.684). No other factor was
found significantly associated with graft dysfunction.
Conclusions: Right sided liver grafts have better out-
comes in patients undergoing LDLT with SFSLG.
PPLT26-018
THE ORGAN-SPECIFIC PROTECTIVE
EFFECTS OF HUMAN ADIPOSE
DERIVED STEM CELLS
Yu Saito, Mitsuo Shimada, Tohru Utsunomiya,
Tetsuya Ikemoto, Shinichiro Yamada, Yuji Morine,
Satoru Imura, Yusuke Arakawa, Mami Kanamoto and
Shuichi Iwahashi
Institute of Health Biosciences, The University of
Tokushima Graduate School, Japan
Introduction: We investigated whether human adipose-
derived stem cells (ADSCs) protected hepatocytes or
islets in vitro, and they had homing ability to injured
liver or pancreas in vivo.
Method: Study1: We co-cultured hepatocytes or islets
with human ADSCs (1.0 9 105 cells / well) in Tran-
swell and examined the viabilities of those cells over
time. Cytokine/growth factor protein concentration in
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culture medium was also evaluated. Study2: We trans-
planted ADSCs intravenously into liver injury (70%
hepatetomy and 15 minutes ischemia reperfusion) or
type 1 diabetes mellitus model mice. We tracked the
dynamics of ADSCs by in vivo imaging.
Results: Study1: ADSCs significantly improved the vi-
abilities of hepatocytes or islets by trophic molecules
such as VEGF, HGF and IL-6. The inhibited produc-
tion of VEGF by bevacizumab affected the viabilities
of isles, but not affected those of hepatocytes. Study 2:
Systemically transplanted ADSCs improved serum liver
function, liver regeneration and serum blood glucose.
In addition, systemically transplanted ADSCs selec-
tively homed to injured liver, on the other hand, not
homed to injured pancreas.
Conclusions: ADSCs had trophic and homing effects
on injured cells, however, those effects might vary
depend on cell types or organs.
PPLT26-019
EXPERIENCE OF LIVER
TRANSPLANTATION FOR HEPATITIS A
VIRUS INDUCED ACUTE LIVER
FAILURE IN ADULTS AT A SINGLE
CENTER
DongHwan Jung, SungGyu Lee, Shin Hwang, KiHun
Kim, ChulSoo Ahn, TaeYong Ha, GiWon Song,
GilChun Park, Bohyun Jung and SungHwa Kang
Asan Medical Center, Ulsan University, Korea
Introduction: Adulthood acute hepatitis A became
widespread in last 10 years in Korea due to decreased
seroprevalence of anti-HAV in adults. The objectives of
this study were to evaluate the results of liver trans-
plantation (LT) for HAV associated acute liver failure
(ALF) and to compare the clinical profiles and out-
comes between the patients with HAV- and HBV-asso-
ciated ALF.
Method: 64 Adult recipients who underwent LT for
acute liver failure from HAV (n = 37) and HBV
(n = 27) between January 2005 and May 2011 at a sin-
gle center were included this study.
Results: Liver transplantation for HAV infection was
substantially increased in recent years at our center.
There was no difference between two groups with
regard to age, gender, total bilirubin, prothrombin
time, platelet count, pressor use, MELD score, CTP
score, Graft type, GRWR, ICU stay, and hospital stay.
HAV infection was associated with younger recipient
age (p = 0.003), higher serum creatinine values
(p = 0.009), AST and ALT (p = <0.001) compared with
HBV infection. 1 year patient survival after LT for
HAV and HBV was 71.4% and 100% respectively
(p = 0.013). HAV infection recurred in 5 patients after
LT (13.5%). Patients with pancreatitis had a poorer
prognosis in recipients with HAV infection
(p = 0.0114). Causes of death after LT for HAV were
sepsis from pancreatitis (n = 3), reinfection of HAV
(n = 3), sepsis from pneumonia (n = 1), intracranial
hemorrhage (n = 1), and brain death (n = 1).
Conclusions: Patient survival after LT was much lower
for HAV than HBV. Multiple drainage procedures
around pancreas and dependent portions are needed, if
patient has pancreatitis in operative field. As the risk of
HAV reinfection after LT may be higher than expected,
routine check of HAV RNA is needed.
PPLT26-020
SEVERITY OF FATIGUE AFTER LIVER
TRANSPLANTATION IS ASSOCIATED
WITH POSTOPERATIVE
COMPLICATION
Jeong-Moo Lee
Seoul National University Hospital, Korea
Introduction: Fatigue is common in chronic hepatitis
and end-stage liver disease. Almost clinical and labora-
tory findings usually recover after transplantation. But
fatigue often remained. The aims of this cross-sectional
study were to assess fatigue after liver transplantation,
and to explore what factor is related to severity of fati-
gue.
Method: From April 2013 to May 2013, we reviewed
94 patients after transplantation. Severity of fatigue
was assessed with the Fatigue Severity Scale (FSS).
Furthermore, age, gender, etiology, immunosuppressant
and complication.
PPLT26-022
RUBBER-BAND TAGGING METHOD TO
LOCALIZE THE PROPER DIVISION
LINE OF THE BILE DUCT IN DONOR
HEPATECTOMY AND
RECONSTRUCTION OF THE BILE
DUCT IN LIVING-DONOR LIVER
TRANSPLANTATION
Sung Gyu Lee, Shin Hwang, Chul Soo Ahn, Duck Bok
Moon, Tae Yong Ha, Gi Won Song and Ki Myung
Moon
Asan Medical Center, Ulsan University, Korea
Introduction: The most common complications in
recipients after LDLT are biliary leakage and stricture.
Several efforts are made to decrease the biliary compli-
cations in recipients such as preserving the sufficient
blood supply and Glissonian tissues to the cut ends of
bile duct in both donor and recipients, stenting the
anastomosis, and obtainig the single ductal opening as
possible.
Method: To localize the proper division site of the bile
duct during the donor hepatectomy, the rubber-band
tagging (RBT) method has been first used in our
department. To determine the bile duct division site, a
short segment of radiopaque rubber band (10–15 mm
in length, 1 mm in diameter) which is a fragment of the
blue-colored radiopaque marker attached to a commer-
cial surgical gauze, was tagged transverslely on the pro-
posed division site of the hepatic duct by holding
sutures to prevent the displacement of the radiopaque
marker during manipulation of the liver.
Results: Subsequently, intraoperative cholangiography
(IOC) via the cystic duct was checked to identify the
relation between the RBT and the proposed division
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site of the hepatic duct. If the RBT was properly posi-
tioned at the planned division site, careful division of
the duct was followed. If the RBT was not properly
positioned, another RBT was applied to the planned
division site and IOC was checked repeatedly to con-
firm correct positioning. The control of the active
bleeding from the cut ends of bile ducts in both donor
and recipients are performed by suture ligations instead
of electrocautery to avoid the burn injury and prevent
the late stricture.
Conclusions: Recently, we insert the external stenting
tube in almost all biliary reconstructions to decrease
the biliary leak and stricture.
PPLT26-023
THE SIZE FOR THE RECIPIENT, THE
FUNCTION FOR THE LIVING DONOR?
AN AUDIT OF 91 CONSECUTIVE CASES
OF RIGHT LIVER DONATION
Daniel Azoulay1, Julie Duclos2, Chady Salloum1,
Prashant Bhangui2, Gerard Pascal2, Paola Andreani2,
Rene Adam2 and Denis Castaing2
1Henri Mondor Hospital - Creteil France, France; 2Paul
Brousse Hospital - Villejuif, France
Introduction: To analyze remnant left liver regeneration
and functional recovery after 91 right liver living donor
(RLLD) procurements and find predictive factors or
relationship between liver regeneration and functional
recovery.
Method: All data concerning RLLD included in a
monocentric transplantation program were prospectively
collected between January 2000 and December 2009.
Results: Ninety-one consecutive RLLD, median age
39  13 years, 66% females, were performed. In 22
patients (24.2%) the median hepatic vein was included
in the right hepatectomy. Mean preoperative remnant
left liver volume was 501  130 g and represented
35.1  5.8% of the total liver volume. Normal liver
function was achieved in 33% of the patients at D7, in
64% at D30, and in 84%, 82% and 83% of the
patients at 3, 6 and 12 months respectively. At 1 year,
most of the biological tests did not reach preoperative
values. Mean liver volumetric recovery showed
63.8  9.4%, 71.3  8.9%, and 84.6  9.2% at D7,
D30, and 1 year respectively. Lowest postoperative PT
value (ß = 0.101, p < 0.01), remnant left liver at D7 to
body weight ratio (ß = 3.20, p < 0.02), intraoperative
blood loss (ß = 0.002, p < 0.05), and major postoper-
ative complications (i.e Clavien III–IV) (ß = 1.90,
p < 0.05) were significantly associated with liver func-
tional recovery. Predictive factors for early liver regen-
eration were donor age (ß = 0.171, p < 0.025), total
liver volume to body weight ratio (ß = 7.905,
p < 0.004) and preoperative remnant left liver to total
liver volume (ß = 0.415, p < 0.017). Early liver func-
tional recovery was not impaired by massive immediate
postoperative liver regeneration.
Conclusions: One year after donation, even asymptom-
atic, RLLD neither show ad integrum liver regenera-
tion, nor complete functional liver recovery in almost
20% of them.
PPLT26-024
DOES TIMING OF FIRST KASAI
PROCEDURE AFFECT OUTCOME OF
SUBSEQUENT LIVE DONOR LIVER
TRANSPLANTATION? – A SINGLE
CENTER ANALYSIS OF LAST 10 YEAR
Bhavin Vasavada1, Chao Long Chen2, Karan Julka1
and Andrezej Komorowski3
1Fellow liver Surgery and Transplant, India;
2Superintendent and Professor, Taiwan; 3Fellow liver
Surgery and liver Transplantation, Poland
Introduction: The Kasai hepatoportoenterostomy has
improved the outcome of BA patients, particularly if
performed on children <90 days old. Still many patients
have to undergo liver transplantation due to failed Ka-
sai procedure. However no one has studied the effect
of timing of Kasai procedure on subsequent liver trans-
plantation. We tried to evaluate timing of first Kasai
procedure on subsequent liver transplantation in case
of failed Kasai procedure.
Method: 107 patients of biliary atresia who have
undergone liver transplantation beween January 2003
to April 2013. Thirteen patients underwent primary
transplant and were excluded from the study rest 94
patients were included in the study and retrospectively
analyzed. Patients were devided in to early (<90 days)
and late (>90 days) according to the timings of first
Kasai. p < 0.05 was considered statistical significant.
Results: Nineteen patients undergone late Kasai proce-
dure after birth and 75 patients underwent early Kasai
procedure. Thirty-five patients in early Kasai group
and 11 patient late Kasai group developed clavein
grade 3 and grade 4 complications giving overall com-
plication rates of 46% and 57% respectively however
there was no statistical significant difference between
two group in complications. (p = 0.382). Three patient
in early Kasai group and 1 patient in late Kasai group
died giving mortality rate of 4% and 5% respectively.
1, 3, and 5 year survival rates were 97.4%, 95.5% and
95.5% and 91.9%, 91.9%, 91.9% respectively. However
there was no statistical significant difference between
two. However multiorgan dysfunction and post opera-
tive pneumonitis was significantly more common in late
Kasai group (p = 0.032 and p = 0.05 respectively).
Conclusions: There was no difference in overall out-
come of living donor living transplant in early versus
late Kasai group however multiorgan dysfunction and
post operative pneumonia is more common with late
Kasai surgery.
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PPLT26-025
IMPACT OF RECONSTRUCTING
SINGLE HEPATIC ARTERY ON SMALL
FOR SIZE GRAFTS IN LIVING DONOR
LIVER TRANSPLANTATION
Karan Julka1, T-S Lin1, Bhavin Vasavade1, Andrzej
Komorowski1, Chao-Long Chen1, Chi_Chih Wang1, C-
C Yong1 and Y-F Cheng2
1Kaohsiung Chang Gung Memorial Hospital, India;
2Kaohsiung Chang Gung Memorial Hospital, Taiwan
Introduction: The recent outcomes of living donor liver
transplantation (LDLT) using small for size grafts
(SFSG; graft recipient weight ratio; GRWR <0.8) along
with portal vein flow modulation has shown encourag-
ing results. However, these liver grafts can at times
have two hepatic arterial stumps. This can result in a
dilemma whether to reconstruct single or both the
arteries. Hepatic artery (HA) thrombosis is the most
dreaded complications in LDLT as it can result in graft
loss and re-transplantation. We herein report the feasi-
bility of reconstructing single HA in LDLT having two
arterial stumps in the liver grafts with GRWR<0.8.
Method: From 2006 to 2009, 54 patients undergoing
LDLT with GRWR <0.8 were retrospectively analyzed
and divided into Group 1 (n = 37): 1 HA stump with 1
HA reconstruction, Group 2 (n = 12): 2 HA stumps
with 1 HA reconstruction and Group 3 (n = 5): 2 HA
stumps with 2 HAs reconstruction. The decision
regarding the reconstruction of single or multiple HAs
was made depending on the pre-operative radiological
and intraoperative assessments. Recipient portal vein
flow modulation was done whenever necessary. Out-
comes with respect to graft dysfunction, graft loss and
patient mortality were compared among the groups.
Results: The incidence of graft dysfunction was compa-
rable among the groups (p = 0.788). There was no graft
loss or patient mortality due to graft dysfunction.
Conclusions: Single HA reconstruction does not
increase the risk of graft dysfunction in recipients
undergoing LDLT having GRWR <0.8 and dual hepa-
tic arterial stumps in the liver graft.
PPLT26-026
PLASMAPHERESIS IS AN EFFECTIVE
TREATMENT FOR EARLY LIVER
ALLOGRAFT DYSFUNCTION
Youngin Yoon, Shin Hwang, Gi-Won Song, Dong-
Hwan Jung, Gil-Chun Park and Sung-Gyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: Early liver allograft dysfunction (EAD) is
a serious complication after liver transplantation. The
mortality is high without emergency retransplantation,
but not all patients are eligible for the procedure and
require other forms of liver supports. This study was
performed to evaluate the effects of plasmapheresis in
EAD patients as a liver support.
Method: EAD was defined as a hyperbilirubinemia
(>10 mg/dL) within 30 days of liver transplantation
without bile duct obstruction and/or hepatic encepha-
lopathy. A total of 107 EAD patients who underwent
plasmapheresis between 2002 and 2010 were compared
with a historical control group of 36 EAD patients
without plasmapheresis. The survival of each group
and the changes of total bilirubin, INR, AST, ALT,
albumin, creatinine, and MELD were evaluated.
Results: Plasmapheresis group had better survival than
non-plasmapheresis group. Statistically significant
decreases (p < 0.05) of total bilirubin (15.2  5.2–
13.1  5.4), INR (1.72  1.0.4–1.38  1.14), AST
(541.5  1260.1 U/L to 124.5  260.1 U/L), ALT
(568.9  1276.9 U/L to 231.4  620.5 U/L), creatinine
(1.3  0.8–1.2  0.7), and model for end-stage liver
disease (MELD) score (20.1  6.5–18.3  7.0) were
seen after plasmapheresis. Plasmapheresis is a factor of
lower relative risk for death.
Conclusions: Plasmapheresis is effective in removing
bilirubin, AST, ALT, and improving coagulation func-
tions and MELD score in EAD patients. The survival
was significantly better in plasmapheresis group than
non-plasmapheresis group. Plasmapheresis appears to
be an effective liver support for EAD patients, thus
plasmapheresis should be accepted as a reasonable liver
support in liver failure patients.
PPLT26-027
TAILORING IMMUNISUPPRESSION IN
PATIENTS SHOWING
HEPATOCELLULAR CARCINOMA
RECURRENCE AFTER LIVER
TRANSPLANTATION
Youngin Yoon, Shin Hwang, Chul-Soo Ahn, Ki-Hun
Kim, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song,
Dong-Hwan Jung, Gil-Chun Park and Sung-Gyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: The use of sirolimus (SRL)-based immu-
nosuppression protocols have been reported to reduce
recurrence rates following liver transplantation (LT) for
hepatocellular carcinoma (HCC), although this is still a
matter for debate. This concept can be applied to the
LT recipients after HCC recurrence. The cornerstone of
pharmacological immunosuppression after posttrans-
plant HCC recurrence is combination of SRL and so-
rafenib.
Method: We describe our experience on the post-recur-
rence immunosuppression using SRL in 8 patients with
HCC recurrence.
Results: The target SRL level as SRL monotherapy
was set at 10 ng/mL at 1 year and 5 ng/mL at 5 years.
During 1 month, precedent use of calcineurine inhibitor
(CNI) was crossover exchanged with SRL with or with-
out minimal-dose CNI. At the same time, sorafenib
was started and the dosage was raised after monitoring
side-effects. Special attention should be paid at this per-
iod because both SRL and sorafenib can induce similar
gastrointestinal manifestation and liver function abnor-
mality. High-dose SRL >10 ng/mL was suggested to
achieve anti-tumor effect, but our limited experience
did not support that it is actually beneficial for HCC
recipients. Combination of SRL-sorafenib was success-
fully installed in 6 of 8 patients within 1 month. Three
of them showed rapid progression of HCC, but other 3
patients showed at least no definite progression of
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HCC for more than 6 months. One of these 6 patients
showed clinical acute rejection, thus SRL monotherapy
was changed to SRL and full-dose CNI.
Conclusions: SRL monotherapy appears to be attempt
for patients having definite HCC recurrence.
PPLT26-028
LIVING DONOR LIVER
TRANSPLANTATION FOR PATIENTS
WITH ALCOHOLIC LIVER DISEASE
Wanjoon Kim, Shin Hwang, Chul-Soo Ahn, Ki-Hun
Kim, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song,
Dong-Hwan Jung, Gil-Chun Park and Hyung-Woo
Park
Asan Medical Center, Ulsan University, Korea
Introduction: Since most transplantation studies for
alcoholic liver disease (ALD) were performed on
deceased donor liver transplantation, little was known
following living donor liver transplantation (LDLT).
Method: The clinical outcome of 36 ALD patients who
underwent LDLT from February 1997 to December
2007 in a large-volume liver transplantation center was
assessed retrospectively.
Results: The model for end-stage liver disease score was
23  11, and mean pretransplant abstinence period was
16  13 months, with 28 (77.8%) patients being absti-
nent for at least 6 months. Graft types were right lobe
grafts in 24, left lobe grafts in 4 and dual grafts in 8.
Graft to recipient body weight ratio was 0.94  0.16.
The relapse rates in patients who did and did not main-
tain 6 months of abstinence were 7.1% and 35%, respec-
tively (p = 0.02). Younger recipient age was a significant
risk factor for alcohol relapse (p = 0.027). Ten recipients
with antibody to hepatitis B surface antigen (HBsAg)
received core antibody-positive liver graft, but two of
them showed positive HBsAg seroconversion. Overall 5-
year patient survival rate following LDLT was 87.8%,
with a 5-year relapse rate of 16.7%.
Conclusions: Pretransplant abstinence for 6 months
appears to be beneficial for preventing posttransplant
relapse. Life-long prophylactic measure should be fol-
lowed after use of anti-HBc-positive liver grafts regard-
less of hepatitis B viral marker status of the recipient.
PPLT26-029
A COMPARATIVE STUDY REGARDING
THE EFFECT OF INTRAPERITONEAL
ANTI-ADHESIVE AGENT APPLICATION
IN LEFT-LIVER LIVING DONORS
Wanjoon Kim, Cheon-Soo Park, Shin Hwang, Chul-
Soo Ahn, Ki-Hun Kim, Deok-Bog Moon, Tae-Yong
Ha, Gi-Won Song, Dong-Hwan Jung and Gil-Chun
Park
Asan Medical Center, Ulsan University, Korea
Introduction: The purpose of this study is to evaluate
the effect of intraperitoneal anti-adhesive agent applica-
tion after living-donor left hepatectomy, compared with
a historical control group.
Method: The study group consisted of 220 consecutive
living donors who donated a left-liver graft during the
time period between January 2006 and December 2011.
The anti-adhesive agent used was composed of sodium
hyaluronate and sodium carboxymethyl cellulose. The
historical control group using no anti-adhesive agent
included 220 consecutive left liver donors during the
time period between January 1998 and December 2004.
Results: Overt gastric stasis requiring fasting was
observed in five (2.3%) of the study group and in seven
(3.2%) of the control group (p = 0.77). An additional
work-up to determine gastric stasis or prolonged ileus
was performed in 17 (7.7%) and 22 (10%) donors,
respectively (p = 0.51). Only one donor in the control
group underwent laparotomy for intestinal obstruction.
No clinical factors, including patient age, sex, body
mass index, remnant right liver proportion, skin inci-
sion shape, and surgery time, were significant risk fac-
tors for gastric stasis or prolonged ileus. No harmful
side-effects of the anti-adhesive agent were identified.
Conclusions: The results of this study revealed that
application of an anti-adhesive agent was not proven to
be effective for preventing gastric stasis and ileus. A
randomized controlled study will be required in order
to demonstrate the true benefits of anti-adhesive appli-
cation in left-liver living donors.
PPLT26-030
LIVING DONOR LIVER
TRANSPLANTATION FOR
METASTATIC COLON
ADENOCARCINOMA: REPORT OF A
CASE WITH 6 YEARS OF FOLLOW-UP
WITHOUT RECURRENCE
Wanjoon Kim, Shin Hwang, Deok-Bog Moon, Chul-
Soo Ahn, Ki-Hun Kim, Tae-Yong Ha, Gi-Won Song,
Dong-Hwan Jung, Gil-Chun Park and Hyung-Woo
Park
Asan Medical Center, Ulsan University, Korea
Introduction: The use of sirolimus (SRL)-based immuno-
suppression protocols have been reported to reduce recur-
rence rates following liver transplantation (LT) for
hepatocellular carcinoma (HCC), although this is still a
matter for debate. This concept can be applied to the LT
recipients after HCC recurrence. The cornerstone of phar-
macological immunosuppression after posttransplant
HCC recurrence is combination of SRL and sorafenib.
Method: We describe our experience on the post-recur-
rence immunosuppression using SRL in 8 patients with
HCC recurrence.
Results: The target SRL level as SRL monotherapy
was set at 10 ng/mL at 1 year and 5 ng/mL at 5 years.
During 1 month, precedent use of calcineurine inhibitor
(CNI) was crossover exchanged with SRL with or with-
out minimal-dose CNI. At the same time, sorafenib
was started and the dosage was raised after monitoring
side-effects. Special attention should be paid at this per-
iod because both SRL and sorafenib can induce similar
gastrointestinal manifestation and liver function
abnormality. High-dose SRL > 10 ng/mL was sug-
gested to achieve anti-tumor effect, but our limited
experience did not support that it is actually beneficial
for HCC recipients. Combination of SRL-sorafenib was
successfully installed in 6 of 8 patients within 1 month.
Three of them showed rapid progression of HCC, but
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other 3 patients showed at least no definite progression
of HCC for more than 6 months. One of these 6
patients showed clinical acute rejection, thus SRL
monotherapy was changed to SRL and full-dose CNI.
Conclusions: SRL monotherapy appears to be attempt
for patients having definite HCC recurrence.
PPLT26-031
TREATMENT OF HEPATIC VENOUS
OUTFLOW OBSTRUCTION AFTER
DECEASED DONOR LIVER
TRANSPLANTATION USING PIGGY-
BACK TECHNIQUE
Minho Shin, Shin Hwang, Deok-Bog Moon, Chul-Soo
Ahn, Tae-Yong Ha, Gi-Won Song and Sung-Gyu Lee
Asan Medical Center, Ulsan University, Korea
Introduction: The piggy-back technique has been used in
many transplantation centers because it does not require
resection or total clamping of the retrohepatic inferior
vena cava (IVC). However, the piggy-back technique
appears to be more vulnerable to the morphological dis-
tortion of the hepatic outflow anastomosis site than the
classical IVC interposition method. Because of its spatial
relationship between the hepatic vein anastomosis and
liver graft, ventrodorsal compression is considered to be
a significant risk factor of outflow obstruction.
Method: We experienced a case suffering from hepatic
venous outflow obstruction due to ventrodorsal com-
pression, which was successfully treated by IVC stent-
ing. The patient underwent liver resection four times
before due to recurrence of hepatocellular carcinoma,
thus usual isolation of the retrohepatic IVC was inter-
fered by heavy intraabdominal adhesion around the
IVC. As an inevitable choice, the full length of shrun-
ken recipient IVC was opened longitudinally and then
the IVC of a whole liver graft was anastomosed as
side-to-side piggy-back method. After graft implanta-
tion, we worried that the graft was so large to com-
pressed anastomosis site because the graft-recipient
weight ratio was 2.5.
Results: During early follow-up, the patient showed no
reduction of ascites and slight stenosis of the IVC anas-
tomosis. At day 4, IVC stent was inserted and the IVC
anastomosis became fully opened. The patient showed
no vascular complication for 18 months to date.
Conclusions: In such a situation, restoration of IVC
diameter by stenting can facilitate re-expansion of the
anastomotic opening.
PPLT26-032
TAILORING IMMUNISUPPRESSION IN
PATIENTS SHOWING
HEPATOCELLULAR CARCINOMA
RECURRENCE AFTER LIVER
TRANSPLANTATION
Deok-Bog Moon, Sung-Gyu Lee, Chul-Soo Ahn, Shin
Hwang, Ki-Hun Kim, Tae-Yong Ha, Gi-Won Song,
Dong-Hwan Jung and Gil-Chun Park
Asan Medical Center, Ulsan University, Korea
Introduction: If most of the splanchnic venous blood
drains into large pericholedochal varix through the
peripancreatic collateral, large pericholedochal varix
can be used for portal inflow to the transplanted liver
and also relieve recipient’s portal hypertension. To
date, however, there has been no successful report
using pericholedochal varix in liver transplantation. We
would like to introduce our successful innovative proce-
dures for those patients.
Method: Four patients among 2166 adult LDLT recipi-
ents (January 2006–May 2013) had totally obstructed
portal vein and co-existing large pericholedochal varix
without large amount of ascites. Pericholedochal varix
was the only available portal inflow securing successful
LDLT in 2 patients, and was also alternative inflow for
superior mesenteric vein in another 2 patients. The sur-
gical strategies are followings: (a) dissection of hepatic
hilum to isolate left hepatic artery using for arterial
reconstruction of implanted right lobe graft, (b) en-
mass clamping of the undissected remaining hilum if
we can leave adequate length of stump from the clamp-
ing site, and then hilum is divided, (c) delay the donor
hepatectomy until the feasibility of the recipient opera-
tion is confirmed.
Results: From divided hepatic hilum under clamp, more
than 1 cm caliber pericholedochal varix was obtained
from single, or more than two varix through venoplasty.
Paper-thin varix walls were re-enforced with bisected
saphenous vein in 3 patients but was not necessary in 1
patient due to enlarged and thickened wall. Donor por-
tal vein was fenced in funnel shape at the bench for safe
and easy anastomosis with plastied cholechal varix.
Implantation and postoperative recovery were unevent-
ful. Currently, all the recipients are doing well without
portal hypertension related complications.
Conclusions: Enlarged pericholedochal varix can be
successfully used for portal inflow of adult LDLT in
patients with totally obliterated portal vein as an alter-
native for cavoportal hemotransposition or superior
mesenteric vein jump graft.
PPLT26-033
UPDATED EXPERIENCE ON
EXCHANGE LIVING DONOR LIVER
TRANSPLANTATION FOR ADULT
PATIENTS AT ASAN MEDICAL CENTER
DongHwan Jung, SungGyu Lee, Shin Hwang, KiHun
Kim, ChulSoo Ahn, TaeYong Ha, GiWon Song and
GilChun Park
Asan Medical Center, Ulsan University, Korea
Introduction: An exchange living donor program for
liver transplantation, similar to the exchange living
donor kidney program, was proposed to avoid ABO-
incompatible adult living donor liver transplantation
(LDLT). The objective of this study was to present
updated changes in exchange adult LDLT program at
our institution.
Method: The study period was set between January
2003 and December 2011, and 2182 cases of adult LDLT
were included in this study. During this period, we
underwent 26 paired cases of exchange LDLT (1.2%).
Results: Of 26 paired cases of donor exchange LDLT,
22 pairs were matched due to ABO-incompatibility and
4 pairs were matched due to cascade allocation of unre-
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lated donors or relatively small graft volume to the recip-
ients. A total of 28 living donors were included in the 26
paired cases of exchange LDLT because of inclusion of 2
dual-graft transplant. Elective surgery was performed in
22 cases, but urgent operation was performed in 4 cases.
The overall 1-year and 5-year patient and graft survival
were both 96.2% and 90.1%, respectively.
Conclusions: We suggest that the exchange donor pro-
gram for adult LDLT seems to be a feasible modality
to overcome donor ABO-incompatibility. Reasonably
acceptable indications for donor exchange LDLT will
be proposed in near future.
PPLT26-034
PREDICTIVE VALUE OF PRE-
TRANSPLANT SERUM ALPHA-
FETOPROTEIN AND DES-GAMMA-
CARBOXY PROTHROMBIN LEVELS ON
HEPATOCELLULAR CARCINOMA
RECURRENCE AFTER LIVER
TRANSPLANTATION
Hyung Soon Lee, Juhan Lee, Gi Hong Choi, Dae
Ryong Kang, Dong Jin Joo, Myoung Soo Kim, Jin
Sub Choi and Soon Il Kim
Yonsei University College of Medicine, Korea
Introduction: This study investigated whether the com-
bined use of pre-transplant serum alpha-fetoprotein
(AFP) and des-gamma-carboxy prothrombin (DCP)
levels improve predictive performance of the Milan cri-
teria (MC) for hepatocellular carcinoma (HCC) recur-
rence after liver transplantation (LT).
Method: We analyzed 162 patients that underwent LT
for HCC between 2001 and 2012. We design the MC
based predictive model for post-transplant HCC recur-
rence and this model incorporated pre-transplant serum
AFP and DCP levels: Model 1 is base model incorpo-
rated AFP, model 2 is base model incorporated DCP
and model 3 is base model incorporated AFP and
DCP. The time-dependent receiver operating character-
istics (ROC) curve analysis was used to compare pre-
dictive performance between each model over the entire
range of follow-up time. To identify prognostic factors
for HCC recurrence, clinicopathologic variables were
assessed by Cox-regression analysis.
Results: At a median follow-up of 23.5 months, 17
(10.5%) patients developed post-transplant HCC recur-
rence. In the time-dependent ROC curve analysis, pre-
dictive performance of model 1 and model 2 show no
significant difference between the base model. However,
model 3 show significantly better predictive perfor-
mance than base model (estimated difference = 0.069,
95% confidence interval = 0.159 to 0.007). And pre-
transplant AFP of 140 ng/mL and DCP of 65 mAU/
mL were taken as a cut-off value in the time-dependent
ROC curve analysis. And multivariate analysis showed
AFP >140 ng/mL and/or DCP >65 mAU/mL and the
presence of satellite nodule were associated with post-
transplant HCC recurrence.
Conclusions: Combined use of pre-transplant AFP and
DCP levels are improved predictive performance of the
MC. Thus, LT candidates with HCC can be assessed
more accurately by adding pre-transplant AFP and
DCP levels to the MC.
PPLT26-035
PNEUMATOSIS INTESTINALIS AFTER
ADULT LIVING DONOR LIVER
TRANSPLANTATION
Cheon Soo Park
Gangneung Asan Hospital, Korea
Introduction: Pneumatosis intestinalis (PI) is a condi-
tion in which multiple, gas-filled, mural cysts are found
in the gastrointestinal tract. Although its exact etiology
remain obscure, PI has been rarely encountered in liver
transplantation (LT) recipients.
Method: In our hospital, three patients undertaking
adult LDLT had PI in 2011.
Results: Two patients had no symptoms of PI and no
signs of secondary complication such as peritonitis,
bowel ischemia, or perforation. The diagnosis was
made incidentally by abdominal X-ray and computed
tomography (CT) scan. Abdominal X-ray and CT scan
demonstrated PI only in the ascending colon with small
pneumoperitoneum. They had regular diet, no antibiot-
ics therapy but immunosuppressive steroid medication
were stopped. In follow up CT scan demonstrated PI
spontaneously resolved without any complication.
Other one patient were admitted via emergency room
post LDLT two years later. His symptoms were poor
oral intake and intermittent abdominal pain and no gas
passage. Abdominal X-ray and CT scan demonstrated
PI in the whole small bowel and small bowel dilatation,
pneumoperitoneum, pneumoretroperitoneum. But no
signs of peritonitis. In the physical examination
revealed abdominal distension but no tenderness, no
rebound tenderness. After one week of conservative
treatment including bowel rest, antibiotics therapy, the
PI and pneumoperitoneum spontaneously resolved
without any complication.
Conclusions: If the patients of pneumatosis intestinal is
in adult LDLT had no symptoms and signs of second-
ary complication such as peritonitis, bowel ischemia, or
perforation, it can be managed successfully by conser-
vative treatment which included bowel rest, antibiotics
therapy.
PPLT26-036
AN ANALYTIC STUDY ON
CORRELATION BETWEEN HB VIRAL
LOAD BEFORE LIVER
TRANSPLANTATION AND
RECURRENCE OF HBV AFTER LIVER
TRANSPLANTATION
Gi-Won Song, Sung-Gyu Lee, Shin Hwang, Yo-Han
Park, Hyung-Woo Park, Sung-Hwa Kang, Bo-Hyun
Jung, Min-Ho Shin and Young-Inn Yoon
Asan Medical Center, Ulsan University, Korea
Introduction: The correlation between concentration of
cccDNA in liver tissue that acts as a main agent at the
time of reproduction of HBV in cell infected by HBV,
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dose of HBIG and antiviral agent required for prevent-
ing recurrence was analyzed.
Method: All 50 patients who underwent liver trans-
plantation in our hospital from January, 2010 were
selected. HBV viral load of blood and liver tissue speci-
men was measured by real-time PCR. The 10000 units
of HBIG was administered daily for first 1 week,
weekly for 1 month thereafter and then that of every
month for 1 year thereafter. If anti-HBs antibody in
blood should be measured below 1000 IU/L, antiviral
agent was concomitantly administered.
Results: In precedent case of 50 patients, inter-liver tis-
sue HBV DNA and cccDNA were detected and its
average load was 0.791.2 (2.932.86) log 10 cop-
ies/cell and 2.281.08 (4.590.62) log 10 copies/cell,
respectively. A significant correlation between serum
HBV DNAm inter-liver tissue HBV DNA (r = 0.65,
p = 0.00) and ccDNA concentration (r = 0.55,
p = 0.00) before transplantation was represented. Dur-
ing follow-up for 1 year, HBV was recurred in 6
patients (12.0%). A statistically significant difference
was not represented in serum HBV DNA load, inter-
tissue HBV DNA and cccDNA concentration before
transplantation in 6 patients of recurrent group and 44
patients of non-recurrent group but in high risk group
and recurrent group after transplantation, inter-tissue
cccDNA concentration was represented to be signifi-
cantly higher than that of low risk group.
Conclusions: High inter-liver tissue cccDNA concentra-
tion has a high failure possibility of high dose HBIG
single therapy in preventing HBV recurrence after liver
transplantation, close follow-up observation of anti-
HBs Ab, extensive administration of HBIG and con-
comitant administration of antiviral agent are recom-
mended.
PPLT26-037
RISK FACTOR ANALYSIS OF BILIARY
STRICTURE IN ABO INCOMPATIBLE
ADULT LIVING DONOR LIVER
TRANSPLANTATION
Gi-Won Song1, Sung-Gyu Lee, Shin Hwang, Chul-Soo
Ahn, Ki-Hun Kim, Deok-Bog Moon, Tae-Yong Ha,
Dong-Hwan Jung and Gil-Chun Park
Asan Medical Center, Ulsan University, Korea
Introduction: Despite of recent improvement of survival
outcome, the concern about high incidence of biliary
stricture (BS) after ABOi ALDLT still exists because
ABO incompatibility is one of major contributing fac-
tors for BS.
Method: From November 2008 to June 2013, 200 cases
of ABOi ALDLTs have been performed. All patients
received a single preoperative dose of rituximab (300–
375 mg/m2), with plasma exchange. Local graft infu-
sion therapy was employed only for the first 20 cases.
Post-transplant immunosuppression consisted of tacrol-
imus, MMF and steroid. We compared patient and
graft survival and biliary stricture-free survival rates
(BSFSR) between ABOi ALDLTs and 1228 ABO-com-
patible (ABOc) ALDLTs which have been performed
during same period. And we analyzed risk factors for
BS in ABOi ALDLT.
Results: There was no IHM among 200 cases. Six
patients underwent re-transplantation due to small-for-
size graft syndrome and intractable BS, respectively.
Overall 1, 2 and 3-year patient survival rate was 96.1,
96.1 and 96.1%, respectively, which was superior to
that of ABOc ALDLT (91.6%, 88.5%, 87.94%,
p = 0.01). BS occurred in 33 (16.5%) patients. There
was significant difference in 1, 2 and 3-year BSFSR
between ABOi and ABOc ALDLT patients (83.2 vs.
80.9% and 80.9 vs. 88.3%, 87.3 vs. 87.3%, p = 0.03).
Among 33 patients with BS, 14 patients showed diffuse
multiple intrahepatic strictures (DIHS) which were
related to the death in 2 patients. In the risk factor
analysis, peak level of post-transplant Ig M more than
1:32 was significant risk factor for BS.
Conclusions: The survival outcome of ABOi ALDLT is
comparable to that of ABOc ALDLT. The incidence of
BS of ABOi ALDLT was not superior to that of ABOc
ALDLT. However, ABO incompatibility is related with
the development of DIHS which are rarely seen in
ABOc ALDLT and can be the cause of graft failure
and patient death.
PPLT26-038
HIGH VOLUME OF LIVING DONOR
LIVER TRANSPLANT WITHOUT
DISEASED DONOR BACKUP:
OUTCOMES, INSIGHT AND LESSONS
TO BE LEARNED
Ibrahim Marwan1, Mahmuod Elmetiny2, Adel Hosny3,
Khalid Aamer4, Magdy Amin5, Mohamed Abd el
Wahaab6, Osama Elmalt7 and Refaat Refaat Kamel2
1National Liver Institute,Menoufeya University, Egypt;
2Ain Shams Unveristy, Egypt; 3Cairo University, Egypt;
4International Medical Center, Egypt; 5El Maady
Military Hospital, Egypt; 6Mansoura University, Egypt;
7National Cancer Institute, Cairo University, Egypt
Introduction: We present the outcome of 1905 LDLT
cases performed in eleven years in Egypt.
Method: Between August 2001 to December 2012, 1905
LDLT cases were performed in ten centers (93.5%
adults, mean age 53 years and 6.5% pediatrics, mean age
7.7 years). Indication in adults was HCV cirrhosis (92%)
with or without hepatocellular carcinoma (HCC) and a
mean MELD score 18. HCC cases were 27% and 86%
of them were within Milan criteria. The main indication
in the pediatric group was biliary atresia (49%). There
was a single case with hepatoblastoma.
Results: Operative mortality occurred in 22 recipients.
Donor mortality was 0.21% (4 donors). In adult recipi-
ents, mortality was 31.4% versus 22.7% in the pediatric
group. Biliary complications were 24.7% and clinical
HCV recurrence requiring anti-viral treatment was
13%. In HCC cases, first year recurrence was 10%
whereas 3 years recurrence was 15%. Five year survival
was 58% and the mortality due to tumor recurrence
was 13.6%. The hepatoblastoma case has been doing
well for the last 10 years. Out of our experience,
aspects favoring a better outcome include: excluding
donors if the graft includes more than 2 bile ducts, per-
forming liver biopsy for all donors with a remaining
liver volume not less than 35%, the age limit of the
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recipients should be 65 years for males and 60 years
for females and lastly HCC cases must be within Milan
criteria.
Conclusions: LDLT is a potentially safe procedure
especially when cadaveric liver transplantation is
unavailable in countries like Egypt. The long term sur-
vival and disease free survival rate in patients with
HCC transplanted by LDLT is comparable to those
using diseased donors. Although LDLT had reasonable
outcomes; yet, it carries considerable risks to healthy
donors, lacks cadaveric back up and is not feasible for
all patients.
PPLT26-039
LIVING DONOR LIVER
TRANSPLANTATION FOR PATIENTS
WITH ALCOHOLIC LIVER DISEASE
Yohan Park and Shin Hwang
Asan Medical Center, Ulsan University, Korea
Introduction: Since most transplantation studies for
alcoholic liver disease (ALD) were performed on
deceased donor liver transplantation, little was known
following living donor liver transplantation (LDLT).
Method: The clinical outcome of 36 ALD patients who
underwent LDLT from February 1997 to December
2007 in a large-volume liver transplantation center was
assessed retrospectively.
Results: The model for end-stage liver disease score
was 23  11, and mean pretransplant abstinence period
was 16  13 months, with 28 (77.8%) patients being
abstinent for at least 6 months. Graft types were right
lobe grafts in 24, left lobe grafts in 4 and dual grafts in
8. Graft to recipient body weight ratio was
0.94  0.16. The relapse rates in patients who did and
did not maintain 6 months of abstinence were 7.1%
and 35%, respectively (p = 0.02). Younger recipient age
was a significant risk factor for alcohol relapse
(p = 0.027). Ten recipients with antibody to hepatitis B
surface antigen (HBsAg) received core antibody-posi-
tive liver graft, but two of them showed positive
HBsAg seroconversion. Overall 5-year patient survival
rate following LDLT was 87.8%, with a 5-year relapse
rate of 16.7%.
Conclusions: Pretransplant abstinence for 6 months
appears to be beneficial for preventing posttransplant
relapse. Life-long prophylactic measure should be fol-
lowed after use of anti-HBc-positive liver grafts regard-
less of hepatitis B viral marker status of the recipient.
PPLT26-040
LONG-TERM OUTCOMES OF LIVER
TRANSPLANTATION FOR COMBINED
HEPATOCELLULAR CARCINOMA AND
CHOLANGIOCARCINOMA
Yohan Park and Shin Hwang
Asan Medical Center, Ulsan University, Korea
Introduction: Combined hepatocelluar carcinoma and
cholangiocellular carcinoma (HCC-CCC) is a rare int-
rahepatic malignancy. Differential diagnoses among
HCC, CCC and combined HCC-CCC are occasionally
difficult, thus malignancies other than ordinary HCC
are unexpectedly found at the explant liver specimens.
This study was conducted to analyze the long-term out-
comes of liver transplantation (LT) in patients having
combined HCC-CCC.
Method: From January 1999 to December 2009, 2137
cases of adult LT operations were performed in our
institution. Fifteen cases of pathologically confirmed
combined HCC-CCC were identified. All of them
underwent LT operation under the pretransplant diag-
nosis of HCC. Their medial record was reviewed retro-
spectively.
Results: Mean patient age was 58.9  7.2 years. Med-
ian preoperative alpha-fetoprotein level was 32.6 ng/
mL. CA19-9 was above normal (≥37 ng/mL) in 3
patients (20%), and ranges of CA19-9 levels were
30.5 U/mL (3.7–110 U/mL). LT types were living-
donor LT in 14 and deceased-donor LT in 1. Milan cri-
teria were met in 11. Tumor number was single in 10
and multiple in 5. Maximal tumor diameter was
3.1  1.7 cm. Seven patients showed tumor recurrence,
in which 6 occurred within the first 12 months. All
recurrent cases died at a median period of 4 months
after diagnosis of tumor recurrence. The overall patient
survival rates were 66.7% at 1 year and 60.0% at 3
and 5 years. Disease-free patient survival rates were
60.0% at 1 year and 53.3% at 3 and 5 years.
Conclusions: Combined HCC-CC showed a high early
recurrence rate especially within the first year, thus
strict tumor surveillance is necessary to detect and
manage recurrence in time.
PPLT26-041
INTENSIVE PULMONARY SUPPORT
USING EXTRACORPOREAL
MEMBRANE OXYGENATION FOR
ADULT LIVER TRANSPLANT
RECIPIENTS WITH RESPIRATORY
FAILURE
Yohan Park and Shin Hwang
Asan Medical Center, Ulsan University, Korea
Introduction: Adult liver transplantation recipients
occasionally show serious acute cardiopulmonary dys-
function, requiring intensive care. In recent year, extra-
corporeal gas exchange system has become a new
therapeutic option for the treatment of patients suffer-
ing from acute respiratory failure. We have assessed
the feasibility of extracorporeal membrane oxygenation
(ECMO) support in adult LT recipients facing acute
pulmonary failure and refractory to conventional
mechanical ventilation and concurrent nitric oxide gas
inhalation.
Method: From January 2008 to March 2011, 18 adult
LT recipients required ECMO support due to pneumo-
nia (n = 12) and adult respiratory distress syndrome
(n = 6). Mean age was 55.7  6.9 years and mean
model for end-stage liver disease score was 24.8  8.5.
Twelve patients underwent living-donor LT and six
underwent deceased-donor LT.
Results: Veno-venous access mode was used and
continuous veno-venous hemodiafiltration was per-
formed concurrently in all 18 patients. No procedure-
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related immediate complications occurred. Successful
ECMO weaning was achieved in 8 patients (44.4%) at
the first attempt, after mean ECMO support of
11.4  6.8 days, but the other 10 patients died due to
overwhelming infection prior to ECMO weaning. Uni-
variate analysis revealed no significant risk factors start
for failing ECMO support before ECMO start. But the
Duration of pre ECMO ventilation shows statistical
significance.
Conclusions: ECMO as rescue therapy seems beneficial
to be considered as a last therapeutic option for LT
recipients with refractory pulmonary dysfunction who
would otherwise die due to hypoxemia.
PPLT26-042
ESTABLISHMENT OF MODIFIED
ORTHOTOPIC LIVER
TRANSPLANTATION USING ELDERLY
DONORS IN RATS
Guo-Ying Wang, Chi Xu, Wei Meng and Wen-Jie
Chen
The Third Affiliated Hospital of Sun Yat-Sen University,
China
Introduction: The use of aging donors has become
common due to the increasing demand for organ dona-
tions. However, the impact of donor age on survival of
liver transplant (LT) recipients is still unclear.
Method: Syngeneic nonarterialized LT was performed
in male Wistar rats. The recipients were divided into
two groups: control group with donor weighing 220–
250 g (n = 12), and aging donor group with donor
weighing 350–600 g at ages of 56–88 weeks (n = 12).
After surgery, the caudate lobe was cut immediately
and oil red O direct staining was performed for detect-
ing lipid accumulation. The postoperative function
recovery was evaluated by serum alanine aminotrans-
ferase (ALT) detection. Every 3 recipients from each
group were sacrificed on days 7 and 14 after LT to
detect the changes of the grafts histology detected by
HE staining. The 3 month survival rate of the rats was
observed.
Results: The 3-month survival rate of all recipients was
100%. Aging liver grafts caused early elevation of ALT
peak level and aggravation of liver tissue damage, and
the liver graft recovery was delayed until postoperative
day 14. The intensity of staining of liver tissue with oil
red O provides a qualitative measure of the lipid con-
tent. We found that aging donors increases the inten-
sity of the oil red O staining but no significant different
compared with control rats.
Conclusions: No arterialized modified two-cuff tech-
nique for rat LT can be regarded as a standard method
to establish LT model. The donor age of the rats is a
crucial factor to affect liver function recovery within
14 days after transplant but do not affect the outcome
of the liver grafts. This model appears to be a suitable
small animal model to study the impact of donor age
on the function of transplanted liver.
PPLT26-043
DEEPLY DYNAMIC ANALYSIS OF
INTESTINAL MICROECOLOGY IN
ACUTE REJECTION OF RATS
FOLLOWING LIVER
TRANSPLANTATION
Zhigang Ren, Lin Zhou, Guangying Cui, Jianwen
Jiang, Haifeng Lu, Haiyang Xie and Shusen Zheng
First Affiliated Hospital, School of Medicine, Zhejiang
University, China
Introduction: Acute rejection (AR) in liver transplanta-
tion (LT) is still a life-threatening complication. This
study aims to identify microbial profile in recipients’
intestine, and explore potential clinical application of
microbial profile as biomarkers for AR in LT.
Method: The study included 3 groups: NC group, non-
rejection group and AR group. All rats were sampled at
days 1, 3 and 7 after LT, respectively. Hepatic graft histol-
ogy, ALT&AST and TEM were performed. Intestinal
ultra-structure was observed. Fecal sIgA, serum TNF-a,
bacterial culture and endotoxin was detected. RT-PCR
was performed to quantify dominant flora in faces. DGGE
profiles were performed to identify microbial diversity and
key bands. The phylogenetic tree of sequences based on
16sRNA sequencing was used to identify key bacteria.
Results: Hepatic histology, ALT&AST and TEM dem-
onstrated hepatic graft injury in recipients on 1 day for
I/R injury and 7 day for AR injury after LT. Mean-
while, intestinal microvilli loss and tight junction dam-
age were noted, and intestinal barrier dysfunction
during AR presented a decrease of fecal sIgA and an
increase of blood bacteremia, endotoxin and TNF-a.
Also, RT-PCR results showed the proportions of genus
Faecalibacterium prausnitzii and Lactobacillus obvi-
ously decreased, but Clostridium bolteae increased dur-
ing AR. Cluster analysis of DGGE profiles showed 3
primary clusters, which were confirmed by MDS and
PCA. Intestinal microbial diversity and species richness
were decreased during AR. Phylogenetic tree analysis
showed during AR, almost all key bacteria corre-
sponded to key bands belong to Firmicutes and Bacter-
oidetes Phylum (11/12). Most of decreased key bacteria
belong to phylum Firmicutes, while increased key bac-
teria belong to phylum Bacteroidosis.
Conclusions: We firstly detailed intestinal microbial pro-
filing during AR in LT. The unique features of intesti-
nal micro biota could be used to predict liver AR, thus
intestinal microbial profiling may become a potential
diagnostic biomarker for acute rejection in LT.
PPLT26-044
DIAGNOSIS AND TREATMENT OF
ACUTE PROMYELOCYTIC LEUKEMIA
AFTER LIVER TRANSPLANTATION
Guo-Ying Wang, Yong Zou, Wei Meng, Min-ru Li,
Nan Jiang, Yang Yang and Gui-hua Chen
The Third Affiliated Hospital of Sun Yat-Sen University,
China
Introduction: Acute myelogenous leukemia (AML) is a
rare complication after liver transplantation (LT). Little
© 2014 The Authors
HPB 2014, 16 (Suppl. 2), 550–602 HPB © 2014 Americas Hepato-Pancreato-Biliary Association
Poster Panel [Liver Transplantation] 601
information is available about the role of commonly
used transplant immunosuppressive drugs in the leuke-
mogenesis.
Method: One patient after LT developed acute prom-
yelocytic leukemia (APL) in our hospital. Clinical data
of the patient were retrospectively analyzed. A litera-
ture search in the medical databases was undertaken.
Results: The patient was found a reduction of white
blood cell count 52 months after LT. After failure of
G-CSF, bone marrow test confirmed the diagnosis of
APL. Induction chemotherapy with all-trans retinoic
acid, and arsenic disulfide, was given and complete
remission was achieved. There were 34 reported cases
of leukemia following LT in the literature including this
case. Among them, there were 22 cases of AML. The
most common AML subtype was APL (8 of 18, 44%).
Induction chemotherapy regimens consisted of all-trans
retinoic acid, arsenic trioxide, or in combination with
daunorubicin or cytosine arabinoside. The overall mor-
tality of AML patients was 59% (13/22). The survival
rate of APL patients was higher than that of the other
types (6 out of 8 and 3 out of 14 cases, respectively,
p < 0.05). Six APL patients achieved complete remis-
sion and the other two died of DIC and sepsis, respec-
tively. The mortality rate of AML patients with a
cyclosporine-based regimen as primary immunosuppres-
sion was relatively higher (5 out of 7, 71%) than that
of patients with a tacrolimus-based regimen as primary
immunosuppression (4 out of 11, 36%) but there was
no significant difference between two groups (p > 0.05).
Conclusions: The prognosis of APL following LT is
better than that of the other types of AML. APL
should be suspected when the recipients display leuco-
penia and fail to G-CSF treatment. Early diagnosis and
timely treatment is the key to improve the prognosis of
APL after LT.
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